Datasets:
ChatDOC
/
OCRFlux-pubtabnet-single

Dataset card Data Studio Files Community
image_name
stringlengths
68
68
type
stringclasses
2 values
gt_table
stringlengths
116
12.6k
49f6ff936bdadf6b69c67a95c7a393014e76e479ff1c0cf6e5a358f5aabd7f60.png
complex
<table><tr><td colspan="2">Training Standards in Implant Dentistry, 2016</td></tr><tr><td>1</td><td>Basic sciences: surgical anatomy, pathological process, bone defects, healing processes</td></tr><tr><td>2</td><td>Implant science: design and materials, limitations</td></tr><tr><td>3</td><td>Patient assessment and medical considerations</td></tr><tr><td>4</td><td>Case assessment and treatment planning: straightforward and complex cases</td></tr><tr><td>5</td><td>Radiographic assessment and Ionising Radiation Medical Exposure Regulations (IRMER)</td></tr><tr><td>6</td><td>Communication and informed consent</td></tr><tr><td>7</td><td>Infection control and asepsis</td></tr><tr><td>8</td><td>Soft tissue management (raising flaps and suturing)</td></tr><tr><td>9</td><td>Hard tissue management (autogenous bone augmentation, guided bone regeneration)</td></tr><tr><td>10</td><td>Pharmacological management</td></tr><tr><td>11</td><td>Surgical techniques for implant placement procedures</td></tr><tr><td>12</td><td>Implant-supported restorative procedures</td></tr><tr><td>13</td><td>Complications and their management</td></tr><tr><td>14</td><td>Long-term monitoring of implants</td></tr><tr><td>15</td><td>Record-keeping, documentation and quality assurance</td></tr></table>
aad6f6f3e2f6f473c20d814f6aa64b4227f6f2739b00cc404d815c5b2afe858c.png
complex
<table><tr><td></td><td>All (<i>n</i> = 91)</td><td colspan="2">CAD groups</td><td><i>p</i>-Value</td></tr><tr><td></td><td></td><td>CAD (<i>n</i> = 46)</td><td>Non-CAD (<i>n</i> = 45)</td><td></td></tr><tr><td>Age (years)</td><td>79 &#177; 9</td><td>79 &#177; 7</td><td>78 &#177; 7</td><td>0.283</td></tr><tr><td>Male gender, <i>n</i> (%)</td><td>47 (52)</td><td>32 (67)</td><td>15 (33)</td><td>0.001</td></tr><tr><td>STS-PROM score</td><td>6 &#177; 5</td><td>7 &#177; 5</td><td>6 &#177; 5</td><td>0.559</td></tr><tr><td>EuroScore 2</td><td>7 &#177; 5</td><td>9 &#177; 4</td><td>5 &#177; 4</td><td>0.004</td></tr><tr><td>Hypertension, <i>n</i> (%)</td><td>71 (78)</td><td>41 (89)</td><td>30 (67)</td><td>0.010</td></tr><tr><td>Dyslipidemia, <i>n</i> (%)</td><td>59 (65)</td><td>35 (76)</td><td>24 (53)</td><td>0.023</td></tr><tr><td>Diabetes, <i>n</i> (%)</td><td>35 (38)</td><td>19 (41)</td><td>16 (36)</td><td>0.573</td></tr><tr><td>Class III or IV NYHA, <i>n</i> (%)</td><td>61 (67)</td><td>30 (65)</td><td>31 (69)</td><td>0.710</td></tr><tr><td>Prior PCI, <i>n</i> (%)</td><td>8 (9)</td><td>8 (17)</td><td></td><td></td></tr><tr><td>Prior CABG, <i>n</i> (%)</td><td>16 (19)</td><td>16 (35)</td><td></td><td></td></tr><tr><td>CVD, <i>n</i> (%)</td><td>21 (23)</td><td>13 (28)</td><td>8 (18)</td><td>0.235</td></tr><tr><td>PAD, <i>n</i> (%)</td><td>35 (17)</td><td>21 (46)</td><td>14 (31)</td><td>0.154</td></tr><tr><td>COPD, <i>n</i> (%)</td><td>39 (43)</td><td>17 (37)</td><td>22 (49)</td><td>0.250</td></tr><tr><td>GFR (mL/min/m<sup>2</sup>)</td><td>58 &#177; 28</td><td>50 &#177; 19</td><td>64 &#177; 33</td><td>0.012</td></tr><tr><td>Renal dysfunction, <i>n</i> (%)</td><td>60 (66)</td><td>37 (82)</td><td>23 (50)</td><td>0.008</td></tr><tr><td>AF, <i>n</i> (%)</td><td>29 (32)</td><td>15 (33)</td><td>14 (31)</td><td>0.878</td></tr><tr><td>Permanent pacemaker, <i>n</i> (%)</td><td>7 (8)</td><td>3 (7)</td><td>4 (9)</td><td>0.672</td></tr><tr><td><i>Echocardiografic evaluation</i></td></tr><tr><td>AVA, cm<sup>2</sup></td><td>0.6 &#177; 0.1</td><td>0.6 &#177; 0.2</td><td>0.6 &#177; 0.1</td><td>0.850</td></tr><tr><td>Mean AV gradient (mmHg)</td><td>51 &#177; 13</td><td>50 &#177; 13</td><td>52 &#177; 13</td><td>0.505</td></tr><tr><td>LVEF (%)</td><td>50 &#177; 10</td><td>47 &#177; 10</td><td>53 &#177; 9</td><td>0.006</td></tr><tr><td>LV dysfunction<sup>a</sup>, <i>n</i> (%)</td><td>30 (33)</td><td>21 (46)</td><td>9 (20)</td><td>0.0210</td></tr><tr><td>Moderate or severe MR, <i>n</i> (%)</td><td>5 (7)</td><td>1 (2)</td><td>4 (9)</td><td>0.125</td></tr><tr><td><i>Procedure features</i></td><td></td><td></td><td></td><td></td></tr><tr><td>Transarterial access, <i>n</i> (%)</td><td>87 (96)</td><td>44 (96)</td><td>43 (96)</td><td>0.982</td></tr><tr><td>Transapical access, <i>n</i> (%)</td><td>4 (4)</td><td>2 (4)</td><td>2 (4)</td><td>0.999</td></tr><tr><td>Medtronic/coreValve, <i>n</i> (%)</td><td>79 (87)</td><td>38 (83)</td><td>41 (91)</td><td>0.231</td></tr><tr><td>Edwards SAPIEN, <i>n</i> (%)</td><td>12 (13)</td><td>8 (17)</td><td>4 (9)</td><td>0.072</td></tr></table>
a3c2f3f1466d2fca57fd45da405c22c1eb2e3d183b6ed5b5ac491e8b7456f879.png
complex
<table><tr><td></td><td>Controls (<i>n</i> = 50)</td><td>Patients (<i>n</i> = 150)</td><td><i>p</i></td></tr><tr><td>Age years</td><td>52.94 &#177; 9.87</td><td>54.72 &#177; 3.46</td><td rowspan="3">&gt;0.05</td></tr><tr><td>Min&#8211;max</td><td>(28&#8211;70)</td><td>(28&#8211;73)</td></tr><tr><td>Gender (M/F)</td><td>(22/28)</td><td>(55/95)</td></tr><tr><td>Total M2BP (ng/mL)</td><td>14.97 &#177; 3.46</td><td>176.65 &#177; 22.14</td><td rowspan="3">&lt;0.001</td></tr><tr><td>Min&#8211;max</td><td>(10&#8211;21.3)</td><td>(40.2&#8211;192.5)</td></tr><tr><td>Percentile 50 median</td><td colspan="2">182.400</td></tr><tr><td>CEA (ng/mL)</td><td></td><td>4.26 &#177; 1.37</td><td rowspan="3"></td></tr><tr><td>Min&#8211;max</td><td></td><td>(2&#8211;5)</td></tr><tr><td>Percentile 50 median</td><td colspan="2">4.800</td></tr></table>
9db9743252ddf862b4747e16fee98c3b7e3f8d3428bd6eea94e0e8b4cbd5a2f5.png
simple
<table><tr><td>Default setting <i>n</i>=25,<i>&#960;</i><sub><i>i</i></sub>=0.5i</td><td><i>n</i>=50,<i>&#960;</i><sub><i>i</i></sub>=0.5i</td><td><i>n</i>=75,<i>&#960;</i><sub><i>i</i></sub>=0.5i</td><td><i>&#960;</i><sub><i>i</i></sub>=0.25i, <i>n</i>=50</td><td><i>&#960;</i><sub><i>i</i></sub>=3i, <i>n</i>=50</td></tr><tr><td>0.41</td><td>0.41</td><td>0.41</td><td>0.41</td><td>0.42</td></tr><tr><td>Default setting <i>&#945;</i>=10<sup>&#8722;5</sup></td><td><i>&#945;</i>=10<sup>&#8722;2</sup></td><td><i>&#945;</i>=10<sup>&#8722;3</sup></td><td><i>&#945;</i>=10<sup>&#8722;4</sup></td><td><i>&#945;</i>=10<sup>&#8722;6</sup></td></tr><tr><td>0.41</td><td>0.37</td><td>0.40</td><td>0.41</td><td>0.42</td></tr><tr><td>Default setting <i>g</i>4=2.0</td><td><i>g</i>4=0.0</td><td><i>g</i>4=1.0</td><td><i>g</i>4=5.0</td><td><i>g</i>4=10.0</td></tr><tr><td>0.41</td><td>0.39</td><td>0.41</td><td>0.41</td><td>0.41</td></tr><tr><td>Default setting <i>r</i>=25.0</td><td><i>r</i>=0.0</td><td><i>r</i>=1.0</td><td><i>r</i>=15.0</td><td><i>g</i>=35.0</td></tr><tr><td>0.41</td><td>0.36</td><td>0.38</td><td>0.41</td><td>0.41</td></tr><tr><td>Default setting <i>a</i>=25.0</td><td><i>a</i>=0.0</td><td><i>a</i>=50.0</td><td><i>a</i>=75.0</td><td><i>a</i>=100.0</td></tr><tr><td>0.41</td><td>0.40</td><td>0.41</td><td>0.41</td><td>0.41</td></tr></table>
7fa4e95286efddb5dcc4325f39100b3ad5cd0aca58d8a6560fd51879d71d5121.png
complex
<table><tr><td> </td><td>Cal. Time</td><td>mu-prob</td><td rowspan="2">mu-prob = 0.2</td><td rowspan="2">mu-prob = 0.1</td><td rowspan="2">mu-prob = 0.01</td></tr><tr><td>Psize</td><td> </td><td> </td></tr><tr><td colspan="3"><i>psize</i> = 50</td><td>2.81</td><td>2.76</td><td>2.60</td></tr><tr><td colspan="3"><i>psize</i> = 100</td><td>2.72</td><td>2.86</td><td>2.45</td></tr><tr><td colspan="3"><i>psize</i> = 200</td><td>2.54</td><td>2.65</td><td>2.33</td></tr><tr><td colspan="3"><i>psize</i> = 500</td><td>2.63</td><td>2.83</td><td>2.58</td></tr></table>
acf1a025885c46723fe0812466d34dd980d64227fcd066e28377fc31dcc7e2ae.png
simple
<table><tr><td></td><td></td><td>PPV (%)</td><td>Sensitivity (%)</td></tr><tr><td>Jitterbug</td><td>raw</td><td>37.16</td><td>89.72</td></tr><tr><td></td><td>filtered</td><td>92.7</td><td>85.05</td></tr><tr><td>RetroSeq</td><td>extended +/- 100 bp and merged</td><td>61.01</td><td>90.26</td></tr><tr><td></td><td>extended, merged and filtered</td><td>87.31</td><td>88.21</td></tr></table>
942dd6e7504b1a637066839d7698ac235c9b120e29ad9d05d6ef088b7dbad64e.png
simple
<table><tr><td>SalB (&#956;g/mL)</td><td></td><td>Re (&#956;g/mL)</td><td></td><td>SalB:Re</td><td>1:2</td></tr><tr><td>Dose</td><td>Effect</td><td>Dose</td><td>Effect</td><td>Dose</td><td>Effect</td></tr><tr><td>10</td><td>0.3399475</td><td>20</td><td>0.34045</td><td>10</td><td>0.6768475</td></tr><tr><td>20</td><td>0.455375</td><td>40</td><td>0.456825</td><td>20</td><td>0.743375</td></tr><tr><td>30</td><td>0.5746225</td><td>60</td><td>0.5885125</td><td>30</td><td>0.8105175</td></tr><tr><td>40</td><td>0.6177875</td><td>80</td><td>0.650175</td><td>40</td><td>0.89841</td></tr><tr><td>50</td><td>0.66165175</td><td>100</td><td>0.70795</td><td>50</td><td>0.929985</td></tr><tr><td>60</td><td>0.7272075</td><td>120</td><td>0.78258</td><td>60</td><td>0.983965</td></tr></table>
2174ac5a7b0e1b01c2689e4bdfe1c748f7cafc9edadacbecb77e2fc192a16a1f.png
complex
<table><tr><td></td><td colspan="2">eMayo</td><td colspan="2">UCEIS</td><td colspan="2">panMayo</td></tr><tr><td></td><td>Spearman coefficient (R)</td><td>p</td><td>Spearman coefficient (R)</td><td>p</td><td>Spearman coefficient (R)</td><td>p</td></tr><tr><td>Disease extension</td><td>&#8722;0,04</td><td>0,687</td><td>&#8722;0,078</td><td>0,429</td><td>0,339</td><td>&lt;0.001</td></tr><tr><td>partial Mayo Score</td><td>0,714</td><td>&lt;0.001</td><td>0,714</td><td>&lt;0.001</td><td>0,692</td><td>&lt;0.001</td></tr><tr><td>CRP</td><td>0,306</td><td>0,004</td><td>0,481</td><td>&lt;0.001</td><td>0,481</td><td>&lt;0.001</td></tr><tr><td>Leukocytes</td><td>0,283</td><td>0,007</td><td>0,276</td><td>0,009</td><td>0,278</td><td>0,009</td></tr><tr><td>Haematocrit</td><td>&#8722;0,237</td><td>0,025</td><td>&#8722;0,3</td><td>0,004</td><td>&#8722;0,3</td><td>0,004</td></tr><tr><td>Haemoglobin</td><td>&#8722;0,238</td><td>0,024</td><td>&#8722;0,337</td><td>0,001</td><td>&#8722;0,337</td><td>0,001</td></tr><tr><td>Thrombocytes</td><td>0,175</td><td>0,102</td><td>0,307</td><td>0,003</td><td>0,307</td><td>0,003</td></tr><tr><td>Serum Iron</td><td>&#8722;0,352</td><td>0,001</td><td>&#8722;0,499</td><td>&lt;0.001</td><td>&#8722;0,499</td><td>&lt;0.001</td></tr><tr><td>Riley Score</td><td>0,724</td><td>&lt;0.001</td><td>0,691</td><td>&lt;0.001</td><td>0,691</td><td>&lt;0.001</td></tr><tr><td>Calprotectin</td><td>0,399</td><td>0,019</td><td>0,349</td><td>0,043</td><td>0,349</td><td>0,043</td></tr><tr><td>MMP-9</td><td>0,505</td><td>&lt;0.001</td><td>0,554</td><td>&lt;0.001</td><td>0,554</td><td>&lt;0.001</td></tr></table>
1c04bcf47e5a54863c8f72b991e1298678f570223270270d7823a1fad5fed4de.png
simple
<table><tr><td>Time (min.)</td><td>Regression Equations</td><td>Correlation Coefficient</td></tr><tr><td>2</td><td>A= -0.029 + 7.7 &#215; 10<sup>-3</sup>C</td><td>r=0.9670</td></tr><tr><td>4</td><td>A= -0.022 + 0.012C</td><td>r=0.9870</td></tr><tr><td>6</td><td>A=-0.029 + 0.016C</td><td>r=0.9950</td></tr><tr><td>8</td><td>A= -0.025 + 0.019C</td><td>r=0.9950</td></tr><tr><td>10</td><td>A= -0.012 + 0.021C</td><td>r=0.9970</td></tr><tr><td>12</td><td>A= -0.018 + 0.024C</td><td>r=0.9997</td></tr><tr><td>14</td><td>A= -0.024 +0.027C</td><td>r=0.9999</td></tr><tr><td>15</td><td>A= -0.023 + 0.026C</td><td>r=0.9999</td></tr></table>
cce4515fb2541a3181bf5b98f4667c7c03d21d5be35031610a14920204f423ee.png
complex
<table><tr><td> </td><td><i>n</i></td><td>%</td><td>Mean (SD)</td></tr><tr><td><i>Overall satisfaction</i><sup>a</sup></td><td> </td><td> </td><td>4.2 (0.77)</td></tr><tr><td>Not at all</td><td>93</td><td>0.9</td><td>-</td></tr><tr><td>To a small extent</td><td>170</td><td>1.7</td><td>-</td></tr><tr><td>To some extent</td><td>955</td><td>9.5</td><td>-</td></tr><tr><td>To a large extent</td><td>4797</td><td>48.0</td><td>-</td></tr><tr><td>To a very large extent</td><td>3987</td><td>39.9</td><td>-</td></tr><tr><td><i>Benefit of treatment</i><sup>a</sup></td><td> </td><td> </td><td>4.0 (0.92)</td></tr><tr><td>No benefit</td><td>189</td><td>1.9</td><td>-</td></tr><tr><td>Little benefit</td><td>424</td><td>4.3</td><td>-</td></tr><tr><td>Some benefit</td><td>1861</td><td>18.8</td><td>-</td></tr><tr><td>Large benefit</td><td>4368</td><td>44.1</td><td>-</td></tr><tr><td>Very large benefit</td><td>3064</td><td>30.9</td><td>-</td></tr><tr><td><i>Malpractice</i><sup>a</sup></td><td> </td><td> </td><td>4.6 (0.86)</td></tr><tr><td>To a very large extent</td><td>182</td><td>1.8</td><td>-</td></tr><tr><td>To a large extent</td><td>235</td><td>2.3</td><td>-</td></tr><tr><td>To some extent</td><td>653</td><td>6.4</td><td>-</td></tr><tr><td>To a small extent</td><td>1018</td><td>10.0</td><td>-</td></tr><tr><td>Not at all</td><td>8051</td><td>79.4</td><td>-</td></tr><tr><td colspan="4"><i>Patient-reported experiences</i><sup>b</sup></td></tr><tr><td>Waiting time (elective patients)</td><td>4535</td><td>-</td><td>64.0 (28.8)</td></tr><tr><td>Doctor services</td><td>10,153</td><td>-</td><td>73.7 (19.0)</td></tr><tr><td>Nursing services</td><td>10,245</td><td>-</td><td>75.4 (17.4)</td></tr><tr><td>Information</td><td>10,124</td><td>-</td><td>71.0 (21.0)</td></tr><tr><td>Contact with next of kin</td><td>7138</td><td>-</td><td>77.7 (20.8)</td></tr><tr><td>Standard</td><td>10,199</td><td>-</td><td>72.6 (17.2)</td></tr><tr><td>Organization</td><td>10,034</td><td>-</td><td>68.0 (20.2)</td></tr><tr><td>Discharge information</td><td>8114</td><td>-</td><td>58.3 (31.3)</td></tr><tr><td>Cooperation with other health services</td><td>6071</td><td>-</td><td>63.8 (29.8)</td></tr><tr><td colspan="4"><i>Sociodemographic variables</i></td></tr><tr><td>Age, years</td><td>10,477</td><td> </td><td>61.1 (17.9)</td></tr><tr><td>Gender, % women</td><td>10,477</td><td>55.1</td><td>-</td></tr><tr><td colspan="4">Self-perceived health</td></tr><tr><td> Excellent</td><td>693</td><td>7.5</td><td>-</td></tr><tr><td> Very good</td><td>1,755</td><td>19.0</td><td>-</td></tr><tr><td> Good</td><td>3,139</td><td>34.0</td><td>-</td></tr><tr><td> Rather good</td><td>2,477</td><td>26.8</td><td>-</td></tr><tr><td> Poor</td><td>1,162</td><td>12.6</td><td>-</td></tr><tr><td colspan="4">Education</td></tr><tr><td>Primary school</td><td>2,504</td><td>27.3</td><td>-</td></tr><tr><td> Secondary school</td><td>3,560</td><td>38.8</td><td>-</td></tr><tr><td> University/college &lt; 4 years</td><td>2,149</td><td>23.4</td><td>-</td></tr><tr><td> University/college 4 years or more</td><td>974</td><td>10.6</td><td>-</td></tr></table>
0bfda96b0f9de7240ae0325b695206c30a5a116fdfa022c073e7f7e97b4d1908.png
simple
<table><tr><td>Models (Prevent/Treatemnt)</td><td>Materials</td><td>Effect</td><td>Dose (Dose-Effect)</td><td>Bioactive Compounds</td><td>References</td></tr><tr><td>Rats treated with ethanol diet (Prevent)</td><td>Green tea</td><td>&#8593; Enzymes, non-enzymatic antioxidants; &#8595; lipid and protein oxidation</td><td>7 g/L in ethanol Lieber-DeCarli diet</td><td>Epicatechin, epicatechin gallate</td><td>[84]</td></tr><tr><td>Rats treated with ethanol (Prevent)</td><td><i>Ziziphus mauritiana</i> leaf</td><td>&#8595; ALT, AST, ALP, total bilirubin, CAT; &#8593; GSH-Px, glutathione reductase and SOD</td><td>200 and 400 mg/kg b.w. (Dose-effect)</td><td>Tannins, saponins and phenolic compounds</td><td>[42]</td></tr><tr><td>Rats sub-chronically exposed to ethanol (Prevent)</td><td><i>Amaranthus hypochondriacus</i> seed</td><td>&#8595; MDA, NADPH; &#8593; Cu, Zn-SOD</td><td>140 g/kg in diet</td><td>Total phenols</td><td>[87]</td></tr><tr><td>Mice with acute alcohol-induced liver injury (Prevent)</td><td>Peduncles of Hoveniadulcis</td><td>&#8595; ALT, AST, MDA; &#8593; SOD, GSH-Px</td><td>100, 350 and 600 mg/kg b.w. (Dose-effect)</td><td>Non-starch polysaccharide</td><td>[86]</td></tr><tr><td>Rats treated with ehanol (Prevent)</td><td>Methanolic extract from <i>Hammada scoparia</i> leaves</td><td>&#8595; Aminotransferase, glycogen synthase kinase-3 &#946;, lipid peroxidation; &#8593; GSH-Px</td><td>200 mg/kg b.w.</td><td>Phenolic compounds</td><td>[85]</td></tr><tr><td>Mice with chronic alcoholic liver damage (Prevent)</td><td>Jujube honey</td><td>&#8595; Lipoprotein oxidation, AST, ALT, MAD, 8-hydroxy-2-deoxyguanosine; &#8593; GSH-Px</td><td>27 and 54 g /kg b.w. (Dose-effect)</td><td>Phenolic acids</td><td>[88]</td></tr><tr><td>Mice with alcohol-induced hepatotoxicity (Treatment)</td><td>Freeze-dried, germinated and fermented mung bean</td><td>&#8593; Antioxidant levels, NO</td><td>200 and 1000 mg/kg b.w.</td><td></td><td>[89]</td></tr><tr><td>Chronic ethanol exposure in rats (Prevent)</td><td>Virgin olive oil</td><td>&#8595; Transaminases levels, hepatic lipid peroxidation; &#8593; GSH-Px, SOD and CAT</td><td>5% (wt/wt) in diet</td><td>Tocopherols, chlorophyll, total polyphenols</td><td>[90]</td></tr></table>
7770cfabb646ec0791e75897a22f8f40362a19e41c2a06faaa2386e142843926.png
complex
<table><tr><td>Ethical considerations</td><td>Supporting arguments</td><td>Opposing arguments</td><td>Questions to direct future research</td></tr><tr><td colspan="4">Tobacco harm reduction</td></tr><tr><td> Potential for smoking cessation</td><td>E-cigarettes may be as effective as the nicotine patch.</td><td>Inconclusive evidence of efficacy for smoking cessation.</td><td>What is the efficacy of nicotine and non-nicotine e-cigarettes for smoking cessation and reduction?</td></tr><tr><td>Potential for smoking reduction</td><td>Demonstrated in multiple studies.</td><td>Unlikely that cigarette reduction results in significant health benefits.</td><td>What is the long-term impact of dual use of e-cigarettes and tobacco cigarettes on health outcomes?</td></tr><tr><td colspan="4">Product safety</td></tr><tr><td rowspan="2"> Potential for long-term adverse effects</td><td>Unknown impact of long-term propylene glycol inhalation.</td><td rowspan="2">No documented serious adverse events to date.</td><td rowspan="2">What are the long-term safety implications of nicotine and non-nicotine e-cigarette use?</td></tr><tr><td>Propylene glycol inhalation causes short-term respiratory irritation.</td></tr><tr><td> Autonomy to use a product of unknown risk</td><td>Ethical imperative given informed consent.</td><td>Public health concerns trump individual rights.</td><td>How should consumer rights be weighed against public health concerns?</td></tr><tr><td colspan="4">Use among non-smokers</td></tr><tr><td> Potential to lead to nicotine addiction</td><td>Perceived harmlessness may lead never smokers to initiate e-cigarettes.</td><td>No evidence for increased nicotine addiction to cause net public health harms.</td><td>What is the long-term health impact of nicotine addiction?</td></tr><tr><td> Potential gateway effect</td><td>Nicotine acts as a priming agent for the brain.</td><td>Unclear implications for transitioning to tobacco cigarettes.</td><td>How many non-smokers initiating e-cigarettes transition to other tobacco products, including cigarettes?</td></tr><tr><td colspan="4">Use among youth</td></tr><tr><td rowspan="2"> Potential to lead to nicotine addiction</td><td>Minors require protection.</td><td rowspan="2">No evidence of increased nicotine addiction causing net public health harms.</td><td rowspan="2">How many youth initiating e-cigarettes report continuous long-term product use (1 year or longer)?</td></tr><tr><td>E-liquid flavorings are attractive to youth.</td></tr><tr><td> Potential gateway effect</td><td>Nicotine is a priming agent for the brain.</td><td>Unclear implications for transitioning to tobacco cigarettes.</td><td>How many youth initiating e-cigarettes transition to other tobacco products, including cigarettes?</td></tr><tr><td rowspan="2"> Nicotine poisoning among children</td><td>Increased calls to poison control centers.</td><td rowspan="2">None.</td><td rowspan="2">To what extent can the risk of nicotine poisoning among children be mitigated?</td></tr><tr><td>E-liquid flavors are appealing to youth.</td></tr><tr><td colspan="4">Use in public places</td></tr><tr><td rowspan="2"> Potential for passive vaping</td><td>Stem cell cytotoxicity.</td><td rowspan="2">Limited evidence that passive vaping poses significant health concerns.</td><td rowspan="2">What is the long-term impact of passive vaping and second-hand vapor exposure?</td></tr><tr><td>Aerosolized nicotine emissions.</td></tr><tr><td colspan="4">Renormalized smoking culture</td></tr><tr><td> Potential to subvert decades of anti-smoking efforts</td><td>Increased acceptability of smoke-like vapor and smoking behavior.</td><td>No evidence that e-cigarettes would be conflated with tobacco cigarettes.</td><td>How are the increased awareness and use of e-cigarettes affecting perceptions of cigarette smoking?</td></tr><tr><td colspan="4">Market ownership</td></tr><tr><td> Unethical collaboration with the tobacco industry</td><td>Public health endorsement of e-cigarettes increases tobacco company market share.</td><td>Possible necessity to collaborate with the tobacco industry to achieve public health gains.</td><td>What are the public health implications of tobacco industry ownership of major e-cigarette brands?</td></tr></table>
52c17a1020e47e5076dfaf23798ba48995a9610977915350caeada56ac446fd0.png
simple
<table><tr><td></td><td>Lesser illness severity (HoNOS &#8805;21) (n = 21)</td><td>Greater illness severity (HoNOS &lt;21) (n = 26)</td><td>P-value ( <i>t</i>-test)</td></tr><tr><td>Counts/ day</td><td>303697 (194674)</td><td>259940 (112820)</td><td>0.12 ns</td></tr><tr><td>Steps/ day</td><td>8563 (3996)</td><td>8562 (3237)</td><td>0.63 ns</td></tr><tr><td>Light activity (mins/day)</td><td>197 (42)</td><td>214 (48)</td><td>0.56 ns</td></tr><tr><td>Moderate activity (mins/day)</td><td>42 (28)</td><td>35 (25)</td><td>0.72 ns</td></tr><tr><td>Vigorous activity (mins/day)</td><td>5 (16)</td><td>2 (3)</td><td>0.05 ns</td></tr><tr><td>Wear time (mins/day)</td><td>784 (89)</td><td>809 (96)</td><td>0.5 ns</td></tr><tr><td>Sedentary time (mins/day)</td><td>540 (75)</td><td>559 (83)</td><td>0.65 ns</td></tr></table>
d6d42b3f929c18e41edd5e134b9d83b87daf5132a0a48ac0bbc74856d1674eea.png
complex
<table><tr><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="4">Genotyped (<i>n</i>)</td></tr><tr><td>DPS</td><td>Tributary/Region</td><td>MPG</td><td># pops</td><td>Lineage</td><td>Run</td><td>Min</td><td>Max</td><td>Mean</td><td>Total</td></tr><tr><td>Southwest WA</td><td>Columbia Estuary</td><td>n/a</td><td>4</td><td>Coastal</td><td>Winter</td><td>43</td><td>164</td><td>85.8</td><td>343</td></tr><tr><td>Lower Columbia</td><td>Clackamas</td><td>Cascade</td><td>4</td><td>Coastal</td><td>Mixed</td><td>43</td><td>92</td><td>60.3</td><td>241</td></tr><tr><td>Lower Columbia</td><td>Other</td><td>Cascade; Gorge</td><td>9</td><td>Coastal</td><td>Mixed</td><td>28</td><td>94</td><td>68.1</td><td>613</td></tr><tr><td>Upper Willamette</td><td>Willamette</td><td>Willamette</td><td>3</td><td>Coastal</td><td>Mixed</td><td>39</td><td>93</td><td>60.7</td><td>182</td></tr><tr><td>Upper Willamette</td><td>Willamette/West Side</td><td>Willamette</td><td>3</td><td>Coastal</td><td>Winter</td><td>25</td><td>30</td><td>27.0</td><td>81</td></tr><tr><td>Middle Columbia</td><td>Klickitat</td><td>Cascade East Slope</td><td>10</td><td>Inland</td><td>Summer</td><td>33</td><td>48</td><td>43.4</td><td>434</td></tr><tr><td>Middle Columbia</td><td>Deschutes</td><td>Cascade East Slope</td><td>5</td><td>Inland</td><td>Summer</td><td>31</td><td>63</td><td>51.4</td><td>257</td></tr><tr><td>Middle Columbia</td><td>John Day</td><td>John Day</td><td>10</td><td>Inland</td><td>Summer</td><td>18</td><td>107</td><td>36.3</td><td>363</td></tr><tr><td>Middle Columbia</td><td>Yakima</td><td>Yakima</td><td>7</td><td>Inland</td><td>Summer</td><td>21</td><td>59</td><td>36.9</td><td>258</td></tr><tr><td>Middle Columbia</td><td>Other</td><td>Mixed</td><td>7</td><td>Inland</td><td>Mixed</td><td>34</td><td>148</td><td>100.1</td><td>701</td></tr><tr><td>Upper Columbia</td><td>Wenatchee</td><td>Upper Columbia/East Slope Cascades</td><td>6</td><td>Inland</td><td>Summer</td><td>19</td><td>99</td><td>40.8</td><td>245</td></tr><tr><td>Upper Columbia</td><td>Other</td><td>Upper Columbia/East Slope Cascades</td><td>5</td><td>Inland</td><td>Summer</td><td>90</td><td>99</td><td>94.3</td><td>475</td></tr><tr><td>Snake</td><td>Lower Snake</td><td>Lower Snake</td><td>6</td><td>Inland</td><td>Summer</td><td>49</td><td>105</td><td>83.5</td><td>501</td></tr><tr><td>Snake</td><td>Lower Clearwater</td><td>Clearwater</td><td>5</td><td>Inland</td><td>Summer</td><td>49</td><td>156</td><td>107.8</td><td>539</td></tr><tr><td>Snake</td><td>M. F. Clearwater</td><td>Clearwater</td><td>14</td><td>Inland</td><td>Summer</td><td>35</td><td>99</td><td>56.4</td><td>789</td></tr><tr><td>Snake</td><td>S. F. Clearwater</td><td>Clearwater</td><td>4</td><td>Inland</td><td>Summer</td><td>36</td><td>104</td><td>57.8</td><td>231</td></tr><tr><td>Snake</td><td>Grande Ronde</td><td>Grande Ronde</td><td>7</td><td>Inland</td><td>Summer</td><td>45</td><td>95</td><td>62.7</td><td>439</td></tr><tr><td>Snake</td><td>Imnaha</td><td>Imnaha</td><td>4</td><td>Inland</td><td>Summer</td><td>23</td><td>61</td><td>41.5</td><td>166</td></tr><tr><td>Snake</td><td>S. F. Salmon</td><td>Salmon</td><td>4</td><td>Inland</td><td>Summer</td><td>39</td><td>45</td><td>43.5</td><td>174</td></tr><tr><td>Snake</td><td>M. F. Salmon</td><td>Salmon</td><td>8</td><td>Inland</td><td>Summer</td><td>23</td><td>84</td><td>48.3</td><td>386</td></tr><tr><td>Snake</td><td>Upper Salmon</td><td>Salmon</td><td>7</td><td>Inland</td><td>Summer</td><td>37</td><td>117</td><td>83.1</td><td>582</td></tr><tr><td>Snake</td><td>Other Salmon</td><td>Salmon</td><td>7</td><td>Inland</td><td>Summer</td><td>43</td><td>99</td><td>55.1</td><td>386</td></tr><tr><td>Snake</td><td>Hatchery</td><td>Mixed</td><td>6</td><td>Inland</td><td>Summer</td><td>89</td><td>146</td><td>104.2</td><td>625</td></tr><tr><td>Total</td><td></td><td></td><td>145</td><td></td><td></td><td></td><td></td><td></td><td>9011</td></tr></table>
b6db26e6122b4275b4e958fa89547c86af1dc336b4a3d9a196a4cfbc788d20ca.png
complex
<table><tr><td rowspan="2">Factor</td><td colspan="2">Discharged alive (<i>n</i> = 135)</td><td colspan="2">In-hospital death (<i>n</i> = 14)</td><td rowspan="2">Hazard Ratio (95% CI)</td><td rowspan="2"><i>P</i>-value</td></tr><tr><td>n</td><td>Summary</td><td>n</td><td>Summary</td></tr><tr><td>Etiology</td><td>122</td><td></td><td>14</td><td></td><td></td><td></td></tr><tr><td>Hepatitis</td><td></td><td>35 (28.7)</td><td></td><td>7 (50.0)</td><td>Reference</td><td></td></tr><tr><td>Alcoholic liver disease</td><td></td><td>26 (21.3)</td><td></td><td>3 (21.4)</td><td>0.34 (0.08, 1.4)</td><td>0.13</td></tr><tr><td>Cryptogenic disease</td><td></td><td>18 (14.8)</td><td></td><td>2 (14.3)</td><td>0.46 (0.09, 2.3)</td><td>0.33</td></tr><tr><td>NASH</td><td></td><td>17 (13.9)</td><td></td><td>1 (7.1)</td><td>0.16 (0.02, 1.3)</td><td>0.09</td></tr><tr><td>Others</td><td></td><td>8 (6.6)</td><td></td><td>0 (0.0)</td><td>0.16 (0.02, 1.3)</td><td>0.091</td></tr><tr><td>Albumin</td><td>129</td><td>3.1 &#177; 0.7</td><td>14</td><td>2.2 &#177; 0.8</td><td>0.34 (0.14,0.81)</td><td>0.015</td></tr><tr><td>Bilirubin</td><td>129</td><td>1.4 [0.9, 2.6]</td><td>14</td><td>11.0 [4.2, 17.3]</td><td>1.07 (1.02, 1.1)</td><td>0.007</td></tr><tr><td>Blood urea nitrogen</td><td>131</td><td>16 [11, 26]</td><td>14</td><td>34 [27, 60]</td><td>1.02 (1.01, 1.03)</td><td>&lt;0.001</td></tr><tr><td>Serum creatinine</td><td>131</td><td>0.86 [0.70, 1.2]</td><td>14</td><td>1.5 [1.2, 2.9]</td><td>1.6 (1.2, 2.3)</td><td>0.004</td></tr><tr><td>Hemoglobin</td><td>134</td><td>10.3 &#177; 2.3</td><td>14</td><td>8.5 &#177; 2.1</td><td>0.75 (0.55, 1.02)</td><td>0.064</td></tr><tr><td>Platelets</td><td>130</td><td>84.5 [57, 142]</td><td>14</td><td>64.5 [37, 92]</td><td>0.99 (0.98, 1.00)</td><td>0.13</td></tr><tr><td>INR</td><td>132</td><td>1.2 &#177; 0.24</td><td>14</td><td>2.0 &#177; 0.84</td><td>3.7 (2.1, 6.5)</td><td>&lt;0.001</td></tr><tr><td>Partial thromboplastin time</td><td>121</td><td>30.9 [27.5, 34.7]</td><td>14</td><td>43.3 [34.4, 63.6]</td><td>1.2 (1.04, 1.3)<sup>a</sup></td><td>0.009</td></tr><tr><td>Ascites</td><td>132</td><td></td><td>12</td><td></td><td>0.93 (0.49, 1.8)</td><td>0.83</td></tr><tr><td>None</td><td></td><td>74 (56.1)</td><td></td><td>5 (41.7)</td><td></td><td></td></tr><tr><td>Mild</td><td></td><td>20 (15.2)</td><td></td><td>1 (8.3)</td><td></td><td></td></tr><tr><td>Moderate/severe</td><td></td><td>38 (28.8)</td><td></td><td>6 (50.0)</td><td></td><td></td></tr><tr><td>Encephalopathy</td><td>131</td><td></td><td>11</td><td></td><td>2.1 (0.99,4.6)</td><td>0.052</td></tr><tr><td>None</td><td></td><td>114 (87.0)</td><td></td><td>4 (36.4)</td><td></td><td></td></tr><tr><td>Grade 1&#8211;2</td><td></td><td>14 (10.7)</td><td></td><td>6 (54.5)</td><td></td><td></td></tr><tr><td>Grade 3&#8211;4</td><td></td><td>3 (2.3)</td><td></td><td>1 (9.1)</td><td></td><td></td></tr><tr><td>MELD score</td><td>124</td><td>12.0 &#177; 5.1</td><td>14</td><td>27.0 &#177; 9.0</td><td>1.1 (1.08, 1.2)</td><td>&lt;0.001</td></tr><tr><td>CTP score</td><td>124</td><td>7.5 &#177; 1.9</td><td>11</td><td>11.0 &#177; 1.8</td><td>1.5 (1.1, 2.0)</td><td>0.005</td></tr><tr><td>Child-Pugh class</td><td>124</td><td></td><td>11</td><td></td><td>4.0 (1.2, 13.4)</td><td>0.025</td></tr><tr><td>A</td><td></td><td>46 (37.1)</td><td></td><td>0 (0.0)</td><td></td><td></td></tr><tr><td>B</td><td></td><td>59 (47.6)</td><td></td><td>3 (27.3)</td><td></td><td></td></tr><tr><td>C</td><td></td><td>19 (15.3)</td><td></td><td>8 (72.7)</td><td></td><td></td></tr></table>
4ac8a6eeb4d747d279acbc42a0a7f6fac655b211c96128139e78542572fe9888.png
complex
<table><tr><td></td><td colspan="3">Mean (&#956;g/L)</td><td colspan="3">Geometric mean (&#956;g/L)</td></tr><tr><td>Surrogate</td><td>Low</td><td>Medium</td><td>High</td><td>Low</td><td>Medium</td><td>High</td></tr><tr><td colspan="7">MEHP</td></tr><tr><td> Day 0</td><td>19.9</td><td>28.9</td><td>44.7</td><td>9.3</td><td>11.5</td><td>18.3</td></tr><tr><td> Day 1</td><td>9.5</td><td>55.7</td><td>19.4</td><td>5.1</td><td>26.3</td><td>11.0</td></tr><tr><td> Day 2</td><td>18.8</td><td>26.2</td><td>49.3</td><td>7.1</td><td>11.1</td><td>25.2</td></tr><tr><td> Day 30</td><td>5.6</td><td>44.9</td><td>37.6</td><td>4.4</td><td>24.3</td><td>14.2</td></tr><tr><td> Day 31</td><td>5.6</td><td>43.8</td><td>39.0</td><td>4.4</td><td>20.1</td><td>18.4</td></tr><tr><td> Day 32</td><td>23.6</td><td>23.2</td><td>48.6</td><td>11.2</td><td>9.2</td><td>20.5</td></tr><tr><td> Day 90</td><td>10.0</td><td>29.7</td><td>53.5</td><td>5.0</td><td>12.7</td><td>29.9</td></tr><tr><td> Day 91</td><td>9.5</td><td>30.1</td><td>53.5</td><td>5.1</td><td>14.3</td><td>24.8</td></tr><tr><td> Day 92</td><td>10.2</td><td>31.1</td><td>51.5</td><td>6.1</td><td>11.7</td><td>27.5</td></tr><tr><td colspan="7">MBzP</td></tr><tr><td> Day 0</td><td>4.9</td><td>11.2</td><td>14.3</td><td>3.1</td><td>7.5</td><td>13.2</td></tr><tr><td> Day 1</td><td>6.6</td><td>9.3</td><td>15.2</td><td>2.9</td><td>7.8</td><td>13.3</td></tr><tr><td> Day 2</td><td>7.8</td><td>9.2</td><td>14.0</td><td>4.3</td><td>6.0</td><td>12.8</td></tr><tr><td> Day 30</td><td>6.3</td><td>11.2</td><td>12.8</td><td>3.9</td><td>8.5</td><td>8.9</td></tr><tr><td> Day 31</td><td>6.6</td><td>10.1</td><td>14.0</td><td>2.9</td><td>8.0</td><td>12.8</td></tr><tr><td> Day 32</td><td>7.2</td><td>10.1</td><td>13.4</td><td>3.5</td><td>7.5</td><td>11.9</td></tr><tr><td> Day 90</td><td>8.3</td><td>11.1</td><td>11.0</td><td>4.2</td><td>7.8</td><td>9.2</td></tr><tr><td> Day 91</td><td>8.0</td><td>9.9</td><td>12.9</td><td>3.7</td><td>7.8</td><td>10.6</td></tr><tr><td> Day 92</td><td>7.2</td><td>9.9</td><td>13.7</td><td>3.5</td><td>7.8</td><td>11.3</td></tr><tr><td colspan="7">MEP</td></tr><tr><td> Day 0</td><td>73.2</td><td>158.4</td><td>172</td><td>28.9</td><td>46.8</td><td>94.4</td></tr><tr><td> Day 1</td><td>26.6</td><td>199.6</td><td>163</td><td>15.8</td><td>98.3</td><td>64.1</td></tr><tr><td> Day 2</td><td>30.2</td><td>113</td><td>276</td><td>6.2</td><td>70.2</td><td>97.8</td></tr><tr><td> Day 30</td><td>146</td><td>92.8</td><td>186</td><td>24.4</td><td>39.7</td><td>139</td></tr><tr><td> Day 31</td><td>26.6</td><td>104</td><td>291</td><td>15.8</td><td>53.1</td><td>146</td></tr><tr><td> Day 32</td><td>26.6</td><td>182</td><td>186</td><td>15.8</td><td>55.0</td><td>139</td></tr><tr><td> Day 90</td><td>30.2</td><td>158</td><td>216</td><td>16.2</td><td>50.2</td><td>153</td></tr><tr><td> Day 91</td><td>33.4</td><td>155</td><td>216</td><td>16.0</td><td>50.7</td><td>153</td></tr><tr><td> Day 92</td><td>63.9</td><td>132</td><td>216</td><td>20.3</td><td>42.4</td><td>153</td></tr><tr><td colspan="7">MBP</td></tr><tr><td> Day 0</td><td>16.3</td><td>30</td><td>30.5</td><td>12.7</td><td>22.8</td><td>28.3</td></tr><tr><td> Day 1</td><td>16.7</td><td>24.9</td><td>37.3</td><td>13.1</td><td>21.6</td><td>29.3</td></tr><tr><td> Day 2</td><td>16.7</td><td>26.3</td><td>35.5</td><td>13.1</td><td>20.5</td><td>31.4</td></tr><tr><td> Day 30</td><td>18.0</td><td>23.4</td><td>38.1</td><td>13.5</td><td>18.6</td><td>34.7</td></tr><tr><td> Day 31</td><td>16.3</td><td>27.7</td><td>34.0</td><td>12.7</td><td>22.7</td><td>28.5</td></tr><tr><td> Day 32</td><td>16.7</td><td>27.7</td><td>33.6</td><td>13.1</td><td>22.7</td><td>27.6</td></tr><tr><td> Day 90</td><td>26.4</td><td>24.4</td><td>28.4</td><td>19.8</td><td>21.6</td><td>19.4</td></tr><tr><td> Day 91</td><td>21.7</td><td>22.0</td><td>36.3</td><td>14.4</td><td>18.7</td><td>32.3</td></tr><tr><td> Day 92</td><td>21.3</td><td>26.6</td><td>30.5</td><td>13.9</td><td>21.3</td><td>28.3</td></tr><tr><td colspan="7">MMP</td></tr><tr><td> Day 0</td><td>4.2</td><td>7.9</td><td>30.2</td><td>2.0</td><td>5.6</td><td>23.2</td></tr><tr><td> Day 1</td><td>4.0</td><td>9.4</td><td>28.3</td><td>2.4</td><td>5.2</td><td>21.3</td></tr><tr><td> Day 2</td><td>5.0</td><td>7.3</td><td>30.2</td><td>4.1</td><td>3.3</td><td>23.2</td></tr><tr><td> Day 30</td><td>3.9</td><td>8.1</td><td>30.2</td><td>2.1</td><td>5.3</td><td>23.2</td></tr><tr><td> Day 31</td><td>4.3</td><td>9.2</td><td>28.3</td><td>2.5</td><td>5.0</td><td>21.3</td></tr><tr><td> Day 32</td><td>4.9</td><td>11.5</td><td>24.8</td><td>3.3</td><td>5.7</td><td>13.7</td></tr><tr><td> Day 90</td><td>4.2</td><td>12.4</td><td>24.3</td><td>2.0</td><td>6.2</td><td>19.9</td></tr><tr><td> Day 91</td><td>4.3</td><td>12.3</td><td>24.3</td><td>2.5</td><td>5.3</td><td>19.9</td></tr><tr><td> Day 92</td><td>4.0</td><td>12.5</td><td>24.3</td><td>2.2</td><td>5.8</td><td>19.9</td></tr></table>
f7071e88683d05b7fb3c20114ecf2a33e16c28da0ce828603767a3e5d184c45a.png
complex
<table><tr><td></td><td></td><td>MBS-RK</td><td>MBS-VK</td><td>RK-VK</td></tr><tr><td rowspan="2">Shoulder joint angle</td><td><i>RMSE</i></td><td>9.5&#176; (&#177;2.9)</td><td>5.2&#176; (&#177;1.5)</td><td>8.5&#176; (&#177;3.6)</td></tr><tr><td><i>p</i></td><td>0.83</td><td>0.92</td><td>0.86</td></tr><tr><td rowspan="2">Elbow joint angle</td><td><i>RMSE</i></td><td>11.4&#176; (&#177;2.0)</td><td>8.2&#176; (&#177;1.3)</td><td>13.0&#176; (&#177;2.3)</td></tr><tr><td><i>p</i></td><td>0.97</td><td>0.98</td><td>0.96</td></tr></table>
9313a785b7e3b9905b009d78fe52ccd061df7d47916de2aad21b6618ae55caf4.png
simple
<table><tr><td> </td><td>Johnson <i>et al</i>.</td><td>Dong <i>et al.</i></td></tr><tr><td>Probe length (nucleotides)</td><td>60</td><td>60</td></tr><tr><td>Median genomic region between probes (nucleotides)</td><td>10</td><td>153</td></tr><tr><td>Number of probes/array</td><td>244 000</td><td>44 000</td></tr><tr><td>Average length of DNA segment hybridized to the array</td><td>497</td><td>600</td></tr><tr><td>Amplification technique</td><td>Ligation-Mediated Amplification</td><td>Whole Genome Amplification</td></tr></table>
3ce5655cb2b0246076126d0eb63c6b2bcc6cfc82927983f6cda08c65478d0348.png
complex
<table><tr><td></td><td colspan="5">Estimates derived by U.S. EPA (2005)</td><td colspan="5">Estimates derived using the Kwon et al. data</td></tr><tr><td>Pathway</td><td>Mean</td><td>50th</td><td>75th</td><td>95th</td><td>99th</td><td>Mean</td><td>50th</td><td>75th</td><td>95th</td><td>99th</td></tr><tr><td>Total (playset + deck)</td><td>11.0</td><td>6.1</td><td>13.0</td><td>39.0</td><td>84.0</td><td>3.0</td><td>2.7</td><td>3.7</td><td>5.6</td><td>8.1</td></tr><tr><td>Total playset</td><td>5.4</td><td>3.0</td><td>5.9</td><td>18.0</td><td>38.0</td><td>1.7</td><td>1.4</td><td>2.2</td><td>3.9</td><td>7.0</td></tr><tr><td>Residue ingestion from playset</td><td>3.1</td><td>1.2</td><td>3.3</td><td>12.0</td><td>26.0</td><td>0.7</td><td>0.6</td><td>0.9</td><td>1.8</td><td>2.5</td></tr><tr><td>Soil ingestion from playset</td><td>0.7</td><td>0.2</td><td>0.7</td><td>2.8</td><td>6.7</td><td>0.5</td><td>0.2</td><td>0.6</td><td>2.1</td><td>4.5</td></tr><tr><td>Residue dermal contact from playset</td><td>1.5</td><td>0.7</td><td>1.8</td><td>6.0</td><td>13.0</td><td>0.4</td><td>0.4</td><td>0.6</td><td>0.8</td><td>1.1</td></tr><tr><td>Soil dermal contact from playset</td><td>0.1</td><td>0.1</td><td>0.2</td><td>0.4</td><td>0.8</td><td>0.1</td><td>0.0</td><td>0.1</td><td>0.2</td><td>0.4</td></tr><tr><td>Total deck</td><td>5.9</td><td>2.8</td><td>6.6</td><td>21.0</td><td>48.0</td><td>1.2</td><td>1.2</td><td>1.6</td><td>2.3</td><td>2.8</td></tr><tr><td>Residue ingestion from deck</td><td>3.6</td><td>1.5</td><td>3.9</td><td>13.0</td><td>33.0</td><td>0.7</td><td>0.6</td><td>0.9</td><td>1.4</td><td>2.0</td></tr><tr><td>Soil ingestion from deck</td><td>0.1</td><td>0.0</td><td>0.1</td><td>0.4</td><td>1.3</td><td>0.1</td><td>0.0</td><td>0.1</td><td>0.4</td><td>0.8</td></tr><tr><td>Residue dermal contact from deck</td><td>2.2</td><td>1.0</td><td>2.4</td><td>8.0</td><td>18.0</td><td>0.5</td><td>0.5</td><td>0.6</td><td>0.8</td><td>1.0</td></tr><tr><td>Soil dermal contact from deck</td><td>0.0</td><td>0.0</td><td>0.0</td><td>0.1</td><td>0.2</td><td>0.0</td><td>0.0</td><td>0.0</td><td>0.1</td><td>0.1</td></tr></table>
0e24deb1b7db78730109b76574ce5d5b26666bd15281b5b8bcfa24c232c222f6.png
complex
<table><tr><td> </td><td colspan="3">All women</td><td colspan="3">Women 66-79 years</td><td colspan="3">Women 80+ years</td></tr><tr><td> </td><td>HRR</td><td>95% Conf int</td><td>P value</td><td>HRR</td><td>95% Conf int</td><td>P value</td><td>HRR</td><td>95% Conf int</td><td>P value</td></tr><tr><td colspan="10">Recurrent MI/Fatal CHD (29 days-365 days)</td></tr><tr><td>N (Events)</td><td>6,528</td><td>(889)</td><td> </td><td>3,646</td><td>(375)</td><td> </td><td>2,882</td><td>(514)</td><td> </td></tr><tr><td>Ed &lt; HS</td><td>1.07</td><td>(0.77, 1.48)</td><td>0.698</td><td>1.40</td><td>(0.79, 2.48)</td><td>0.245</td><td>0.97</td><td>(0.65, 1.44)</td><td>0.869</td></tr><tr><td>Ed HS &lt; BS</td><td>1.01</td><td>(0.73, 1.40)</td><td>0.957</td><td>1.44</td><td>(0.82, 2.55)</td><td>0.206</td><td>0.87</td><td>(0.58, 1.31)</td><td>0.504</td></tr><tr><td>Zip Inc q1</td><td>1.02</td><td>(0.77, 1.33)</td><td>0.914</td><td>0.89</td><td>(0.59, 1.32)</td><td>0.555</td><td>1.11</td><td>(0.77, 1.60)</td><td>0.580</td></tr><tr><td>Zip Inc q2</td><td>1.09</td><td>(0.86, 1.39)</td><td>0.465</td><td>0.91</td><td>(0.64, 1.29)</td><td>0.602</td><td>1.24</td><td>(0.90, 1.71)</td><td>0.198</td></tr><tr><td>Zip Inc q3</td><td>1.04</td><td>(0.83, 1.30)</td><td>0.740</td><td>0.87</td><td>(0.62, 1.20)</td><td>0.394</td><td>1.19</td><td>(0.88, 1.60)</td><td>0.263</td></tr><tr><td>Zip Inc q4</td><td>1.00</td><td>(0.80, 1.25)</td><td>0.983</td><td>0.81</td><td>(0.58, 1.14)</td><td>0.228</td><td>1.17</td><td>(0.87, 1.59)</td><td>0.296</td></tr><tr><td colspan="10">Recurrent MI/Fatal CHD (366 days-5 years)</td></tr><tr><td>N (Events)</td><td>4,681</td><td>(833)</td><td> </td><td>2,837</td><td>(402)</td><td> </td><td>1,844</td><td>(431)</td><td> </td></tr><tr><td>Ed &lt; HS</td><td>1.36</td><td>(0.99, 1.88)</td><td>0.060</td><td>1.19</td><td>(0.76, 1.88)</td><td>0.445</td><td>1.52</td><td>(0.98, 2.37)</td><td>0.064</td></tr><tr><td>Ed HS &lt; BS</td><td>1.17</td><td>(0.85, 1.62)</td><td>0.335</td><td>0.92</td><td>(0.58, 1.44)</td><td>0.700</td><td>1.46</td><td>(0.94, 2.27)</td><td>0.096</td></tr><tr><td>Zip Inc q1</td><td>0.80</td><td>(0.61, 1.05)</td><td>0.104</td><td>0.78</td><td>(0.52, 1.17)</td><td>0.226</td><td>0.82</td><td>(0.57, 1.19)</td><td>0.300</td></tr><tr><td>Zip Inc q2</td><td>0.97</td><td>(0.77, 1.22)</td><td>0.816</td><td>1.06</td><td>(0.77, 1.46)</td><td>0.717</td><td>0.89</td><td>(0.65, 1.23)</td><td>0.493</td></tr><tr><td>Zip Inc q3</td><td>0.88</td><td>(0.71, 1.09)</td><td>0.235</td><td>0.88</td><td>(0.64, 1.20)</td><td>0.421</td><td>0.89</td><td>(0.66, 1.20)</td><td>0.429</td></tr><tr><td>Zip Inc q4</td><td><i>0.70</i></td><td><i>(0.56, 0.87)</i></td><td><i>0.002</i></td><td>0.75</td><td>(0.54, 1.03)</td><td>0.072</td><td><i>0.65</i></td><td><i>(0.47, 0.90)</i></td><td><i>0.009</i></td></tr></table>
909a476e9832e461160907d809882a3aa8bc1e11ed021f455de08f176a466942.png
complex
<table><tr><td></td><td></td><td colspan="3">EmA</td><td></td><td colspan="3">TG2-ab (U)</td></tr><tr><td>Patient</td><td>GFD years</td><td>Medium 24 h</td><td>PT-gliadin 24 h</td><td>PT-gliadin 48 h</td><td></td><td>Medium 24 h</td><td>PT-gliadin 24 h</td><td>PT-gliadin 48 h</td></tr><tr><td>12</td><td>1</td><td>neg</td><td>neg</td><td>neg</td><td></td><td>2.0</td><td>4.8</td><td>13.3</td></tr><tr><td>13</td><td>2</td><td>neg</td><td>neg</td><td>neg</td><td></td><td>8.8</td><td>6.9</td><td>4.4</td></tr><tr><td>14</td><td>4</td><td>neg</td><td>neg</td><td>neg</td><td></td><td>2.2</td><td>6.2</td><td>10.3</td></tr><tr><td>15</td><td>4</td><td>neg</td><td>neg</td><td>neg</td><td></td><td>2.5</td><td>1.7</td><td>2.6</td></tr><tr><td>16</td><td>6</td><td>neg</td><td>neg</td><td>neg</td><td></td><td>8.1</td><td>7.7</td><td>12.4</td></tr><tr><td>17</td><td>7</td><td>neg</td><td>neg</td><td>neg</td><td></td><td>2.4</td><td>3.7</td><td>1.9</td></tr><tr><td>18</td><td>8</td><td>neg</td><td>neg</td><td>neg</td><td></td><td>2.5</td><td>1.3</td><td>1.7</td></tr><tr><td>19</td><td>14</td><td>neg</td><td>neg</td><td>neg</td><td></td><td>0.9</td><td>2.9</td><td>0.7</td></tr><tr><td>20</td><td>20</td><td>neg</td><td>neg</td><td>neg</td><td></td><td>11.6</td><td>2.5</td><td>11.6</td></tr><tr><td>Median</td><td></td><td>neg</td><td>neg</td><td>neg</td><td>Median</td><td>2.5</td><td>3.7</td><td>4.4*</td></tr></table>
a7301f2e3f2dde260d9c75e0f92dadc234163739b98f6699beaca0907efe896f.png
complex
<table><tr><td rowspan="2">Case number</td><td colspan="2">Date of collection*</td><td colspan="2">Temperature (&#176;C)&#8224;</td><td colspan="2">Humidity (%)&#8224;</td></tr><tr><td>Pre&#8225;</td><td>Post</td><td>Pre</td><td>Post</td><td>Pre</td><td>Post</td></tr><tr><td>6</td><td>June 30</td><td>July 21</td><td>24.6</td><td>28.3</td><td>78.1</td><td>61.3</td></tr><tr><td>7</td><td>July 9</td><td>July 30</td><td>26.3</td><td>30.1</td><td>65.4</td><td>62.3</td></tr><tr><td>8 (R) and 8 (O)&#167;</td><td>July 13</td><td>August 3</td><td>26.3</td><td>29.1</td><td>69.1</td><td>65.4</td></tr><tr><td>9</td><td>July 28</td><td>August 18</td><td>29.7</td><td>28.9</td><td>79.0</td><td>79.3</td></tr><tr><td>10</td><td>August 19</td><td>September 9</td><td>28.9</td><td>27.6</td><td>69.5</td><td>71.7</td></tr><tr><td>11</td><td>August 26</td><td>September 16</td><td>24.6</td><td>23.8</td><td>82.9</td><td>84.8</td></tr><tr><td>12</td><td>September 14</td><td>October 5</td><td>24.5</td><td>23.3</td><td>64.1</td><td>82.0</td></tr><tr><td>13</td><td>September 19</td><td>October 10</td><td>22.0</td><td>21.5</td><td>69.3</td><td>55.1</td></tr><tr><td>14</td><td>September 23</td><td>October 14</td><td>21.4</td><td>20.6</td><td>57.9</td><td>61.8</td></tr></table>
374f292fdac3ae839a0078452232de95ce34d30ccfa8d9f9a6c9d882a48c6c75.png
complex
<table><tr><td>Main options</td><td>Choices among main options</td><td>Ancillary manoeuvres among main option and choices</td></tr><tr><td>Loop colostomy (C) (bridge to resection or palliation)</td><td></td><td></td></tr><tr><td>Primary resection with end colostomy: Hartmann&#8217;s procedure (HP)</td><td></td><td></td></tr><tr><td rowspan="2">Resection and primary anastomosis (RPA)</td><td>Total/subtotal colectomy (TC)</td><td rowspan="2">Intraoperative colonic irrigation (ICI)Manual decompression (MD)Covering stoma</td></tr><tr><td>Segmental colectomy (SC)</td></tr><tr><td>Tube decompression</td><td></td><td></td></tr><tr><td rowspan="2">Endoscopic colonic stenting by self-expanding metallic stents (SEMS)</td><td>Bridge to surgery</td><td rowspan="2"></td></tr><tr><td>Palliation</td></tr></table>
0c07f94fd0495346e434c161669357918d86a6878ccd8cbefcf18faaced88c06.png
complex
<table><tr><td rowspan="2">Factor</td><td rowspan="2">Subgroup</td><td>Patients on glargine</td><td>Patients on other types of insulin</td><td rowspan="2">p-value</td></tr><tr><td>(N = 13)</td><td>(N = 66)</td></tr><tr><td rowspan="2">Breast surgical procedure</td><td rowspan="2">Quadrantectomy or lumpectomy Mastectomy</td><td>7</td><td>23</td><td rowspan="2">0.20</td></tr><tr><td>6</td><td>43</td></tr><tr><td rowspan="2">Axillary surgical procedure</td><td>Sentinel node biopsy</td><td>5</td><td>24</td><td rowspan="2">0.78</td></tr><tr><td>Lymphadenectomy</td><td>8</td><td>42</td></tr><tr><td rowspan="2">Adjuvant Chemotherapy</td><td>No</td><td>9</td><td>50</td><td rowspan="2">0.72</td></tr><tr><td>Yes</td><td>4</td><td>16</td></tr><tr><td rowspan="2">Adjuvant Hormone therapy</td><td>No</td><td>3</td><td>6</td><td rowspan="2">0.17</td></tr><tr><td>Yes</td><td>10</td><td>60</td></tr><tr><td rowspan="2">Adjuvant Trastuzumab</td><td>No</td><td>13</td><td>62</td><td rowspan="2">1.00</td></tr><tr><td>Yes</td><td>0</td><td>4</td></tr><tr><td rowspan="2">Adjuvant Radiotherapy</td><td>No</td><td>5</td><td>32</td><td rowspan="2">0.49</td></tr><tr><td>Yes</td><td>8</td><td>34</td></tr><tr><td rowspan="2">Outcome</td><td>Alive</td><td>13</td><td>63</td><td rowspan="2">1.00</td></tr><tr><td>Died of disease</td><td>0</td><td>3</td></tr></table>
0089178261f38f4b10f9e8aee50d026bb98e380c4c527f87cfd2db99aa08c1e5.png
complex
<table><tr><td>SNP IDHit Orientation</td><td>Group</td><td colspan="3">Genotype Frequency</td><td colspan="2">Allele Frequency</td><td>Association SignificanceP-value/Odds ratio (95% CI)</td></tr><tr><td>rs35069869</td><td>Women</td><td>AA</td><td>AG</td><td>GG</td><td>A</td><td>G</td><td></td></tr><tr><td>A/G</td><td>T1D without DN</td><td>174 (0.489)</td><td>153 (0.430)</td><td>29 (0.081)</td><td>0.704</td><td>0.211</td><td></td></tr><tr><td></td><td>T1D with DN</td><td>135 (0.509)</td><td>109 (0.411)</td><td>21 (0.079)</td><td>0.715</td><td>0.285</td><td>0.661 <sup>a</sup></td></tr><tr><td></td><td>Men</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>T1D without DN</td><td>125 (0.519)</td><td>101 (0.419)</td><td>15 (0.062)</td><td>0.728</td><td>0.272</td><td></td></tr><tr><td></td><td>T1D with DN</td><td>150 (0.479)</td><td>137 (0.438)</td><td>26 (0.083)</td><td>0.698</td><td>0.302</td><td>0.273 <sup>a</sup></td></tr><tr><td>rs35368790</td><td>Women</td><td>GG</td><td>GC</td><td>CC</td><td>G</td><td>C</td><td></td></tr><tr><td>G/C</td><td>T1D without DN</td><td>168 (0.471)</td><td>151 (0.423)</td><td>38 (0.106)</td><td>0.682</td><td>0.318</td><td></td></tr><tr><td></td><td>T1D with DN</td><td>134 (0.511)</td><td>107 (0.408)</td><td>33 (0.105)</td><td>0.716</td><td>0.284</td><td>0.204 <sup>a</sup></td></tr><tr><td></td><td>Men</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>T1D without DN</td><td>107 (0.442)</td><td>110 (0.455)</td><td>25 (0.103)</td><td>0.669</td><td>0.331</td><td></td></tr><tr><td></td><td>T1D with DN</td><td>146 (0.466)</td><td>134 (0.428)</td><td>33 (0.105)</td><td>0.681</td><td>0.319</td><td>0.696 <sup>a</sup></td></tr><tr><td>rs7639705</td><td>Women</td><td>TT</td><td>TG</td><td>GG</td><td>T</td><td>G</td><td></td></tr><tr><td>T1165G</td><td>T1D without DN</td><td>213 (0.603) </td><td>125 (0.354)</td><td>15 (0.043)</td><td>0.780</td><td>0.220</td><td></td></tr><tr><td>Leu359Ile</td><td>T1D with DN</td><td>188 (0.712)</td><td>65 (0.246)</td><td>11 (0.042)</td><td>0.835</td><td>0.165</td><td>0.017/0.701 (0.524-0.938) <sup>a</sup>0.018/0.757 <sup>b</sup></td></tr><tr><td></td><td>Men</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>T1D without DN</td><td>157 (0.651)</td><td>73 (0.303)</td><td>11 (0.046)</td><td>0.803</td><td>0.197</td><td></td></tr><tr><td></td><td>T1D with DN</td><td>183 (0.590)</td><td>115 (0.371)</td><td>12 (0.039)</td><td>0.776</td><td>0.224</td><td>0.275 <sup>a</sup></td></tr></table>
92a747f5dc78344d233405b2c6e238f862f5557885e63e21f829ae2701df81ff.png
complex
<table><tr><td rowspan="2"></td><td>Systemic</td><td>Oligoarthritis</td><td>RF &#8722; poly-arthritis</td><td>RF + poly-arthritis</td><td>Enthesitis-related arthritis</td><td>All JIA patients</td><td>Healthy</td></tr><tr><td><i>N</i> = 25</td><td><i>N</i> = 19</td><td><i>N</i> = 38</td><td><i>N</i> = 3</td><td><i>N</i> = 15</td><td><i>N</i> = 100</td><td><i>N</i> = 198</td></tr><tr><td>Female</td><td>17 (68%)</td><td>13 (68.4%)</td><td>28 (73.7%)</td><td>3 (100%)</td><td>7 (46.7%)</td><td>68 (68%)</td><td>98 (49.5%)*</td></tr><tr><td>Age at visit</td><td>9.7 (5.5&#8211;13.8)</td><td>13.1 (10.9&#8211;15.2)</td><td>14.1 (10.3&#8211;16.2)</td><td>17.1 (16&#8211;17.9)</td><td>13.1 (9.5&#8211;16.2)</td><td>12.9 (9.6&#8211;16)*</td><td>10.4 (8.7&#8211;12.7)*</td></tr><tr><td>Age at onset</td><td>2.7 (2&#8211;5.8)</td><td>4 (3&#8211;6.2)</td><td>4.9 (2&#8211;7.2)</td><td>10 (9&#8211;14.7)</td><td>8.6 (3.9&#8211;10.7)</td><td>4.8 (2.2&#8211;7.4)*</td><td></td></tr><tr><td>Disease duration</td><td>4.5 (1.1&#8211;8.9)</td><td>8.1 (5.4&#8211;11.2)</td><td>9 (4.7&#8211;11.1)</td><td>7.9 (1.3&#8211;8.1)</td><td>4.7 (1.5&#8211;7.2)</td><td>7.4 (2.6&#8211;10.2)*</td><td></td></tr><tr><td>ESR</td><td>15 (7&#8211;22)</td><td>9 (9&#8211;15)</td><td>12.5 (8&#8211;19)</td><td>(&#8211;)</td><td>11 (3&#8211;14)</td><td>12 (8&#8211;18)</td><td></td></tr><tr><td>MD VAS (0&#8211;10 cm)</td><td>1.5 (0.5&#8211;4)</td><td>1.5 (1&#8211;3)</td><td>3.3 (1&#8211;4.5)</td><td>1 (0.5&#8211;1.5)</td><td>1.5 (0.5&#8211;3)</td><td>2 (0.5&#8211;3.8)</td><td></td></tr><tr><td>No. of swollen joints</td><td>0 (0&#8211;1)</td><td>0 (0&#8211;2)</td><td>1.5 (0&#8211;4)</td><td>0 (0&#8211;1)</td><td>1 (0&#8211;2)</td><td>0 (0&#8211;3)</td><td></td></tr><tr><td>No. of joints with pain</td><td>0 (0&#8211;0)</td><td>0 (0&#8211;0)</td><td>0 (0&#8211;0)</td><td>0 (0&#8211;0)</td><td>0 (0&#8211;0)</td><td>0 (0&#8211;0)</td><td></td></tr><tr><td>No. of joints with LOM</td><td>0 (0&#8211;0)</td><td>0 (0&#8211;0)</td><td>0 (0&#8211;0)</td><td>0 (0&#8211;0)</td><td>0 (0&#8211;0)</td><td>0 (0&#8211;0)</td><td></td></tr><tr><td>No. of active joints</td><td>0 (0&#8211;2)</td><td>0 (0&#8211;2)</td><td>1.5 (0&#8211;4)</td><td>0 (0&#8211;1)</td><td>1 (0&#8211;2)</td><td>1 (0&#8211;3)</td><td></td></tr><tr><td>Active systemic features</td><td>1 (4%)</td><td>0 (0%)</td><td>0 (0%)</td><td>0 (0%)</td><td>0 (0%)</td><td>1 (1%)</td><td></td></tr><tr><td>ANA status</td><td>0 (0%)</td><td>0 (0%)</td><td>0 (0%)</td><td>0 (0%)</td><td>0 (0%)</td><td>0 (0%)</td><td></td></tr><tr><td>Uveitis</td><td>0 (0%)</td><td>1 (5.3%)</td><td>1 (2.6%)</td><td>0 (0%)</td><td>0 (0%)</td><td>2 (2%)</td><td></td></tr><tr><td>PF total score</td><td>0 (0&#8211;5)</td><td>0 (0&#8211;1)</td><td>1.5 (0&#8211;4)</td><td>0 (0&#8211;3)</td><td>1 (0&#8211;3)</td><td>0 (0&#8211;3.5)</td><td>0 (0&#8211;0)<sup>#</sup></td></tr><tr><td>Pain VAS</td><td>1 (0&#8211;4)</td><td>1.5 (0.5&#8211;3.5)</td><td>2 (1&#8211;5)</td><td>1 (0&#8211;1.5)</td><td>1.5 (0.5&#8211;4)</td><td>1.5 (0.5&#8211;4)</td><td>0 (0&#8211;0)<sup>#</sup></td></tr><tr><td>Disease activity VAS</td><td>1.5 (0.5&#8211;4)</td><td>1 (0.5&#8211;1.5)</td><td>2.8 (1&#8211;5)</td><td>1 (0&#8211;1)</td><td>1.5 (1&#8211;3.5)</td><td>1.5 (0.5&#8211;4)</td><td></td></tr><tr><td>Well-being VAS</td><td>1.5 (0.5&#8211;3.5)</td><td>2 (0.5&#8211;4)</td><td>2.8 (1&#8211;4)</td><td>0.5 (0&#8211;2)</td><td>1.5 (0.5&#8211;4)</td><td>2 (0.5&#8211;3.8)</td><td></td></tr><tr><td>HRQoL-PhH</td><td>2 (0&#8211;4)</td><td>0 (0&#8211;1)</td><td>1 (0&#8211;3)</td><td>0 (0&#8211;2)</td><td>1 (0&#8211;2)</td><td>1 (0&#8211;3)</td><td>0 (0&#8211;0)<sup>#</sup></td></tr><tr><td>HRQoL-PsH</td><td>3 (0&#8211;5)</td><td>1 (0&#8211;3)</td><td>1.5 (0&#8211;3)</td><td>0 (0&#8211;4)</td><td>3 (1&#8211;3)</td><td>2 (0&#8211;3)</td><td>0 (0&#8211;1)<sup>#</sup></td></tr><tr><td>HRQoL total score</td><td>5 (1&#8211;9)</td><td>3 (0&#8211;3)</td><td>3 (0&#8211;6)</td><td>2 (0&#8211;4)</td><td>3 (1&#8211;5)</td><td>3 (0&#8211;5)</td><td>0 (0&#8211;1)<sup>#</sup></td></tr><tr><td>Pain/swell. in &gt; 1 joint</td><td>7 (28%)</td><td>7 (36.8%)</td><td>22 (57.9%)</td><td>0 (0%)</td><td>9 (60%)</td><td>45 (45%)*</td><td>0 (0%)<sup>#</sup></td></tr><tr><td>Morning stiffness &gt; 15 min</td><td>2 (8%)</td><td>0 (0%)</td><td>7 (18.4%)</td><td>0 (0%)</td><td>1 (6.7%)</td><td>10 (10%)</td><td>0 (0%)<sup>#</sup></td></tr><tr><td>Subjective remission</td><td>9 (36%)</td><td>3 (15.8%)</td><td>18 (47.4%)</td><td>0 (0%)</td><td>4 (26.7%)</td><td>34 (34%)</td><td></td></tr><tr><td>In treatment</td><td>23 (92%)</td><td>19 (100%)</td><td>38 (100%)</td><td>3 (100%)</td><td>13 (86.7%)</td><td>96 (96%)</td><td></td></tr><tr><td>Reporting side effects</td><td>5/23 (21.7%)</td><td>1 (5.3%)</td><td>5 (13.2%)</td><td>0 (0%)</td><td>1/13 (7.7%)</td><td>12/96 (12.5%)</td><td></td></tr><tr><td>Taking medication regularly</td><td>22/23 (95.7%)</td><td>19 (100%)</td><td>36 (94.7%)</td><td>2 (66.7%)</td><td>13/13 (100%)</td><td>92/96 (95.8%)</td><td></td></tr><tr><td>With problems attending school</td><td>0 (0%)</td><td>0 (0%)</td><td>3/31 (9.7%)</td><td>0 (0%)</td><td>0 (0%)</td><td>3/75 (4%)</td><td>0 (0%)*</td></tr><tr><td>Satisfied with disease outcome</td><td>23 (92%)</td><td>19 (100%)</td><td>33 (86.8%)</td><td>3 (100%)</td><td>14 (93.3%)</td><td>92 (92%)</td><td></td></tr></table>
44f32cbacb1911a5e05d4029cba0f5c86366a7c43c3aa088068039cb81522b3f.png
simple
<table><tr><td>Manufacturer and phantom type</td><td>Speed of sound [m/s]</td><td>Attenuation [dB/cm/MHz]</td><td>Young&#8217;s modulus [kPa]</td></tr><tr><td>ATS hydrogel-based [25]</td><td>1540</td><td>n/a</td><td>n/a</td></tr><tr><td>ATS rubber-based [25]</td><td>1440&#8211;1460</td><td>0.48&#8211;0.52</td><td>n/a</td></tr><tr><td>CIRS hydrogels [26, 27]</td><td>1480&#8211;1600</td><td>0.45&#8211;0.75</td><td>3&#8211;48</td></tr><tr><td>Madsen agar with evaporated milk [16]</td><td>1541&#8211;1543</td><td>0.1&#8211;0.7</td><td>n/a</td></tr><tr><td>Hall gelatins [28]</td><td>1559&#8211;1600</td><td>n/a</td><td>3&#8211;126</td></tr><tr><td>King hydrogel-based<sup>a</sup> [29]</td><td>1539&#8211;1583</td><td>0.51&#8211;0.55</td><td>n/a</td></tr><tr><td>Our gelatins with evaporated milk:</td><td></td><td></td><td></td></tr><tr><td>125-bloom</td><td>1532&#8211;1574</td><td>0.45&#8211;0.55</td><td>8&#8211;11</td></tr><tr><td>175-bloom</td><td>1536&#8211;1566</td><td>0.45&#8211;0.61</td><td>16&#8211;22</td></tr><tr><td>250-bloom</td><td>1543&#8211;1563</td><td>0.46&#8211;0.62</td><td>24&#8211;34</td></tr></table>
1f2005881f2d5c54771629c0eb66f843fecc44752a4bf1863000ca2beba05b61.png
complex
<table><tr><td>Parameter</td><td>Search</td><td>Approach</td><td colspan="4">Terminal phase</td></tr><tr><td></td><td></td><td></td><td><i>F</i></td><td><i>M</i></td><td><i>S</i></td><td><i>L</i></td></tr><tr><td>Pulse duration [ms]</td><td>2.4 &#177; 0.3</td><td>2.1 &#177; 0.1</td><td>1.7 &#177; 0.1</td><td>1.4 &#177; 0.2</td><td>1.0 &#177; 0.1</td><td>0.9 &#177; 0.1</td></tr><tr><td></td><td>1.9 &#8722; 2.8</td><td>1.9 &#8722; 2.2</td><td>1.6 &#8722; 1.9</td><td>1.1 &#8722; 1.7</td><td>0.8 &#8722; 1.3</td><td>0.8 &#8722; 1.2</td></tr><tr><td>Pulse interval [ms]</td><td>41.6 &#177; 10.5</td><td>17.9 &#177; 1.5</td><td>11.0 &#177; 1.2</td><td>7.9 &#177; 1.6</td><td>5.9 &#177; 0.7</td><td></td></tr><tr><td></td><td>24 &#8722; 62</td><td>15 &#8722; 21</td><td>8.9 &#8722; 14</td><td>6.2 &#8722; 11</td><td>5.1 &#8722; 7.8</td><td></td></tr><tr><td>Repetition rate [calls/s]</td><td>25.6 &#177; 6.8</td><td>56.3 &#177; 4.9</td><td>91.9 &#177; 9.6</td><td>130.7 &#177; 22.8</td><td>172.3 &#177; 18.0</td><td></td></tr><tr><td></td><td>16 &#8722; 42</td><td>48 &#8722; 66</td><td>74 &#8722; 113</td><td>87 &#8722; 161</td><td>129 &#8722; 195</td><td></td></tr><tr><td>Bandwidth [kHz]</td><td>22.9 &#177; 3.1</td><td>25.4 &#177; 1.9</td><td>23.5 &#177; 2.8</td><td>19.6 &#177; 2.6</td><td>15.1 &#177; 2.2</td><td>13.6 &#177; 1.7</td></tr><tr><td></td><td>17 &#8722; 29</td><td>23 &#8722; 29</td><td>18 &#8722; 28</td><td>16 &#8722; 24</td><td>11 &#8722; 20</td><td>11 &#8722; 16</td></tr><tr><td>Peak frequency [kHz]</td><td>56.4 &#177; 2.2</td><td>55.4 &#177; 2.1</td><td>55.9 &#177; 2.7</td><td>54.8 &#177; 3.2</td><td>54.2 &#177; 2.8</td><td>53.2 &#177; 3.6</td></tr><tr><td></td><td>53 &#8722; 60</td><td>50 &#8722; 58</td><td>52 &#8722; 62</td><td>47 &#8722; 59</td><td>49 &#8722; 59</td><td>47 &#8722; 58</td></tr><tr><td>Sweep rate [kHz/ms]</td><td>9.7 &#177; 0.9</td><td>12.3 &#177; 1.1</td><td>13.5 &#177; 1.5</td><td>14.5 &#177; 1.7</td><td>15.3 &#177; 2.4</td><td>15.2 &#177; 2.0</td></tr><tr><td></td><td>7.9 &#8722; 11</td><td>10 &#8722; 14</td><td>11 &#8722; 16</td><td>12 &#8722; 18</td><td>10 &#8722; 19</td><td>12 &#8722; 19</td></tr><tr><td>Duty cycle [%]</td><td>6.4 &#177; 1.3</td><td>12.2 &#177; 1.2</td><td>16.0 &#177; 1.9</td><td>17.6 &#177; 3.0</td><td>17.2 &#177; 2.7</td><td></td></tr><tr><td></td><td>4.2 &#8722; 8.9</td><td>9.8 &#8722; 14</td><td>13 &#8722; 20</td><td>13 &#8722; 24</td><td>13 &#8722; 23</td><td></td></tr></table>
a4c9c028d6ccf163f6bbae0643fe86c31fcd185ce3a30002028d9a88b227f3da.png
complex
<table><tr><td></td><td>Kawasaki Disease</td><td>Febrile Condition</td><td><i>P</i>-value</td></tr><tr><td></td><td>n = 23 (59.0%)</td><td>n = 16 (41.0%)</td><td></td></tr><tr><td>Age (months)<sup>a</sup></td><td>43.2 [5.0, 152.0, 27.1-49.6]</td><td>64.3 [6.0, 188.0, 38.1-90.6]</td><td>0.125</td></tr><tr><td>Male</td><td>15 (65.2%)</td><td>9 (69.2%)</td><td>1.000</td></tr><tr><td colspan="3">Ethnicity</td><td></td></tr><tr><td> Asian</td><td>8 (34.8%)</td><td>0 (0%)</td><td>0.044</td></tr><tr><td> African American</td><td>1 (4.4%)</td><td>0 (0%)</td><td></td></tr><tr><td> Caucasian</td><td>5 (21.7%)</td><td>7 (43.8%)</td><td></td></tr><tr><td> Hispanic</td><td>6 (26.1%)</td><td>8 (50.0%)</td><td></td></tr><tr><td> Mixed</td><td>3 (13.0%)</td><td>1 (6.3%)</td><td></td></tr></table>
ed1198bfd93c5c1df607db8e37de27181c120b84b5c3e5498e06d145609f22cf.png
simple
<table><tr><td></td><td>Precision</td><td>Recall</td><td>F-Measure</td><td>Accuracy</td></tr><tr><td>ALL-40</td><td>0.927</td><td>0.886</td><td>0.906</td><td>0.982</td></tr><tr><td>ALL-90</td><td>0.955</td><td>0.88</td><td>0.916</td><td>0.984</td></tr><tr><td>ALL-140</td><td>0.952</td><td>0.91</td><td>0.93</td><td>0.986</td></tr><tr><td>ALL-190</td><td>0.951</td><td>0.903</td><td>0.926</td><td>0.986</td></tr><tr><td>ALL-240</td><td>0.949</td><td>0.904</td><td>0.926</td><td>0.985</td></tr><tr><td>ALL-290</td><td>0.948</td><td>0.899</td><td>0.923</td><td>0.985</td></tr><tr><td>ALL-340</td><td>0.945</td><td>0.902</td><td>0.923</td><td>0.985</td></tr></table>
1587effaa4a3e4bc7a7a76e6f33fbc179e4ae72565144e7cf2682f60a8327b98.png
complex
<table><tr><td>Outcome</td><td>No. of studies</td><td>Factor tested</td><td>P</td><td>Adjusted R<sup>2</sup></td></tr><tr><td rowspan="2">Total symptom score</td><td rowspan="2">9</td><td>age</td><td>0.296</td><td>2.69%</td></tr><tr><td>ethnicity</td><td>0.254</td><td>6.74%</td></tr><tr><td></td><td></td><td>risk of bias</td><td>0.026</td><td>49.92%</td></tr><tr><td rowspan="2">Severity of inattention</td><td rowspan="2">5</td><td>age</td><td>0.16</td><td>54.94%</td></tr><tr><td>ethnicity</td><td>0.421</td><td>&#8722;5.75%</td></tr><tr><td></td><td></td><td>risk of bias</td><td>0.345</td><td>0.80%</td></tr><tr><td rowspan="2">Severity of Hyp-Imp</td><td rowspan="2">5</td><td>age</td><td>0.972</td><td>&#8722;40.99%</td></tr><tr><td>ethnicity</td><td>0.257</td><td>29.91%</td></tr><tr><td></td><td></td><td>risk of bias</td><td>0.022</td><td>100.00%</td></tr></table>
86b15bccb147f7e07d4a881d1968b97068dee3cfd0c18fb03a224449f45a7240.png
complex
<table><tr><td></td><td colspan="8">Age (in years)</td></tr><tr><td></td><td>3</td><td>4</td><td>5</td><td>6</td><td>7</td><td>8&#8211;9</td><td>10&#8211;11</td><td>Total</td></tr><tr><td>Boys</td><td>32</td><td>31</td><td>31</td><td>31</td><td>15</td><td>14</td><td>13</td><td>167</td></tr><tr><td>Girls</td><td>29</td><td>24</td><td>32</td><td>26</td><td>16</td><td>12</td><td>18</td><td>157</td></tr><tr><td>All</td><td>61</td><td>55</td><td>63</td><td>57</td><td>31</td><td>26</td><td>31</td><td>324</td></tr></table>
d872420d4a49d2ee060414407740f86bc87df24d55b55e81d8d6788d96d1025c.png
complex
<table><tr><td rowspan="2"></td><td>Normal</td><td>BCA</td></tr><tr><td><i>n</i> = 30</td><td><i>n</i> = 88</td></tr><tr><td colspan="3">Sex</td></tr><tr><td> Male</td><td>22 (73%)</td><td>70 (79.5%)</td></tr><tr><td> Female</td><td>8 (27%)</td><td>18 (20.5%)</td></tr><tr><td colspan="3">Age</td></tr><tr><td> Mean</td><td>66.3</td><td>69.1</td></tr><tr><td> Range</td><td>43&#8211;81</td><td>40&#8211;91</td></tr><tr><td colspan="3">Staging pT-stage</td></tr><tr><td>pTa</td><td>n.a.</td><td>13 (14.8%)</td></tr><tr><td>pTis</td><td>n.a.</td><td>13 (14.8%)</td></tr><tr><td>pT1</td><td>n.a.</td><td>18 (20.5%)</td></tr><tr><td>pT2</td><td>n.a.</td><td>12 (13.6%)</td></tr><tr><td>pT3</td><td>n.a.</td><td>15 (17.0%)</td></tr><tr><td>pT4</td><td>n.a.</td><td>17 (19.3%)</td></tr><tr><td> Lymph node metastasis</td><td>n.a.</td><td>23 (26.1%)</td></tr><tr><td> Distant metastasis</td><td>n.a.</td><td>2 (2.3%)</td></tr><tr><td colspan="3">Grading</td></tr><tr><td> grade 1</td><td>n.a.</td><td>9 (10.2%)</td></tr><tr><td> grade 2</td><td>n.a.</td><td>31 (35.2%)</td></tr><tr><td> grade 3</td><td>n.a.</td><td>48 (54.5%)</td></tr></table>
e165b9587c644a8ed7c9cc59075b03b93396ffb90c529cd7eba771bab2ce8ec3.png
simple
<table><tr><td>Variables</td><td>&#946;</td><td>SE</td><td>Wald &#967;<sup>2</sup></td><td><i>P</i>-value</td><td>OR</td><td>95% CI of OR</td></tr><tr><td>Age</td><td>0.055</td><td>0.006</td><td>73.581</td><td>0.000</td><td>1.056</td><td>1.043&#8211;1.070</td></tr><tr><td>Female</td><td>0.947</td><td>0.158</td><td>35.953</td><td>0.000</td><td>2.578</td><td>1.892&#8211;3.514</td></tr><tr><td>BMI</td><td>0.073</td><td>0.024</td><td>8.851</td><td>0.003</td><td>1.075</td><td>1.025&#8211;1.128</td></tr><tr><td>TSH</td><td>-0.243</td><td>0.083</td><td>8.630</td><td>0.003</td><td>0.784</td><td>0.667&#8211;0.922</td></tr><tr><td><i>H. pylori</i> infection</td><td>0.329</td><td>0.139</td><td>5.633</td><td>0.018</td><td>1.390</td><td>1.059&#8211;1.824</td></tr></table>
804eba4b2d5c67388ce76ace92698b7b71ee3df690f97622b56084cc21034f59.png
simple
<table><tr><td>Characteristic</td><td></td><td>HR</td><td>95% CI</td><td><i>p</i>-value</td></tr><tr><td>Age</td><td>Per year</td><td>0.99</td><td>0.96&#8211;1.02</td><td>0.47</td></tr><tr><td>Hormone receptor status</td><td>Negative</td><td>1 (reference)</td><td></td><td></td></tr><tr><td></td><td>Positive</td><td>1.50</td><td>0.56&#8211;4.06</td><td>0.41</td></tr><tr><td>HER2 Status</td><td>Negative</td><td>1 (reference)</td><td></td><td></td></tr><tr><td></td><td>Positive</td><td>0.89</td><td>0.35&#8211;2.25</td><td>0.80</td></tr><tr><td>Grading</td><td>Per grade</td><td>1.45</td><td>0.70&#8211;3.00</td><td>0.32</td></tr><tr><td>Therapy line</td><td>Per line</td><td>0.98</td><td>0.75&#8211;1.26</td><td>0.85</td></tr><tr><td>CTC count</td><td>0</td><td>1 (reference)</td><td></td><td></td></tr><tr><td></td><td>&#8805;1</td><td>4.20</td><td>1.86&#8211;9.46</td><td>0.001</td></tr></table>
ac9ecc3f128eb45f4008542096544ea3bf6405bb12ce7b0fc3a14d5f1192988a.png
simple
<table><tr><td>Subset</td><td>No outbreaks (%)</td><td>One outbreak (%)</td><td>Two or more outbreaks (%)</td><td>Number of self-reported A(H5N1) outbreaks (average)</td></tr><tr><td>1</td><td>15.4</td><td>38.5</td><td>46.2</td><td>1.6</td></tr><tr><td>2</td><td>50.0</td><td>30.0</td><td>20.0</td><td>0.8</td></tr><tr><td>3</td><td>35.7</td><td>35.7</td><td>28.6</td><td>1.1</td></tr><tr><td>4</td><td>58.7</td><td>33.3</td><td>8.3</td><td>0.5</td></tr><tr><td>5</td><td>45.0</td><td>20.0</td><td>35.0</td><td>1.2</td></tr><tr><td>6</td><td>37.5</td><td>62.5</td><td>0.0</td><td>0.6</td></tr></table>
c5b885e626b2796fa22d30c653e8f44bccb3585c4f07a2024def3ca7b75cd52b.png
complex
<table><tr><td></td><td></td><td colspan="2">DHEA IM group compared to CTR1</td><td colspan="2">DHEA IM group compared to CTR3</td></tr><tr><td>Name gene set</td><td># Genes</td><td><i>p</i>-value</td><td>FDR</td><td><i>p</i>-value</td><td>FDR</td></tr><tr><td>DHEA_IM_vs_CTR1_up</td><td>98</td><td>-</td><td>-</td><td>0.000*</td><td>0.000</td></tr><tr><td>DHEA_IM_vs_CTR1_down</td><td>208</td><td>-</td><td>-</td><td>0.000*</td><td>0.071</td></tr><tr><td>DHEA_IM_vs_CTR3_up</td><td>46</td><td>0.000*</td><td>0.000</td><td>-</td><td>-</td></tr><tr><td>DHEA_IM_vs_CTR3_down</td><td>19</td><td>0.826</td><td>0.823</td><td>-</td><td>-</td></tr><tr><td>DHEA_PO_vs_CTR1_up</td><td>65</td><td>0.000*</td><td>0.000</td><td>0.751</td><td>0.887</td></tr><tr><td>DHEA_PO_vs_CTR1_down</td><td>73</td><td>0.000*</td><td>0.000</td><td>0.861</td><td>0.899</td></tr><tr><td>DHEA_PO_vs_CTR3_up</td><td>31</td><td>0.032*</td><td>0.073</td><td>0.000*</td><td>0.000</td></tr><tr><td>DHEA_PO_vs_CTR3_down</td><td>34</td><td>0.312</td><td>0.413</td><td>0.000*</td><td>0.000</td></tr><tr><td>Depreter_et_al_up</td><td>11</td><td>0.015*</td><td>0.031</td><td>0.381</td><td>0.657</td></tr><tr><td></td><td></td><td colspan="2">DHEA PO group compared to CTR1</td><td colspan="2">DHEA PO group compared to CTR3</td></tr><tr><td>Name gene set</td><td># Genes</td><td><i>p</i>-value</td><td>FDR</td><td><i>p</i>-value</td><td>FDR</td></tr><tr><td>DHEA_PO_vs_CTR1_up</td><td>65</td><td>-</td><td>-</td><td>0.000*</td><td>0.000</td></tr><tr><td>DHEA_PO_vs_CTR1_down</td><td>73</td><td>-</td><td>-</td><td>0.007*</td><td>0.002</td></tr><tr><td>DHEA_PO_vs_CTR3_up</td><td>31</td><td>0.173</td><td>0.292</td><td>-</td><td>-</td></tr><tr><td>DHEA_PO_vs_CTR3_down</td><td>34</td><td>0.015*</td><td>0.014</td><td>-</td><td>-</td></tr><tr><td>DHEA_IM_vs_CTR1_up</td><td>98</td><td>0.000*</td><td>0.000</td><td>0.000</td><td>0.479</td></tr><tr><td>DHEA_IM_vs_CTR1_down</td><td>208</td><td>0.000*</td><td>0.000</td><td>0.000*</td><td>0.000</td></tr><tr><td>DHEA_IM_vs_CTR3_up</td><td>46</td><td>0.706</td><td>0.738</td><td>0.000*</td><td>0.000</td></tr><tr><td>DHEA_IM_vs_CTR3_down</td><td>19</td><td>0.009*</td><td>0.006</td><td>0.002*</td><td>0.001</td></tr><tr><td>Depreter_et_al_up</td><td>11</td><td>0.029*</td><td>0.030</td><td>0.887</td><td>1.000</td></tr></table>
df9805664f5b20b1b4287f3621508732389a4e0d49dec1cd064c8cd646d4594c.png
simple
<table><tr><td>Data process</td><td>How and when measured</td></tr><tr><td>Frequency of dressing changes in both trial arms</td><td>This was calculated from the number of treatment monitoring forms completed by the research nurses indicating a dressing change and included forms completed both prospectively and retrospectively</td></tr><tr><td> </td><td>Such data were collected retrospectively when a participant changed location or was self-caring. In such instances, the research nurse would consult patient notes or records kept by the patient to determine the number of dressing changes over a specified period of time</td></tr><tr><td>Duration of treatment with allocated trial treatment</td><td>Calculated as the difference between the date a patient receiving their allocated treatment to the date they stopped receiving this treatment. This information was available from treatment monitoring forms (as described above)</td></tr><tr><td>Reasons for ceasing allocated trial treatment</td><td>When, in the clinical judgement of the nurses, a patient could no longer receive their allocated trial treatment, the reason for treatment change was recorded on a treatment monitoring form</td></tr><tr><td>Define common adverse events in the study population</td><td>All serious and non-serious adverse events that occurred in participants were recorded on adverse events forms. The nature, description and relationship of the event to trial treatment were recorded. The research nurse indicated whether the event was considered to be related to the reference pressure ulcer</td></tr></table>
278ecb1cd9e5e99f494df99d6d33bb9bac38f4cb1441e2f46c109d36c5084e3c.png
complex
<table><tr><td rowspan="2" colspan="2">Tumor types</td><td colspan="2"><sub>56</sub> expression CD</td></tr><tr><td>Negative</td><td>Positive</td></tr><tr><td colspan="2">Pleomorphic adenoma</td><td>6 cases(40%)</td><td>9cases(60%)</td></tr><tr><td colspan="2">Low-grade malignant tumors(Mucoepidermoid carcinoma grade I)</td><td>8 cases(100%)</td><td>0 case(0%)</td></tr><tr><td rowspan="2">high-grade malignant tumors</td><td>Mucoepidermoid carcinoma grade III</td><td>6 cases(27.3%)</td><td>1 case(4.5%)</td></tr><tr><td>Adenoid cystic carcinoma</td><td>3 cases(13.6%)</td><td>12 cases(54.5%)</td></tr></table>
0f97247dc4f74339fe8cf8ced562c613bb2ed694c5e48082941602ae6ba76c09.png
simple
<table><tr><td></td><td>Excluded from Analysis</td><td>Included in Analysis</td><td></td></tr><tr><td>Basic Stats</td><td>N = 1534</td><td>N = 946</td><td>ANOVA</td></tr><tr><td><underline>Age at NAF visit:</underline></td><td></td><td></td><td></td></tr><tr><td>Mean</td><td>43.9 *</td><td>42.6</td><td></td></tr><tr><td>Median</td><td>42</td><td>41</td><td></td></tr><tr><td>Std Err</td><td>0.39</td><td>0.42</td><td></td></tr><tr><td>Min-max</td><td>16&#8211;89</td><td>16&#8211;87</td><td></td></tr><tr><td></td><td></td><td></td><td>p = 0.04</td></tr><tr><td><underline>Age at breast cancer diagnosis:</underline></td><td></td><td></td><td></td></tr><tr><td>N</td><td>81 **</td><td>93</td><td></td></tr><tr><td>Mean</td><td>62.0</td><td>60.8</td><td></td></tr><tr><td>Median</td><td>62</td><td>62</td><td></td></tr><tr><td>Std Err</td><td>1.5</td><td>1.27</td><td></td></tr><tr><td>Min-max</td><td>30&#8211;89</td><td>34&#8211;86</td><td></td></tr><tr><td></td><td></td><td></td><td>p = 0.54</td></tr><tr><td><underline>Breast cancer:</underline></td><td><underline>n (%)</underline></td><td><underline>n (%)</underline></td><td></td></tr><tr><td></td><td>90 (6%)</td><td>93 (10%)</td><td>Chi Square</td></tr><tr><td></td><td></td><td></td><td><i>p </i>&lt;<i>0.001</i></td></tr><tr><td><underline>NAF Cytology:</underline></td><td><underline>n (%)</underline></td><td><underline>n (%)</underline></td><td></td></tr><tr><td>No fluid</td><td>929 (61%)</td><td>714 (75%)</td><td></td></tr><tr><td>Insufficient specimen</td><td>45 (3%)</td><td>19 (2%)</td><td></td></tr><tr><td>Normal</td><td>232 (15%)</td><td>89 (9%)</td><td></td></tr><tr><td>Hyperplasia</td><td>234 (15%)</td><td>97 (10%)</td><td></td></tr><tr><td>Atypia</td><td>81 (5%)</td><td>27 (3%)</td><td></td></tr><tr><td>[Unable to classify]</td><td>13 (1%)</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td><i>p </i>&lt;<i>0.001</i></td></tr></table>
dfaf4b88649c044a5c9daee649458390ddd71c4344d63b38704c78f2e6c52ecb.png
complex
<table><tr><td rowspan="3"> </td><td rowspan="2">Total</td><td colspan="2"><i>EDSS mild</i></td><td colspan="2"><i>EDSS moderate</i></td><td colspan="2"><i>EDSS severe</i></td></tr><tr><td>Depressive symptoms</td><td>No depressive symptoms</td><td>Depressive symptoms</td><td>No depressive symptoms</td><td>Depressive symptoms</td><td>No depressive symptoms</td></tr><tr><td>n = 173</td><td>n = 39<sup>a</sup></td><td>n = 72</td><td>n = 16<sup>b</sup></td><td>n = 14</td><td>n = 16<sup>c</sup></td><td>n = 16</td></tr><tr><td>Women, n (%)</td><td>116 (67)</td><td>28 (72)</td><td>51 (71)</td><td>9 (56)</td><td>7 (47)</td><td>10 (62)</td><td>11 (69)</td></tr><tr><td>Mean age, years (sd)</td><td>46 (12)</td><td>42 (13)</td><td>43 (11)</td><td>47 (9)</td><td>55 (10)</td><td>56 (11)</td><td>53 (12)</td></tr><tr><td>Cohabiting, n (%)</td><td>123 (71)</td><td>31 (79)</td><td>51 (71)</td><td>11 (69)</td><td>9 (64)</td><td>11 (69)</td><td>11 (69)</td></tr><tr><td>Working full- or part-time, n (%)<sup>d</sup></td><td>114 (66)</td><td>24 (65)</td><td>59 (84)</td><td>7 (47)</td><td>7 (64)</td><td>0</td><td>7 (46)</td></tr><tr><td>Immunomodulatory treatment, n (%)</td><td>146 (84)</td><td>30 (77)</td><td>57 (79)</td><td>15 (94)</td><td>14 (100)</td><td>14 (88)</td><td>16 (100)</td></tr><tr><td>Mean years since diagnosis, (sd)</td><td>13 (10)</td><td>9 (7)</td><td>12 (10)</td><td>15 (10)</td><td>15 (10)</td><td>19 (9)</td><td>20 (11)</td></tr><tr><td>Disease severity, n (%)</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>EDSS mild 1.0-3.5</td><td>111 (64)</td><td>1.8 (1.0-3.5)</td><td>1.8 (1.0-3.5)</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>EDSS moderate 4.0-5.5</td><td>30 (17)</td><td> </td><td> </td><td>4.7 (4.0-5.5)</td><td>4.6 (4.0-5.5)</td><td> </td><td> </td></tr><tr><td>EDSS severe 6.0-9.5</td><td>32 (18)</td><td> </td><td> </td><td> </td><td> </td><td>7.3 (6.0-8.0)</td><td>7.0 (6.0-8.0)</td></tr><tr><td>Disease course, n (%)</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Relapsing remitting</td><td>106 (61)</td><td>35 (90)</td><td>62 (86)</td><td>3 (19)</td><td>4 (29)</td><td>0</td><td>2 (13)</td></tr><tr><td>Secondary progressive</td><td>58 (34)</td><td>1 (2)</td><td>7 (10)</td><td>12 (75)</td><td>9 (64)</td><td>16 (100)</td><td>13 (81)</td></tr><tr><td>Primary progressive</td><td>9 (5)</td><td>3 (8)</td><td>3 (4)</td><td>1 (6)</td><td>1 (7)</td><td>0</td><td>1 (6)</td></tr></table>
8f1ae991423463130dd63703d0db790bd32de677b91dc5d9b0f9aeef56949f02.png
simple
<table><tr><td>Chinese name</td><td>Full scientific name</td><td>Parts of plant use</td><td>%</td><td>Dose of dry plant</td><td>Constituent</td><td>Dose after extraction</td><td>Function in Chinese medicine</td></tr><tr><td><i>Huang Qi </i></td><td><i>Radix Astragali </i></td><td>Dry root </td><td> </td><td>15</td><td>Astragaloside </td><td>3.75</td><td>Tonifies Qi</td></tr><tr><td><i>Sheng Di </i></td><td><i>Rehmannia glutinosa </i>Libosch</td><td>Dry root</td><td> </td><td>15</td><td> </td><td>3.75</td><td>Nourishes Yin</td></tr><tr><td><i>Shan Zhu Yu </i></td><td>Fructus Cornus </td><td>Dry fruit</td><td> </td><td>5</td><td>Loganin</td><td>1.25</td><td>Tonifies the liver and kidney and retains the essence</td></tr><tr><td><i>Bai Shao </i></td><td><i>Paeonia lactiflora </i></td><td>Dry root </td><td> </td><td>15</td><td>Paeoniflorin</td><td>3.75</td><td>Nourishes blood and preserves Yin</td></tr><tr><td><i>Dan Pi </i></td><td>Cortex Moutan Radicis</td><td>Dry root and stem </td><td> </td><td>15</td><td>Paeonol</td><td>3.75</td><td>Clears deficient fire and heat</td></tr><tr><td><i>She She Cao </i></td><td>Herba Hedyotidis Diffusae</td><td>Dry leaf</td><td> </td><td>15</td><td>Oleanic acid</td><td>3.75</td><td>Clears heat and resolves toxins</td></tr><tr><td>Total</td><td> </td><td> </td><td>100</td><td>80</td><td> </td><td>20</td><td> </td></tr></table>
5fc6d38a8b70e2cdda81d0d212228711f369d07598658ef9b22e664a1d6dcb5f.png
simple
<table><tr><td>Genes</td><td>5&#8217; Primer sequence</td><td>3&#8217; Primer sequence</td></tr><tr><td>CD14</td><td>CCGCTGCCTCTGGAAG</td><td>GGCGAGTGTGCTTGGG</td></tr><tr><td>TLR4</td><td>GTCCTCAGTGTGCTTGTAG</td><td>ATCCTGGCTTGAGTAGATAAC</td></tr><tr><td>MD-2</td><td>CACCATGAATCTTCCAAAGC</td><td>CTTGAAGGAGAATGATATTGTTG</td></tr><tr><td>MyD88</td><td>CGGATGGTGGTGGTTGTCTC</td><td>CGCTTCTGATGGGCACCT</td></tr><tr><td>GAPDH</td><td>CTGAGTACGTCGTGGAGTC</td><td>AAATGAGCCCCAGCCTTC</td></tr></table>
e3ceb15a01037f89055543bf6d47a9ab91628e20b2be86495a83d6083870bd60.png
complex
<table><tr><td></td><td></td><td>Total Number of Samples</td><td>Number of Samples &lt; Background PM<sub>2.5</sub> Level <i>N</i> (%)</td><td>Area (m<sup>2</sup>) Med (IQR)</td><td>Number of Smokers Occupied Med (IQR)</td><td>Number of Ventilator Med (IQR)</td></tr><tr><td rowspan="4">Pre-ban (2013)</td><td>Overall</td><td>99</td><td>23 (23.2)</td><td>204.5 (107.5&#8211;360)</td><td>4 (1&#8211;9)</td><td>10 (4&#8211;16)</td></tr><tr><td>Billiards</td><td>30</td><td>5 (16.7)</td><td>232.0 (110.0&#8211;484.0)</td><td>3 (2&#8211;6)</td><td>8 (4&#8211;10)</td></tr><tr><td>Pubs</td><td>30</td><td>10 (33.3)</td><td>132.5 (55.0&#8211;225.0)</td><td>2 (0&#8211;4)</td><td>5 (2&#8211;14)</td></tr><tr><td>Computer game rooms</td><td>39</td><td>8 (20.5)</td><td>262.5 (156.0&#8211;368.0)</td><td>6 (4&#8211;13)</td><td>16 (9&#8211;26)</td></tr><tr><td rowspan="4">Post-ban (2014)</td><td>Overall</td><td>64</td><td>18 (28.1)</td><td>114.7 (72.0&#8211;206.1)</td><td>0 (0&#8211;4)</td><td>13 (7&#8211;18)</td></tr><tr><td>Billiards</td><td>15</td><td>3 (20.0)</td><td>198.0 (117.6&#8211;286.0)</td><td>4 (3&#8211;6)</td><td>12 (9&#8211;16)</td></tr><tr><td>Pubs</td><td>29</td><td>10 (34.5)</td><td>75.0 (54.0&#8211;112.8)</td><td>0</td><td>10 (3&#8211;15)</td></tr><tr><td>Computer game rooms</td><td>20</td><td>5 (25.0)</td><td>141.2 (106.5&#8211;284.7)</td><td>1 (0&#8211;10)</td><td>19 (15&#8211;34)</td></tr></table>
dcfabc70cd06a91959e49be803c95e8bb9909198cdf19a2d5317cf0e4cd235c1.png
complex
<table><tr><td colspan="5">Maternal PCB concentration (ng/g lipid)</td><td>Model <i>R</i><sup>2</sup></td></tr><tr><td colspan="5">Model 1: preconception PCBs</td><td>0.22</td></tr><tr><td> Explained variation</td><td>22%</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="5">Model 2: preconception PCBs + prenatal PCBs</td><td>0.26</td></tr><tr><td> Explained variation</td><td>25%</td><td>6%</td><td></td><td></td><td></td></tr><tr><td colspan="5">Model 3: preconception PCBs + prenatal PCBs + postnatal PCBs</td><td>0.28</td></tr><tr><td> Explained variation</td><td>20%</td><td>8%</td><td>2%</td><td></td><td></td></tr><tr><td colspan="5">Model 4: preconception PCBs + prenatal PCBs + postnatal PCBs + breast-feeding duration</td><td>0.56</td></tr><tr><td>Explained variation</td><td>15%</td><td>2%</td><td>&lt; 1%</td><td>32%</td><td></td></tr></table>
a67b43e013028958f5340786df4f73acdc10cb1a2d4f9bb4f46b378b96ede7fa.png
simple
<table><tr><td></td><td>Variables</td><td>Expected difference, mean</td><td>Expected standard deviation</td><td>&#945;</td><td>Power %</td></tr><tr><td>Primary outcome</td><td>10 years risk of CVD (%)</td><td>2.5</td><td>5.9</td><td>0.0166</td><td>0.90</td></tr><tr><td>Secondary outcomes</td><td>WC (cm)</td><td>5</td><td>14</td><td>0.0166</td><td>0.75</td></tr><tr><td></td><td>BP (mm Hg)</td><td>5</td><td>12</td><td>0.0166</td><td>0.88</td></tr><tr><td></td><td>RHR (per minutes)</td><td>10</td><td>20</td><td>0.0166</td><td>0.97</td></tr><tr><td></td><td>HDL (mmol/l)</td><td>0.2</td><td>0.4</td><td>0.0166</td><td>0.97</td></tr><tr><td></td><td>Non-HDL (mmol/l)</td><td>0.45</td><td>1.1</td><td>0.0166</td><td>0.87</td></tr><tr><td></td><td>HbA1c (mmol/mol)</td><td>0.5</td><td>1.1</td><td>0.0166</td><td>0.94</td></tr><tr><td></td><td>FEV1 (L)</td><td>-0.36</td><td>0.92</td><td>00166</td><td>0.84</td></tr><tr><td></td><td>VO<sub>2max</sub></td><td>3.5</td><td>9</td><td>0.0166</td><td>0.73</td></tr><tr><td></td><td>Sedentary (minutes/day)</td><td>60</td><td>140</td><td>0.0166</td><td>0.90</td></tr><tr><td></td><td>MVPA (Minutes/day)</td><td>20</td><td>40</td><td>0.0166</td><td>0.97</td></tr></table>
343b24bfc71af65f1ae1f002369dd349f77eed9e4e42b85761dd3ca629984d22.png
complex
<table><tr><td></td><td>GmPOPB-S577A_25mer</td><td>GmPOPB-D661A_25mer</td><td>GmPOPB-S577A_35mer</td><td>GmPOPB-H698A_35mer</td><td>apo_GmPOPB</td></tr><tr><td colspan="6"><i>Data collection</i></td></tr><tr><td> Space group</td><td><i>P</i> 2<sub>1</sub> 2<sub>1</sub> 2<sub>1</sub></td><td><i>P</i> 2<sub>1</sub> 2<sub>1</sub> 2<sub>1</sub></td><td><i>P</i> 2<sub>1</sub></td><td><i>P</i> 2<sub>1</sub> 2<sub>1</sub> 2<sub>1</sub></td><td><i>P</i> 2<sub>1</sub> 2<sub>1</sub> 2</td></tr><tr><td colspan="6"> Cell dimensions</td></tr><tr><td><i>a</i>, <i>b</i>, <i>c</i></td><td>99.1, 114.7, 141.3</td><td>99.0, 114.9, 141.3</td><td>100.8, 142. 6, 116.4</td><td>99.2, 115 141. 5</td><td>90.89, 105.62, 86.96</td></tr><tr><td><i>&#945;</i>, <i>&#946;</i>, <i>&#947;</i></td><td>90.0, 90.0, 90.0</td><td>90.0, 90.0, 90.0</td><td>90.0, 90.29, 90.0</td><td>90.0, 90.0, 90.0</td><td>90.0, 90.0, 90.0</td></tr><tr><td> Resolution</td><td>1.44 (1.49&#8211;1.44)</td><td>1.62 (1.678&#8211;1.62)</td><td>2.19 (2.268&#8211;2.19)</td><td>2.9 (3.0&#8211;2.9)</td><td>2.4 (2.49&#8211;2.4)</td></tr><tr><td> Unique reflections</td><td>288,485 (28,320)</td><td>204,059 (20,188)</td><td>163,136 (16,107)</td><td>32,664 (1690)</td><td>31,441 (2534)</td></tr><tr><td> Completeness (%)</td><td>99.7 (99)</td><td>100 (100)</td><td>97 (96)</td><td>97 (93)</td><td>99 (77)</td></tr><tr><td> Mean <i>I</i>/sigma (<i>I</i>)</td><td>9.3 (1.3)</td><td>6.9 (1.0)</td><td>6.7 (1.2)</td><td>6.8 (1.7)</td><td>14.5 (2.2)</td></tr><tr><td><i>R</i>-merge</td><td>0.114 (1.01)</td><td>0.059 (0.69)</td><td>0.112 (1.0)</td><td>0.068 (0.53)</td><td>0.029 (0.56)</td></tr><tr><td><i>R</i>-meas</td><td>0.063 (0.588)</td><td>0.084 (0.98)</td><td>0.27 (1.5)</td><td>0.096 (0.52)</td><td>0.036 (0.72)</td></tr><tr><td> Redundancy</td><td>6.0 (6.6)</td><td>6.7 (6.6)</td><td>2.0 (2.0)</td><td>1.8 (1.6)</td><td>5.1 (3.3)</td></tr><tr><td colspan="6"><i>Refinement</i></td></tr><tr><td> Resolution range</td><td>43.3&#8211;1.44</td><td>46.9&#8211;1.62</td><td>82.3&#8211;2.19</td><td>32.0&#8211;2.9</td><td>45.44&#8211;2.4</td></tr><tr><td> Reflections used in refinement</td><td>288,428 (28,313)</td><td>203,960 (20,185)</td><td>163,135 (16,107)</td><td>32,664 (1690)</td><td>31,437 (2534)</td></tr><tr><td> <i>R</i><sub>work</sub>/<i>R</i><sub>free</sub></td><td>0.17/0.19</td><td>0.20/0.23</td><td>0.23/0.26</td><td>0.255/0.303</td><td>0.21/0.25</td></tr><tr><td> Protein residues</td><td>1478</td><td>1478</td><td>3014</td><td>1484</td><td>703</td></tr><tr><td>RMS(bonds)</td><td>0.015</td><td>0.020</td><td>0.012</td><td>0.007</td><td>0.007</td></tr><tr><td>RMS(angles)</td><td>1.28</td><td>1.82</td><td>1.42</td><td>1.10</td><td>1.17</td></tr><tr><td> Ramachandran favored (%)</td><td>97</td><td>97</td><td>97</td><td>97</td><td>97</td></tr><tr><td> Ramachandran allowed (%)</td><td>2.5</td><td>2.5</td><td>3.1</td><td>2.9</td><td>2.3</td></tr><tr><td> Ramachandran outliers (%)</td><td>0.14</td><td>0.3</td><td>0.3</td><td>0.48</td><td>0.29</td></tr><tr><td> Rotamer outliers (%)</td><td>0.24</td><td>1.4</td><td>0.95</td><td>1.1</td><td>0.34</td></tr><tr><td> Clashscore</td><td>3.73</td><td>1.63</td><td>1.02</td><td>3.42</td><td>2.64</td></tr><tr><td> Average B-factor</td><td>15</td><td>21</td><td>15</td><td>32</td><td>44</td></tr><tr><td> Macromolecules</td><td>14</td><td>20</td><td>14</td><td>34</td><td>43</td></tr><tr><td> Solvent</td><td>27</td><td>31</td><td>43</td><td>37</td><td>38</td></tr></table>
6f98de7dee4e93050970a8388e263b60c10d475659c259f0f974de6baf65ae9a.png
simple
<table><tr><td>Point of view</td><td>OQRA</td><td>PQRA</td></tr><tr><td>Computation</td><td> Every time a request initiated.</td><td>Precomputes paths from a source to all destinations.</td></tr><tr><td>Scalability</td><td>Limited.</td><td> Large-scale networks.</td></tr><tr><td>Suitability</td><td>When requests arise infrequently.</td><td> When requests arise very frequent.</td></tr><tr><td>Pros</td><td>Optimal routing during congestion state.</td><td>(i) Saves time.(ii) Better scalability.(iii) Improved load balancing.</td></tr><tr><td>Cons</td><td>Puts excessive time on packet processing.</td><td>(i) Path oscillation.(ii) Nonoptimal routing during congestion.(iii) Resources consumption.(iv) Complexity.</td></tr></table>
09fc5864f22523051b467cd83c4910cc6a38bfba32665d23186de870c9c21756.png
complex
<table><tr><td rowspan="2">Research</td><td rowspan="2">Altitude (m)</td><td colspan="2">Sample size</td><td colspan="2">AMS</td><td colspan="2">Normal</td><td rowspan="2">Diagnosis of AMS with cut-off value</td><td colspan="2">Age (mean)</td><td colspan="2">BMI (mean)</td><td colspan="2">Sex (m/f)</td></tr><tr><td>Smoking</td><td>Non-smoking</td><td>Smoking</td><td>Non-smoking</td><td>Smoking</td><td>Non-smoking</td><td>AMS</td><td>Normal</td><td>AMS</td><td>Normal</td><td>AMS</td><td>Normal</td></tr><tr><td>Ren, 2015 [14]</td><td>4300</td><td>16</td><td>64</td><td>3</td><td>32</td><td>13</td><td>32</td><td>LLS &gt; 3</td><td>38.1</td><td>38.6</td><td>24.7</td><td>26.2</td><td>9/26</td><td>22/23</td></tr><tr><td>Wu, 2012 [17]</td><td>4525</td><td>182</td><td>200</td><td>71</td><td>102</td><td>111</td><td>98</td><td>LLS &gt;3 OR LLS &gt;4</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>You, 2012 [19]</td><td>4300</td><td>138</td><td>176</td><td>36</td><td>83</td><td>102</td><td>93</td><td>LLS &gt; 4</td><td>20.08</td><td>20.25</td><td>21.31</td><td>21.47</td><td>119/0</td><td>195/0</td></tr><tr><td>MacInnis, 2013 [26]</td><td>4380</td><td>147</td><td>344</td><td>42</td><td>125</td><td>105</td><td>219</td><td>LLS &#8805; 3</td><td></td><td></td><td></td><td></td><td>100/67</td><td>244/80</td></tr><tr><td>Mairer, 2010(a) [28]</td><td>3454</td><td>9</td><td>66</td><td>4</td><td>26</td><td>5</td><td>40</td><td rowspan="2">LLS &#8805; 4</td><td>35.1</td><td>34.5</td><td>23.4</td><td>23.3</td><td>25/5</td><td>39/6</td></tr><tr><td>Mairer, 2010(b) [28]</td><td>3817</td><td>13</td><td>67</td><td>3</td><td>25</td><td>10</td><td>42</td><td>36.2</td><td>38.1</td><td>23.5</td><td>22.8</td><td>22/6</td><td>41/11</td></tr><tr><td>Mairer, 2009 [27]</td><td>3500</td><td>61</td><td>370</td><td>12</td><td>58</td><td>49</td><td>312</td><td>LLS &#8805; 4</td><td>38.4</td><td>37.2</td><td>23.7</td><td>23.3</td><td>50/20</td><td>266/86</td></tr><tr><td>Schneider, 2002(a) [4]</td><td>4559</td><td>56</td><td>331</td><td>16</td><td>103</td><td>40</td><td>228</td><td rowspan="2">ESQ &#8805; 0.70</td><td colspan="2">38.2</td><td colspan="2">22.6</td><td colspan="2">314/73</td></tr><tr><td>Schneider, 2002(b) [4]</td><td>4559</td><td>72</td><td>368</td><td>21</td><td>99</td><td>51</td><td>269</td><td colspan="2">37.0</td><td colspan="2">22.7</td><td colspan="2">359/81</td></tr></table>
61935000dd37f8bf861005b9154d7f6c078ee2dc7f7d8f4b074ea4085581dfc5.png
complex
<table><tr><td>Variable</td><td>Total population, N=565</td><td>Current use of LARC, N=179</td></tr><tr><td> </td><td>n (%)</td><td>n (%)</td></tr><tr><td>Knowledge of LARC</td><td> </td><td> </td></tr><tr><td colspan="3">a) Knowledge of duration of protection from pregnancy</td></tr><tr><td>IUD</td><td>387 (68.5)</td><td>136 (75.98)</td></tr><tr><td>Implant</td><td>395 (69.9)</td><td>139 (77.65)</td></tr><tr><td>Injectable</td><td>494 (87.4)</td><td>161 (89.94)</td></tr><tr><td colspan="3">b) Knowledge of site of administration</td></tr><tr><td>IUD</td><td>429 (75.9)</td><td>148 (82.68)</td></tr><tr><td>Implant</td><td>453 (80.2)</td><td>158 (88.27)</td></tr><tr><td>Injectable</td><td>519 (91.9)</td><td>171 (95.53)</td></tr></table>
25ef0d440524fda325223e59a6c599756e3bd4d25a4950b2e1817927d7286055.png
simple
<table><tr><td>Pathway/substance</td><td><i>n</i></td><td>%</td><td><i>P</i>-value</td></tr><tr><td>Animal faeces</td><td>73</td><td>48.7</td><td></td></tr><tr><td>Raw meat</td><td>57</td><td>38.0</td><td></td></tr><tr><td>Soil</td><td>40</td><td>26.7*</td><td><i>P</i> = 0.036<sup>a</sup></td></tr><tr><td>Food</td><td>39</td><td>26.0</td><td></td></tr><tr><td>Arthropods</td><td>37</td><td>24.7</td><td></td></tr><tr><td>No idea</td><td>37</td><td>24.7</td><td></td></tr><tr><td>Mother to child</td><td>31</td><td>20.7</td><td></td></tr><tr><td>Plants</td><td>20</td><td>13.3</td><td></td></tr><tr><td>Environmental contamination</td><td>18</td><td>12</td><td></td></tr><tr><td>Claw scratch</td><td>1</td><td>0.7*</td><td><i>P</i> &lt; 0.0001<sup>b</sup></td></tr></table>
fd4579d58d44d2e1439211cdecc8cf9f51b3025365781abc34edc6bb3cfac728.png
complex
<table><tr><td colspan="3">TOP 20 Nthy-ori-3.1 down-regulated genes</td><td colspan="3">TOP 20 Nthy-ori-3.1 up-regulated genes</td></tr><tr><td>Gene</td><td>Control FPKM</td><td>siRNA FPKM</td><td>Gene</td><td>Control FPKM</td><td>siRNA FPKM</td></tr><tr><td>MIR103A2</td><td>26.53</td><td>0</td><td>OR5H14</td><td>0</td><td>0.70</td></tr><tr><td>MIR103B2</td><td>205.72</td><td>0</td><td>ACKR1</td><td>0</td><td>1.19</td></tr><tr><td>MIR1227</td><td>8.63</td><td>0</td><td>MIR5193</td><td>0</td><td>1.35</td></tr><tr><td>MIR1231</td><td>10.49</td><td>0</td><td>PTGIR</td><td>0</td><td>1.39</td></tr><tr><td>MIR1260B</td><td>12.48</td><td>0</td><td>BAALCOS</td><td>0</td><td>1.48</td></tr><tr><td>MIR1279</td><td>314.85</td><td>0</td><td>CASC8</td><td>0</td><td>1.48</td></tr><tr><td>MIR1304</td><td>11.15</td><td>0</td><td>CTSE</td><td>0</td><td>1.79</td></tr><tr><td>MIR1324</td><td>8.08</td><td>0</td><td>FDCSP</td><td>0</td><td>2.03</td></tr><tr><td>MIR15A</td><td>47.29</td><td>0</td><td>MIR5572</td><td>0</td><td>2.08</td></tr><tr><td>MIR181B2</td><td>12.28</td><td>0</td><td>MIR548I2</td><td>0</td><td>2.75</td></tr><tr><td>MIR191</td><td>13.06</td><td>0</td><td>CCL4</td><td>0</td><td>4.53</td></tr><tr><td>MIR192</td><td>5.77</td><td>0</td><td>MIR1178</td><td>0</td><td>4.86</td></tr><tr><td>MIR194-1</td><td>16.51</td><td>0</td><td>SNORA16B</td><td>0</td><td>5.04</td></tr><tr><td>MIR2278</td><td>14.21</td><td>0</td><td>MIR1224</td><td>0</td><td>5.21</td></tr><tr><td>MIR27B</td><td>10.30</td><td>0</td><td>MIR492</td><td>0</td><td>5.58</td></tr><tr><td>MIR302C</td><td>25.72</td><td>0</td><td>MIR221</td><td>0</td><td>5.72</td></tr><tr><td>MIR3176</td><td>43.99</td><td>0</td><td>SNORA79</td><td>0</td><td>6.68</td></tr><tr><td>MIR3190</td><td>22.54</td><td>0</td><td>MIR577</td><td>0</td><td>7.14</td></tr><tr><td>MIR3192</td><td>17.62</td><td>0</td><td>MIR1207</td><td>0</td><td>7.28</td></tr><tr><td>MIR320B2</td><td>2.41</td><td>0</td><td>SNORA70B</td><td>0</td><td>7.43</td></tr></table>
2d5c9506bc5e27d4f42936c4e82c0e485b1d39cbc64c28fd5b8e8a7010d4afa6.png
simple
<table><tr><td></td><td>ALT (%)</td><td>AST (%)</td><td>GLDH (%)</td></tr><tr><td>HepG2</td><td>100</td><td>100</td><td>100</td></tr><tr><td>cHCC</td><td>25.8</td><td>27.7</td><td>19</td></tr><tr><td>MDCK</td><td>0</td><td>8</td><td>10</td></tr></table>
4e3c7e1e53822499822f2a3f1ef1c5075a38d7868b51be748dd0f4ba9cb21e1c.png
simple
<table><tr><td>Characteristic</td><td>Percentage<sup>*</sup></td><td>Sample size</td></tr><tr><td>Gender (female)</td><td>87.8%</td><td>983</td></tr><tr><td>Age</td><td> </td><td>983</td></tr><tr><td> &lt;50 years</td><td>2.0%</td><td> </td></tr><tr><td> 50&#8211;59 years</td><td>14.5%</td><td> </td></tr><tr><td> 60&#8211;69 years</td><td>30.0%</td><td> </td></tr><tr><td> 70&#8211;79 years</td><td>33.7%</td><td> </td></tr><tr><td> &#8805;80 years</td><td>19.7%</td><td> </td></tr><tr><td>BMD based on most recent lowest <i>T</i>-score, mean (SD) </td><td>&#8722;2.16 (1.55)</td><td>946</td></tr><tr><td>Additional fracture risk factors</td><td> </td><td>977</td></tr><tr><td> Previous fragility fracture</td><td>27.8%</td><td> </td></tr><tr><td> Systemic glucocorticoids for &gt;3 months</td><td>8.5%</td><td> </td></tr><tr><td> Previous fragility fracture and systemic glucocorticoids for &gt;3 months</td><td>3.3%</td><td> </td></tr><tr><td>Length of treatment for osteoporosis</td><td> </td><td>980</td></tr><tr><td> &lt;1 year</td><td>11.3%</td><td> </td></tr><tr><td> 1&#8211;5 years</td><td>43.8%</td><td> </td></tr><tr><td> &gt;5 years</td><td>44.9%</td><td> </td></tr><tr><td>Osteoporosis therapy</td><td> </td><td>983</td></tr><tr><td> Bisphosphonate</td><td>79.0%</td><td> </td></tr><tr><td> Selective estrogen-receptor modulator</td><td>3.0%</td><td> </td></tr><tr><td> Hormone therapy</td><td>2.3%</td><td> </td></tr><tr><td> Parathyroid hormone</td><td>2.2%</td><td> </td></tr><tr><td> Calcitonin</td><td>1.3%</td><td> </td></tr><tr><td>Prescribed supplementation</td><td> </td><td>983</td></tr><tr><td> Calcium</td><td>84.8%</td><td> </td></tr><tr><td> Vitamin D</td><td>84.8%</td><td> </td></tr></table>
a3db7f160bcf82f0a31fae789a6825d79702b830e62c0e340162ffe24eba3f47.png
complex
<table><tr><td colspan="5">A: Comparison between patients with active TB and control subjects</td></tr><tr><td></td><td></td><td><i>P </i>&lt; 0.02</td><td>0.02&#8804;<i>P &lt; 0.05</i></td><td>0.05&#8804;<i>P </i>&lt; 0.10</td></tr><tr><td>Patients versus control subjects</td><td></td><td>18</td><td>12</td><td>24</td></tr><tr><td colspan="5">B: Comparison between stimulated and unstimulated conditions</td></tr><tr><td></td><td></td><td>P &lt; 0.02</td><td>0.02&#8804;P &lt; 0.05</td><td>0.05&#8804;P &lt; 0.10</td></tr><tr><td>Patients</td><td><i>Mtb </i>antigens versus no stimuli</td><td>0</td><td>2</td><td>2</td></tr><tr><td></td><td>Mitogen versus no stimuli</td><td>3</td><td>5</td><td>11</td></tr><tr><td>Control subjects</td><td><i>Mtb </i>antigens versus no stimuli</td><td>0</td><td>1</td><td>13</td></tr><tr><td></td><td>Mitogen versus no stimuli</td><td>2</td><td>83</td><td>8</td></tr></table>
68dae944e20fdcbf973fa7ba95fffe594189d94a037538c73f66b1e9e9d1e88c.png
complex
<table><tr><td rowspan="2">Study/year</td><td rowspan="2">Sample size (I/C)</td><td rowspan="2">Setting</td><td rowspan="2">Prophylaxis drugs</td><td rowspan="2">Comparator</td><td colspan="5">Patient characteristics (I/C)</td></tr><tr><td>Age, mean, (years)</td><td>Disease severity, median (IQR) or mean (SD)</td><td>Patient receiving EN, n/N (%)</td><td>MV (%)</td><td>Follow up (months)</td></tr><tr><td>Alhazzani et al. 2017 [18]</td><td>49/42</td><td>Mixed</td><td>Pantoprazole 40 mg once daily IV</td><td>Placebo</td><td>62/55</td><td>APACHE II score21 (17&#8211;26)/22(14&#8211;27)</td><td>81/91 (89)</td><td>100/100</td><td>Unknown</td></tr><tr><td>El-Kersh et al. 2017 [29]</td><td>55/47</td><td>MICU</td><td>Pantoprazole 40 mg once daily IV</td><td>Placebo</td><td>62/58</td><td>SAPS II score41 (34.5&#8211;53)/44 (34&#8211;54)</td><td>102/102 (100)</td><td>100/100</td><td>Unknown</td></tr><tr><td>Selvanderan et al. 2016 [27]</td><td>106/108</td><td>Mixed</td><td>Pantoprazole 40 mg once daily IV</td><td>Placebo</td><td>52/52</td><td>APACHE III score66 (26)/66 (28)</td><td>214/214 (100)</td><td>100/100</td><td>12</td></tr><tr><td>Lin et al. 2016 [28]</td><td>60/60</td><td>Mixed</td><td>Lansoprazole OD 30 mg once daily</td><td>No prophylaxis</td><td>67/65</td><td>APACHE II score21.3 (6.7)/19.9 (6.9)</td><td>120/120 (100)</td><td>100/100</td><td>1</td></tr><tr><td>Ben-menachem et al. 1994 [22]</td><td>200/100</td><td>MICU</td><td>Cimetidine 900 mg InfusionSucralfate OD 1 g every 6 h</td><td>No prophylaxis</td><td>60/60</td><td>APACHE II score17.4 (7.3)/16.5 (6.9)</td><td>198/300 (67)</td><td>74/65</td><td>10</td></tr><tr><td>Apte et al. 1992 [21]</td><td>16/18</td><td>MICU</td><td>Ranitidine 50 mg/every 6 h IV</td><td>No prophylaxis</td><td>27/26</td><td>MTS score11 (4&#8211;16)/10 (6&#8211;16)</td><td>34/34 (100)</td><td>31/22</td><td>Unknown</td></tr><tr><td>Van den Berg et al. 1985 [23]</td><td>14/14</td><td>Mixed</td><td>Cimetidine 20 mg/kg/every 24 h IV</td><td>Placebo</td><td>44/48</td><td>-</td><td>17/28 (61)</td><td>100/100</td><td>Unknown</td></tr></table>
408ce699126f6878e548a3c3f6d01264550a0be595fb32cc379a30ad7cfb5105.png
simple
<table><tr><td>Experiment</td><td>Power (W)</td><td>Duration (s)</td><td>Tip-to-Tip Distance (mm)</td><td>Orientation</td><td>Peak Pressure (kPa)</td></tr><tr><td>1</td><td>5</td><td>74</td><td>0.5</td><td>Parallel</td><td>71.6</td></tr><tr><td>2</td><td>3</td><td>105</td><td>1.2</td><td>Parallel</td><td>48.4</td></tr><tr><td>3</td><td>4</td><td>60</td><td>2.5</td><td>Parallel</td><td>5.8</td></tr><tr><td>4</td><td>5</td><td>52</td><td>5</td><td>Perpendicular</td><td>1.9</td></tr></table>
4f656adad9b0f0ac6bb3ec31071f0f5822820cbccc70a2551c34982eeb658e4e.png
simple
<table><tr><td>Parameters </td><td>NC Group </td><td>HFD Group</td><td>HFD + Met </td><td>HFD + WE</td><td>HFD + 50% ME</td><td>HFD + ME</td></tr><tr><td>CRI-I = TC/HDL</td><td>1.53 &#177; 0.03 <sup>b</sup></td><td>4.50 &#177; 0.57 <sup>d</sup></td><td>2.40 &#177; 0.10 <sup>b</sup></td><td>3.53 &#177; 0.26 <sup>d</sup></td><td>3.18 &#177; 0.16 <sup>a,d</sup></td><td>4.48 &#177; 0.39 <sup>d</sup></td></tr><tr><td>CRI-II = LDL/HDL</td><td>0.41 &#177; 0.05 <sup>b</sup></td><td>5.62 &#177; 1.10 <sup>d</sup></td><td>1.42 &#177; 0.19 <sup>b</sup></td><td>2.28 &#177; 0.24 <sup>b</sup></td><td>1.92 &#177; 0.17 <sup>b</sup></td><td>3.29 &#177; 0.44 <sup>a,d</sup></td></tr><tr><td>AC = (TC&#8211;HDL)/HDL</td><td>0.60 &#177; 0.06 <sup>b</sup></td><td>6.14 &#177; 1.18 <sup>d</sup></td><td>1.64 &#177; 0.21 <sup>b</sup></td><td>2.52 &#177; 0.26 <sup>b</sup></td><td>2.18 &#177; 0.16 <sup>b</sup></td><td>3.93 &#177; 0.64 <sup>a,d</sup></td></tr></table>
c0f6727e8f476f1c3ac1092241365a53f87835daaa9c53280e3c37477e48f1cf.png
complex
<table><tr><td colspan="2">Variables</td><td>Frequency</td><td>%</td></tr><tr><td rowspan="4">Age in years</td><td>10&#8211;29</td><td>276</td><td>71.5</td></tr><tr><td>30&#8211;39</td><td>70</td><td>18.1</td></tr><tr><td>40&#8211;49</td><td>25</td><td>6.5</td></tr><tr><td>&gt;50</td><td>15</td><td>3.9</td></tr><tr><td>Sex</td><td>Male</td><td>220</td><td>57</td></tr><tr><td></td><td>Female</td><td>166</td><td>43</td></tr><tr><td rowspan="3">Marital status</td><td>Single</td><td>247</td><td>64</td></tr><tr><td>Married</td><td>21</td><td>5.4</td></tr><tr><td>Divorced/Separated</td><td>118</td><td>30.6</td></tr><tr><td rowspan="4">Income/$ USD</td><td>&lt;117.5</td><td>56</td><td>14.5</td></tr><tr><td>117.5&#8211;177.5</td><td>182</td><td>47.2</td></tr><tr><td>178&#8211;250</td><td>112</td><td>29</td></tr><tr><td>&gt;250</td><td>36</td><td>9.3</td></tr><tr><td rowspan="3">Educational level</td><td>Diploma</td><td>37</td><td>9.6</td></tr><tr><td>BSc</td><td>328</td><td>85</td></tr><tr><td>MSc</td><td>21</td><td>5.4</td></tr><tr><td rowspan="6">Service years</td><td>&lt; year</td><td>80</td><td>20.7</td></tr><tr><td>1&#8211;5 years</td><td>192</td><td>49.7</td></tr><tr><td>6&#8211;10</td><td>40</td><td>10.4</td></tr><tr><td>11&#8211;15</td><td>29</td><td>7.5</td></tr><tr><td>16&#8211;20</td><td>25</td><td>6.5</td></tr><tr><td>&gt;20</td><td>20</td><td>5.2</td></tr></table>
00b84fa9716cbe9bc9a807d189ef9536773e7c0e03bf90a2790e20057fe13687.png
complex
<table><tr><td>Position</td><td><i>&#948;</i><sub>H</sub> (<i>J</i> in Hz)</td><td><i>&#948;</i><sub>C</sub></td><td>HMBC<sup>a</sup></td></tr><tr><td>2</td><td>&#8212;</td><td>162.7</td><td> </td></tr><tr><td>3</td><td>6.16 1H, d (9.6)</td><td>115.7</td><td>C-2, 4a</td></tr><tr><td>4</td><td>7.64 1H, d (9.6)</td><td>145.7</td><td>C-2, 5</td></tr><tr><td>4a</td><td>&#8212;</td><td>116.9</td><td> </td></tr><tr><td>5</td><td>6.90 1H, s</td><td>105.9</td><td>C-4, 6, 7, 8a</td></tr><tr><td>6</td><td>&#8212;</td><td>151.8</td><td> </td></tr><tr><td>7</td><td>&#8212;</td><td>143.1</td><td> </td></tr><tr><td>8</td><td>&#8212;</td><td>142.7</td><td> </td></tr><tr><td>8a</td><td>&#8212;</td><td>144.0</td><td> </td></tr><tr><td>1&#8242;</td><td>5.20 1H, d (7.5)</td><td>103.9</td><td>C-7</td></tr><tr><td>2&#8242;</td><td>3.55 1H, dd (7.5, 9.0)</td><td>75.7</td><td>C-1&#8242;, 3&#8242;,</td></tr><tr><td>3&#8242;</td><td>3.47 1H, t (9.0)</td><td>77.9</td><td>C-2&#8242;, 4&#8242;</td></tr><tr><td>4&#8242;</td><td>3.40 (1H, t, 9.0)</td><td>72.2</td><td>C-3&#8242;, 5&#8242;</td></tr><tr><td>5&#8242;</td><td>3.50 1H, m</td><td>75.9</td><td>C-4&#8242;</td></tr><tr><td rowspan="2">6&#8242;</td><td>4.39 1H, dd (11.4, 7.2)</td><td rowspan="2">64.4</td><td rowspan="2">C-4&#8242;, 5&#8242;</td></tr><tr><td>4.34 1H, dd (11.4, 2.0)</td></tr><tr><td>1&#8242;&#8242;</td><td>&#8212;</td><td>127.1</td><td> </td></tr><tr><td>2&#8242;&#8242;/6&#8242;&#8242;</td><td>7.32 2H, d (8.7)</td><td>131.3</td><td>C-4&#8242;&#8242;</td></tr><tr><td>3&#8242;&#8242;/5&#8242;&#8242;</td><td>6.80 2H, d (8.7)</td><td>117.1</td><td>C-1&#8242;&#8242;, 4&#8242;&#8242;</td></tr><tr><td>4&#8242;&#8242;</td><td>&#8212;</td><td>161.5</td><td> </td></tr><tr><td>7&#8242;&#8242;</td><td>7.37 1H, d (15.9)</td><td>146.5</td><td>C-1&#8242;&#8242;, 2&#8242;&#8242;/6&#8242;&#8242;, 9&#8242;&#8242;</td></tr><tr><td>8&#8242;&#8242;</td><td>6.10 1H, d (15.9)</td><td>114.9</td><td>C-7&#8242;&#8242;, 9&#8242;&#8242;</td></tr><tr><td>9&#8242;&#8242;</td><td>&#8212;</td><td>168.7</td><td> </td></tr><tr><td>6-OMe</td><td>3.88 3H, s</td><td>57.2</td><td>C-6</td></tr><tr><td>8-OMe</td><td>3.99 3H, s</td><td>62.5</td><td>C-8</td></tr></table>
a9ad38acc6b5c412d7a583375df5a8c49c6be5ec71fe488e6955dc0b0e609925.png
simple
<table><tr><td>Parameter</td><td>DB</td></tr><tr><td>HISTogram parameter ( HIST )</td><td>0.53</td></tr><tr><td>Zero Crossing parameter (ZC)</td><td>0.70</td></tr><tr><td>Auto Regressive coefficients (AR)</td><td>1.01</td></tr><tr><td>Integral Absolute Value (IAV)</td><td>1.24</td></tr></table>
683c763cf5942afbbfbce925486b860b1cf258935f065d7bcde9c8cfa74f5883.png
simple
<table><tr><td>Name</td><td>Sequence 5'-3'</td><td>Description</td></tr><tr><td>H-exon 2-3 reverse</td><td>ATTTGTGATACCCCTCGACGAG</td><td>Normal human ERCC1 transcript reverse primer</td></tr><tr><td>Hskin4RTreverse</td><td>TGTACAGAGATCGCCCTGCTCTATGC</td><td>Larger Human ERCC1 transcript reverse primer</td></tr><tr><td>REV1</td><td>CGGTCCTCCAGAACCATAGA</td><td>Larger Human ERCC1 transcript reverse primer</td></tr><tr><td>Oligo dT anchor</td><td>GACCACGCGTATCGATGTCGACTTTTTTTTTTTTTTTTV (V=A, C or G)</td><td>Anchor primer</td></tr><tr><td>PCR anchor</td><td>GACCACGCGTATCGATGTCGA</td><td>Internal anchor primer</td></tr></table>
850cc88ae4f07198d3d3bc93758f216a207f84904aaae56e8cc29e0c777daecf.png
simple
<table><tr><td>Antibiotics</td><td>Disk Potency (&#956;g)</td><td>Susceptible</td><td>Intermediate</td><td>Resistant</td></tr><tr><td>Chloramphenicol (C)</td><td>30</td><td>41(100%)</td><td>0</td><td>0</td></tr><tr><td>Erythromycin (E)</td><td>15</td><td>38(92.5%)</td><td>0</td><td>3(7.5%)</td></tr><tr><td>Ampicillin (AMP)</td><td>10</td><td>35(85.4%)</td><td>0</td><td>6(14.6%)</td></tr><tr><td>Vancomycin (VA)</td><td>30</td><td>34(83%)</td><td>0</td><td>7(17%)</td></tr><tr><td>Penicillin G (P)</td><td>10</td><td>33(80.5%)</td><td>0</td><td>8(19.5%)</td></tr><tr><td>Clindamycin (DA)</td><td>2</td><td>30(73.2%)</td><td>0</td><td>11(26.8%)</td></tr><tr><td>Cefotaxime (CTX)</td><td>30</td><td>27(65.9%)</td><td>0</td><td>14(34.1%)</td></tr><tr><td>Tetracycline (TE)</td><td>30</td><td>3(7.3%)</td><td>1(2.4%)</td><td>37(90.2%)</td></tr></table>
e524dc9e6ee79fef98c43025535188dc2bb4f4625d881aea0c79787f486acc6a.png
simple
<table><tr><td></td><td></td><td>2008</td><td>2009</td><td>2010</td><td>2011</td></tr><tr><td>N</td><td>CM</td><td>304</td><td>295</td><td>269</td><td>297</td></tr><tr><td></td><td>ICHM</td><td>366</td><td>366</td><td>375</td><td>376</td></tr><tr><td>Female (n (%))</td><td>CM</td><td>187 (61.5%)</td><td>166 (56.3%)</td><td>150 (55.8%)</td><td>171 (57.6%)</td></tr><tr><td></td><td>ICHM</td><td>222 (60.7%)</td><td>213 (58.2%)</td><td>207 (55.2%)</td><td>223 (59.3%)</td></tr><tr><td>Age (mean (SD) (median, range))</td><td>CM</td><td>80.8 (8.5) (83, 60 to 101)</td><td>80.6 (9.3) (83, 60 to 101)</td><td>81.3 (9.2) (83, 60 to 98)</td><td>81.3 (9.5) (83, 60 to 100)</td></tr><tr><td></td><td>ICHM</td><td>80.5 (8.4) (82, 60 to 100)</td><td>79.5 (8.9) (81, 60 to 99)</td><td>80.3 (8.8) (82, 60 to 99)</td><td>79.9 (9.3) (81, 60 to 100)</td></tr><tr><td>Functional status (mean (SD) (median, range))</td><td>CM</td><td>2.0 (0.8) (2, 1 to 4)</td><td>2.3 (0.9) (2, 1 to 5)</td><td>2.3 (0.9) (2, 1 to 5)</td><td>2.3 (0.9) (2, 1 to 5)</td></tr><tr><td></td><td>ICHM</td><td>2.2 (0.9) (2, 1 to 5)</td><td>2.2 (0.9) (2, 1 to 5)</td><td>2.1 (0.9) (2, 1 to 5)</td><td>2.1 (0.9) (2, 1 to 5)</td></tr></table>
2282bf6b5a4f0a60b45ad11ad6a77a401cd924622cfed2c5e61ec16487774a8f.png
complex
<table><tr><td rowspan="2"></td><td colspan="3">Diamniadio District</td><td colspan="3">Rufisque District</td></tr><tr><td>Before</td><td>During</td><td>% Increase</td><td>Before</td><td>During</td><td>% Increase</td></tr><tr><td>Number of contraceptives provided</td><td>8,351</td><td>11,935</td><td>43%</td><td>17,551</td><td>22,779</td><td>30%</td></tr><tr><td>Pills</td><td>4,540</td><td>6,097</td><td>34%</td><td>9,465</td><td>11,867</td><td>25%</td></tr><tr><td>Injectables</td><td>3,568</td><td>5,277</td><td>48%</td><td>7,224</td><td>9,373</td><td>30%</td></tr><tr><td>Implants</td><td>187</td><td>470</td><td>151%</td><td>536</td><td>1,097</td><td>105%</td></tr><tr><td>Intrauterine devices (IUDs)</td><td>56</td><td>91</td><td>63%</td><td>326</td><td>442</td><td>36%</td></tr><tr><td>Long-acting methods</td><td>243</td><td>561</td><td>131%</td><td>862</td><td>1,539</td><td>79%</td></tr><tr><td>Couple-years of protection</td><td>2,164</td><td>3,932</td><td>82%</td><td>5,977</td><td>9,340</td><td>56%</td></tr></table>
ae71b744ceb7836973bbdd63a7b7a1b9506791c7ba760cbe87ecf0948f575d51.png
complex
<table><tr><td></td><td colspan="2">Men with varicocele</td><td colspan="2">Men without varicocele</td></tr><tr><td></td><td>Normal sperm</td><td>Sperm disturbances</td><td>Normal sperm</td><td>Sperm disturbances</td></tr><tr><td>Dark-eyed men </td><td>25.6%</td><td>74.4%</td><td>16.7%</td><td>83.3%</td></tr><tr><td>Light-eyed men</td><td>44.4%</td><td>55.6%</td><td>23.4%</td><td>76.6%</td></tr><tr><td><i>P</i></td><td colspan="2">0.419</td><td colspan="2">0.586</td></tr></table>
3787c370c372de4b0226fbd11c8d88abbf2be424e71ba8682cbcb6998f6599b0.png
complex
<table><tr><td>Variables</td><td>No (%)</td></tr><tr><td colspan="2">Perceived need*</td></tr><tr><td> Food</td><td>114 (97.4%)</td></tr><tr><td> Shelter</td><td>88 (75.2%)</td></tr><tr><td> Water (Drinking &amp; Washing)</td><td>74 (63.2%)</td></tr><tr><td> Clothes</td><td>55 (47.0%)</td></tr><tr><td> Information about Family Members/relatives</td><td>35 (29.9%)</td></tr><tr><td> Adsorbents for Menstrual Hygiene</td><td>22 (18.8%)</td></tr><tr><td> Mobiles</td><td>17 (14.5%)</td></tr><tr><td> Medicine/First aid</td><td>13 (11.1%)</td></tr><tr><td> Safe place</td><td>12 (10.3%)</td></tr><tr><td> Soap</td><td>8 (6.8%)</td></tr><tr><td> Cattle</td><td>7 (6.0%)</td></tr></table>
2930504993e0e67ab781457d687d2fc832bea6b43b62c7b838a2dac3b154b544.png
complex
<table><tr><td></td><td colspan="4"><i>X. dendrorhous</i>strains</td></tr><tr><td></td><td colspan="2">CBS 6938</td><td colspan="2">CBS<i>-CYP51</i><sup>+/&#8722;</sup></td></tr><tr><td>Cultivation Time (h)</td><td>48</td><td>120</td><td>48</td><td>120</td></tr><tr><td>Sterols:</td><td>5.6 &#177; 0.2</td><td>3.8 &#177; 0.4</td><td>3.2 &#177; 0.7</td><td>4.9 &#177; 0.8</td></tr><tr><td>Total Carotenoids:</td><td>24 &#177; 5 (100)</td><td>256 &#177; 18 (100)</td><td>325 &#177; 115 (100)</td><td>486 &#177; 54 (100)</td></tr><tr><td> Astaxanthin</td><td>19 &#177; 4 (78)</td><td>174 &#177; 23 (68)</td><td>95 &#177; 27 (29)</td><td>203 &#177; 20 (42)</td></tr><tr><td> Phoenicoxanthin</td><td>2.5 &#177; 0.7(10)</td><td>30.0 &#177; 0.8 (12)</td><td>37 &#177; 15 (11)</td><td>74 &#177; 14 (15)</td></tr><tr><td> Canthaxanthin</td><td>ND</td><td>ND</td><td>9 &#177; 5 (3)</td><td>12 &#177; 6 (3)</td></tr><tr><td> Echinenone</td><td>ND</td><td>ND</td><td>4 &#177; 7 (1)</td><td>ND</td></tr><tr><td> &#946;-carotene</td><td>ND</td><td>12 &#177; 6 (5)</td><td>67 &#177; 33 (21)</td><td>55 &#177; 15 (11)</td></tr><tr><td> Lycopene</td><td>ND</td><td>ND</td><td>7 &#177; 6 (2)</td><td>ND</td></tr><tr><td> Monocyclic carotenoids</td><td>2.8 &#177; 0.8 (11)</td><td>40 &#177; 3 (16)</td><td>107 &#177; 40 (33)</td><td>149 &#177; 27 (31)</td></tr></table>
1487285ad65d495cff62cf4678169b3cbd5511d760172bb33b19b558e485cc00.png
simple
<table><tr><td>Taxon</td><td>Dry (<i>n</i> = 16)</td><td>Wet (<i>n</i> = 16)</td><td>Pooled SEM</td><td><i>P</i>-value</td><td><i>q-</i>value</td></tr><tr><td>Actinobacteria</td><td>16.5</td><td>0.1</td><td>3.8</td><td>0.011</td><td>0.068</td></tr><tr><td>Bacteroidetes</td><td>8.7</td><td>15.9</td><td>4.7</td><td>0.010</td><td>0.062</td></tr><tr><td>Firmicutes</td><td>73.6</td><td>57.6</td><td>7.7</td><td>0.090</td><td>0.539</td></tr><tr><td>Fusobacteria</td><td>0.3</td><td>23.1</td><td>2.9</td><td>&lt;0.000</td><td>&lt;0.000</td></tr><tr><td>Proteobacteria</td><td>0.4</td><td>1.1</td><td>0.2</td><td>0.008</td><td>0.047</td></tr><tr><td>Unclassified bacteria</td><td>0.5</td><td>2.1</td><td>0.2</td><td>&lt;0.000</td><td>0.002</td></tr></table>
ca325e693654dff2b2cabfb0e82e5c0ebfe6c50cd92cb82fc97d9f9b5f5784f1.png
simple
<table><tr><td>Past Week NSSI Measures</td><td><i>n</i></td><td><i>d</i></td><td><i>p</i></td></tr><tr><td>Number of NSSI episodes (ABASI)</td><td>1514</td><td>.13</td><td>.01</td></tr><tr><td>Medical severity of NSSI (ABASI)</td><td>1239</td><td>.29</td><td>&lt;.001</td></tr><tr><td>Impulsivity of NSSI (ABASI)</td><td>1234</td><td>-.01</td><td>.87</td></tr><tr><td>Craving for NSSI (ABUSI total score)</td><td>1476</td><td>1.16</td><td>&lt;.001</td></tr><tr><td>Past Year NSSI Methods (ABASI)</td><td></td><td></td><td></td></tr><tr><td>Cut</td><td>676</td><td>.13</td><td>.09</td></tr><tr><td>Scratch</td><td>676</td><td>.20</td><td>.01</td></tr><tr><td>Burn</td><td>676</td><td>.12</td><td>.11</td></tr><tr><td>Tattoo/Pierce</td><td>676</td><td>.01</td><td>.91</td></tr><tr><td>Choke</td><td>676</td><td>.33</td><td>&lt;.001</td></tr><tr><td>Pull Hair</td><td>676</td><td>.20</td><td>.01</td></tr><tr><td>Draw Blood</td><td>676</td><td>.09</td><td>.25</td></tr><tr><td>Insert/Embed</td><td>676</td><td>.19</td><td>.01</td></tr><tr><td>Hit</td><td>345</td><td>.45</td><td>&lt;.001</td></tr><tr><td>Bang</td><td>676</td><td>.28</td><td>&lt;.001</td></tr><tr><td>Prevent Wound Healing</td><td>676</td><td>.24</td><td>.002</td></tr><tr><td>Fall Down</td><td>676</td><td>.00</td><td>.99</td></tr><tr><td>Break Bones</td><td>676</td><td>.11</td><td>.16</td></tr><tr><td>Gouge</td><td>676</td><td>.05</td><td>.51</td></tr><tr><td>Fight</td><td>676</td><td>.11</td><td>.14</td></tr><tr><td>Ingest/Swallow</td><td>676</td><td>.09</td><td>.25</td></tr><tr><td>Mutilate Genitals</td><td>343</td><td>.00</td><td>1</td></tr><tr><td>Worsen Medical Condition/Ignore Medical Advice</td><td>676</td><td>.23</td><td>.003</td></tr><tr><td>Past Year Number of NSSI Methods (ABASI)</td><td>676</td><td>.52</td><td>&lt;.001</td></tr><tr><td>Past Year Number of Days with NSSI (ABASI)</td><td>345</td><td>.65</td><td>&lt;.001</td></tr></table>
b89fa5df166412fa840e4ca257a41b2ea6f7af7cd8d39e1b8a2f113bb95695d6.png
complex
<table><tr><td rowspan="2">Variable</td><td colspan="2">Univariate Analysis</td><td colspan="2">Multivariate Analysis</td></tr><tr><td>HR (95% CI)</td><td><i>p</i> Value</td><td>HR (95% CI)</td><td><i>p</i> Value</td></tr><tr><td>Age (years)</td><td>0.976 (0.944&#8211;1.008)</td><td>0.140</td><td></td><td></td></tr><tr><td>BMI (kg/m<sup>2</sup>)</td><td>0.863 (0.715&#8211;1.042)</td><td>0.127</td><td></td><td></td></tr><tr><td>L3 SMI (cm<sup>2</sup>/m<sup>2</sup>)</td><td>0.904 (0.830&#8211;0.984)</td><td>0.020</td><td>0.909 (0.836&#8211;0.985)</td><td>0.020</td></tr><tr><td>Child-Pugh score</td><td>0.840 (0.312&#8211;2.265)</td><td>0.730</td><td></td><td></td></tr><tr><td>Albumin (g/dL)</td><td>0.556 (0.180&#8211;1.722)</td><td>0.309</td><td></td><td></td></tr><tr><td>PLT (&#215;10<sup>4</sup>/mL)</td><td>1.049 (0.992&#8211;1.111)</td><td>0.096</td><td></td><td></td></tr><tr><td>log (AFP)</td><td>1.793 (1.162&#8211;2.767)</td><td>0.008</td><td>1.274 (1.0580&#8211;1.534)</td><td>0.010</td></tr><tr><td>log (PIVKA-II)</td><td>1.024 (0.857&#8211;1.224)</td><td>0.794</td><td></td><td></td></tr><tr><td>Stage (IVB <i>vs.</i> others)</td><td>1.062 (0.407&#8211;2.770)</td><td>0.902</td><td></td><td></td></tr><tr><td>Combination therapy (yes <i>vs.</i> no)</td><td>0.533 (0.188&#8211;1.509)</td><td>0.236</td><td></td><td></td></tr></table>
a9b3ce2adeadcdcf75287c6177ff2076488815036645d1596e1284b56a784d9c.png
complex
<table><tr><td>Gene ID</td><td>Gene</td><td>Protein description</td><td>Mean RPKM WT</td><td>Mean RPKM <i>&#916;gacA</i></td><td><i>&#916;gacA</i>/WT</td><td><i>P</i>-value</td></tr><tr><td colspan="7"><i>gacS</i>/<i>gacA</i></td></tr><tr><td> Pchl3084_3491</td><td><i>gacA</i></td><td>Response regulator</td><td>266.9</td><td>1.43</td><td>0.01</td><td>0.00</td></tr><tr><td> Pchl3084_4333</td><td><i>gacS</i></td><td>Sensor protein</td><td>29.17</td><td>21.15</td><td>0.73</td><td>0.05</td></tr><tr><td colspan="7"><i>phz</i> genes</td></tr><tr><td> Pchl3084_4951</td><td><i>phzX</i></td><td>Phenazine biosynthesis protein</td><td>40.50</td><td>4.52</td><td>0.11</td><td>0.03</td></tr><tr><td> Pchl3084_4952</td><td><i>phzY</i></td><td>Phenazine biosynthesis protein</td><td>37.87</td><td>5.28</td><td>0.14</td><td>0.03</td></tr><tr><td> Pchl3084_4953</td><td><i>phzF</i></td><td>Phenazine biosynthesis protein</td><td>20.00</td><td>2.63</td><td>0.13</td><td>0.03</td></tr><tr><td> Pchl3084_4954</td><td><i>phzA</i></td><td>Phenazine biosynthesis protein</td><td>8.52</td><td>0.78</td><td>0.09</td><td>0.15</td></tr><tr><td> Pchl3084_4955</td><td><i>phzB</i></td><td>Phenazine biosynthesis protein</td><td>13.47</td><td>2.08</td><td>0.15</td><td>0.04</td></tr><tr><td> Pchl3084_4956</td><td><i>phzC</i></td><td>Phenazine biosynthesis protein</td><td>8.24</td><td>1.90</td><td>0.23</td><td>0.00</td></tr><tr><td> Pchl3084_4957</td><td><i>phzD</i></td><td>Phenazine biosynthesis protein</td><td>7.63</td><td>1.40</td><td>0.18</td><td>0.10</td></tr><tr><td> Pchl3084_4958</td><td><i>phzO</i></td><td>Phenazine biosynthesis protein</td><td>44.23</td><td>21.70</td><td>0.49</td><td>0.06</td></tr><tr><td colspan="7">Regulatory genes</td></tr><tr><td> Pchl3084_4949</td><td><i>phzI</i></td><td>Autoinducer synthase</td><td>5.24</td><td>1.50</td><td>0.29</td><td>0.01</td></tr><tr><td> Pchl3084_4950</td><td><i>phzR</i></td><td>Transcriptional activator</td><td>125.1</td><td>67.12</td><td>0.54</td><td>0.02</td></tr><tr><td> Pchl3084_1189</td><td><i>rpoS</i></td><td>Sigma factor</td><td>1045.7</td><td>101.8</td><td>0.10</td><td>0.03</td></tr><tr><td> Pchl3084_5155</td><td><i>pip</i></td><td>Phenazine-inducing protein</td><td>123.4</td><td>105.4</td><td>0.85</td><td>0.04</td></tr><tr><td> Pchl3084_1659</td><td><i>iopA</i></td><td>Inducer of phenazine A</td><td>49.10</td><td>8.35</td><td>0.17</td><td>0.01</td></tr><tr><td> Pchl3084_1660</td><td><i>iopB</i></td><td>Inducer of phenazine B</td><td>20.71</td><td>2.51</td><td>0.12</td><td>0.00</td></tr><tr><td> Pchl3084_3224</td><td><i>rpeA</i></td><td>Sensor histidine kinase</td><td>46.78</td><td>49.28</td><td>1.05</td><td>0.67</td></tr><tr><td> Pchl3084_3225</td><td><i>rpeB</i></td><td>Response regulator</td><td>45.37</td><td>55.20</td><td>1.22</td><td>0.07</td></tr><tr><td> Pchl3084_2449</td><td><i>csaI</i></td><td>Autoinducer synthase</td><td>8.15</td><td>8.72</td><td>1.07</td><td>0.65</td></tr><tr><td> Pchl3084_2451</td><td><i>csaR</i></td><td>Transcriptional activator</td><td>0.54</td><td>0.38</td><td>0.71</td><td>0.50</td></tr><tr><td> Pchl3084_0554</td><td><i>hfq</i></td><td>RNA chaperone</td><td>1642.19</td><td>1408.2</td><td>0.84</td><td>0.28</td></tr><tr><td> Pchl3084_4387</td><td><i>rsmA</i></td><td>Translational regulator</td><td>151.82</td><td>307.24</td><td>2.02</td><td>0.03</td></tr><tr><td> Pchl3084_2024</td><td><i>rsmE</i></td><td>Translational regulator</td><td>292.7</td><td>204.83</td><td>0.70</td><td>0.06</td></tr><tr><td> Pchl3084_3970</td><td><i>rsmX</i></td><td>ncRNA</td><td>1486.51</td><td>201.13</td><td>0.14</td><td>0.02</td></tr><tr><td> Pchl3084_5419</td><td><i>rsmY</i></td><td>ncRNA</td><td>38112.4</td><td>329.2</td><td>0.01</td><td>0.02</td></tr><tr><td> Pchl3084_1190</td><td><i>rsmZ</i></td><td>ncRNA</td><td>1679.64</td><td>261.26</td><td>0.16</td><td>0.05</td></tr></table>
cd7115a595cab782db338a8b3f9677cbc584e21e3df87d9cc06bd42055b8afcc.png
simple
<table><tr><td>Grade</td><td>Description</td></tr><tr><td>0</td><td>No changes</td></tr><tr><td>1</td><td>Doubtful narrowing of joint space and possible osteophytic lipping</td></tr><tr><td>2</td><td>Definite osteophytes and possible narrowing of joint space</td></tr><tr><td>3</td><td>Moderate multiple osteophytes, definite narrowing of joint space, and some sclerosis, and possible deformity of bone ends</td></tr><tr><td>4</td><td>Large osteophytes, marked narrowing of joint space, severe sclerosis and definite deformity of bone ends</td></tr></table>
46ee6d84e872912fc4b0484d1bfd2f8a9e5f7a86cb6eebc1d864a76afdd7f7a4.png
complex
<table><tr><td rowspan="2" colspan="2"></td><td colspan="2">cELISA assay</td><td rowspan="2">Total</td></tr><tr><td><i>P</i></td><td><i>N</i></td></tr><tr><td rowspan="2">Skin test</td><td><i>P</i></td><td>45</td><td>31</td><td>76</td></tr><tr><td><i>N</i></td><td>45</td><td>177</td><td>222</td></tr><tr><td colspan="2">Total</td><td>90</td><td>208</td><td>298</td></tr></table>
f3a903fc71bedd91e4b3360f7b5b22740776198637d6f6b64e72dac10a486c92.png
complex
<table><tr><td rowspan="3">Indicator</td><td colspan="4">Baseline</td><td colspan="4">Mid-term</td><td colspan="4">End-term</td><td rowspan="3">DID adjusted BL-ML</td><td rowspan="3">Sig.</td><td rowspan="3">DID adjusted BL-EL</td><td rowspan="3">Sig.</td></tr><tr><td colspan="2">Comparison</td><td colspan="2">Intervention</td><td colspan="2">Comparison</td><td colspan="2">Intervention</td><td colspan="2">Comparison</td><td colspan="2">Intervention</td></tr><tr><td>%</td><td><i>N</i></td><td>%</td><td><i>N</i></td><td>%</td><td><i>N</i></td><td>%</td><td><i>N</i></td><td>%</td><td><i>N</i></td><td>%</td><td><i>N</i></td></tr><tr><td>Proportion of women reporting health worker introduction</td><td>26%</td><td>53</td><td>37%</td><td>68</td><td>30%</td><td>89</td><td>38%</td><td>120</td><td>40%</td><td>62</td><td>49%</td><td>85</td><td>&#8722;4%</td><td>0.77</td><td>&#8722;4%</td><td>0.82</td></tr><tr><td>Proportion of women reporting having been clinically examined</td><td>57%</td><td>53</td><td>46%</td><td>68</td><td>99%</td><td>89</td><td>96%</td><td>120</td><td>92%</td><td>62</td><td>91%</td><td>85</td><td>5%</td><td>0.73</td><td>6%</td><td>0.75</td></tr><tr><td>Proportion of women reporting having received an explanation of the examination</td><td>100%</td><td>30</td><td>100%</td><td>31</td><td>64%</td><td>88</td><td>58%</td><td>115</td><td>54%</td><td>57</td><td>58%</td><td>77</td><td>&#8722;5%</td><td>0.69</td><td>&#8722;2%</td><td>0.85</td></tr><tr><td>Proportion of women reporting having received medication/treatment</td><td>92%</td><td>53</td><td>71%</td><td>68</td><td>87%</td><td>89</td><td>88%</td><td>120</td><td>66%</td><td>62</td><td>79%</td><td>85</td><td>23%</td><td>0.07</td><td>29%</td><td>0.03*</td></tr><tr><td>Proportion of women reporting having received an explanation for the medication</td><td>59%</td><td>49</td><td>63%</td><td>48</td><td>42%</td><td>77</td><td>46%</td><td>106</td><td>56%</td><td>41</td><td>73%</td><td>67</td><td>&#8722;3%</td><td>0.85</td><td>12%</td><td>0.54</td></tr><tr><td>Proportion of women reporting having had a blood test done</td><td>26%</td><td>53</td><td>47%</td><td>68</td><td>21%</td><td>89</td><td>8%</td><td>120</td><td>23%</td><td>62</td><td>36%</td><td>85</td><td>&#8722;35%</td><td>0.03</td><td>&#8722;2%</td><td>0.90</td></tr><tr><td>Proportion of women reporting having received an explanation for the test</td><td>93%</td><td>14</td><td>75%</td><td>32</td><td>32%</td><td>19</td><td>30%</td><td>10</td><td>64%</td><td>14</td><td>65%</td><td>31</td><td>9%</td><td>0.69</td><td>10%</td><td>0.65</td></tr><tr><td>Proportion of women reporting consent being sought before procedures were performed</td><td>55%</td><td>53</td><td>61%</td><td>66</td><td>62%</td><td>87</td><td>63%</td><td>112</td><td>68%</td><td>60</td><td>75%</td><td>77</td><td>&#8722;5%</td><td>0.73</td><td>1%</td><td>0.96</td></tr><tr><td>Proportion of women having been encouraged to ask questions</td><td>36%</td><td>53</td><td>49%</td><td>68</td><td>25%</td><td>89</td><td>33%</td><td>120</td><td>45%</td><td>62</td><td>58%</td><td>85</td><td>&#8722;8%</td><td>0.63</td><td>2%</td><td>0.89</td></tr><tr><td>Proportion of women reporting being offered to have guardian during delivery</td><td>42%</td><td>53</td><td>57%</td><td>68</td><td>22%</td><td>89</td><td>58%</td><td>120</td><td>50%</td><td>62</td><td>55%</td><td>85</td><td>18%</td><td>0.29</td><td>3%</td><td>0.87</td></tr><tr><td>Proportion of women reporting their privacy/confidentiality being protected</td><td>96%</td><td>53</td><td>96%</td><td>68</td><td>91%</td><td>89</td><td>94%</td><td>120</td><td>90%</td><td>62</td><td>96%</td><td>85</td><td>3%</td><td>0.67</td><td>8%</td><td>0.55</td></tr><tr><td>Proportion of women reporting blood pressure was checked before delivery</td><td>53%</td><td>53</td><td>51%</td><td>68</td><td>49%</td><td>89</td><td>37%</td><td>120</td><td>61%</td><td>62</td><td>65%</td><td>85</td><td>&#8722;15%</td><td>0.22</td><td>19%</td><td>0.26</td></tr><tr><td>Proportion of women reporting blood pressure was checked after delivery</td><td>40%</td><td>53</td><td>44%</td><td>68</td><td>66%</td><td>89</td><td>57%</td><td>116</td><td>45%</td><td>58</td><td>68%</td><td>81</td><td>&#8722;13%</td><td>0.36</td><td>19%</td><td>0.25</td></tr></table>
09cd72a5bdf9942af78d7052ce66f85f6a30ed93adbce376e795bfe3e55be402.png
simple
<table><tr><td>Country</td><td>Region</td><td>Classification category of country for ZIKV transmission as per WHO</td><td>Number of cases reported</td></tr><tr><td>American Samoa</td><td>American Samoa</td><td>Category 3 (interrupted transmission areas)</td><td>51</td></tr><tr><td>Angola</td><td>Angola</td><td>Category 1 (virus transmission areas followed by new/re introduction of virus)</td><td>2</td></tr><tr><td>Argentina</td><td>Chaco, Formosa, Salta, Tucuman</td><td>Category 1 (virus transmission areas followed by new/re introduction of virus)</td><td>4</td></tr><tr><td>Bahamas</td><td>Bahamas</td><td>Category 1 (virus transmission areas followed by new/re introduction of virus)</td><td>25</td></tr><tr><td>Bangladesh</td><td>Bangladesh</td><td>Category 2 (virus transmission areas following previous circulation of virus)</td><td>1</td></tr><tr><td>Brazil</td><td>Acre, Alagoas, Amapa Amazonas, Ceara, Distrito Federal, Espirito Santo, Goias, Mato Grosso, Mato Grosso Do Sul, Minas Gerais, Para, Paraiba, Parana, Pernambuco, Piaui, Rio Grande Do Norte, Rio Grande Do Sul, Rondonia, Roraima, Santa Catarina, Sao Paulo, Sergipe, Tocantin</td><td>Category 1 (virus transmission areas followed by new/re introduction of virus)</td><td>27</td></tr><tr><td></td><td>Bahia, Maranhao</td><td>Category 2 (newly documented intense transmission areas)</td><td></td></tr><tr><td></td><td>Rio de Janeiro</td><td>Category 2 (virus transmission areas following previous circulation of virus)</td><td></td></tr><tr><td>Colombia</td><td>Colombia</td><td>Category 1 (virus transmission areas followed by new/re introduction of virus)</td><td>46</td></tr><tr><td>Costa Rica</td><td>Costa Rica</td><td>Category 1 (virus transmission areas followed by new/re introduction of virus)</td><td>23</td></tr><tr><td>Dominican Republic</td><td>Dominican Republic</td><td>Category 1 (virus transmission areas followed by new/re introduction of virus)</td><td>30</td></tr><tr><td>India</td><td>Gujarat, Tamil Nadu</td><td>Category 2 (virus transmission areas following previous circulation of virus)</td><td>2</td></tr><tr><td>Indonesia</td><td>Bali, Bangka Belitung, Banten, Bengkulu, Daerah Istimewa Yogyakarta, Dki Jakarta, Gorontalo, Jambi, Jawa Barat, Jawa Tengah, Jawa Timur, Kalimantan Barat, Kalimantan Selatan, Kalimantan Tengah, Kalimantan Timur, Kepulauan-Riau, Lampung, Maluku, Maluku Utara, Nanggroe Aceh Darussalam, Nusa Tenggara Barat, Nusa Tenggara Timur, Papua, Papua Barat, Riau, Sulawesi Barat, Sulawesi Selatan, Sulawesi Tengah, Sulawesi Tenggara, Sulawesi Utara, Sumatera Barat, Sumatera Selatan, Sumatera Utara</td><td>Category 2 (virus transmission areas following previous circulation of virus)</td><td>31</td></tr><tr><td>Malaysia</td><td>Malaysia</td><td>Category 2 (virus transmission areas following previous circulation of virus)</td><td>8</td></tr><tr><td>Mexico</td><td>Aguascalientes, Baja California, Baja California Sur, Campeche, Chiapas, Coahuila, Colima, Guerrero, Hidalgo, Jalisco, Michoacan, Morelos, Nayarit, Nuevo Leon, Oaxaca, Puebla, Quintana Roo, San Luis Potosi, Sinaloa, Sonora, Tabasco, Tamaulipas, Veracruz, Yucatan, Zacatecas</td><td>Category 1 (virus transmission areas followed by new/re introduction of virus)</td><td>25</td></tr><tr><td>Philippines</td><td>Philippines</td><td>Category 2 (virus transmission areas following previous circulation of virus)</td><td>57</td></tr><tr><td>Thailand</td><td>Thailand</td><td>Category 2 (newly documented intense transmission areas)</td><td>33</td></tr><tr><td>United States of America</td><td>Cameron</td><td>Category 1 (virus transmission areas followed by new/re introduction of virus)</td><td>202</td></tr><tr><td></td><td>Broward, Miami-Dade, Palm Beach, Pinellas</td><td>Category 3 (interrupted transmission areas)</td><td></td></tr><tr><td>Vietnam</td><td>Vietnam</td><td>Category 2 (newly documented intense transmission areas)</td><td>232</td></tr></table>
f7e7d489878d0afd65e2d6a47d6a72ca08f2c034121af4bf7d19083d0450ed9e.png
simple
<table><tr><td> </td><td> </td><td>Total</td><td>East</td><td>West</td><td>p-value<sup>*</sup></td></tr><tr><td>Age</td><td>mean (95% CI)</td><td>31.6 (30.8, 32.3)</td><td>35.2 (33.9, 36.5)</td><td>30.0 (29.1, 30.9)</td><td>p &lt; 0.001</td></tr><tr><td> </td><td>range</td><td>(5, 80)</td><td>(8, 74)</td><td>(5, 80)</td><td> </td></tr><tr><td> </td><td>missing</td><td>61</td><td>7</td><td>54</td><td> </td></tr><tr><td>Weight (kg)</td><td>mean (95% CI)</td><td>52.9 (52.3, 53.5)</td><td>55.2 (53.9, 56.4)</td><td>52.3 (51.6, 53.0)</td><td>p &lt; 0.001</td></tr><tr><td> </td><td>range</td><td>(15, 92)</td><td>(18, 85)</td><td>(15, 92)</td><td> </td></tr><tr><td> </td><td>missing</td><td>223</td><td>164</td><td>59</td><td> </td></tr><tr><td>Initial parasite</td><td>geometric mean (95% CI)</td><td>17998 (16861, 19135)</td><td>20478 (18189, 22766)</td><td>16958 (15663, 18253)</td><td>p = 0.007</td></tr><tr><td>density</td><td>range</td><td>(520, 116960)</td><td>(560, 116000)</td><td>(520, 116960)</td><td> </td></tr><tr><td> </td><td>missing</td><td>0</td><td>0</td><td>0</td><td> </td></tr><tr><td>Sex</td><td>male (%)</td><td>1071 (81.1)</td><td>334 (85.2)</td><td>737 (79.4)</td><td>p = 0.014</td></tr><tr><td> </td><td>female (%)</td><td>249 (18.9)</td><td>58 (14.8)</td><td>191 (20.6)</td><td> </td></tr><tr><td> </td><td>missing</td><td>7</td><td>0</td><td>7</td><td> </td></tr></table>
283f16f0ab314d2b3f1a0370c18984769e42e49a21893d6543d18df3ddac81c6.png
simple
<table><tr><td>Number of criteria positively scored</td><td>Sensitivity</td><td>Specificity</td></tr><tr><td>1. criteria or more</td><td>0.88</td><td>0.31</td></tr><tr><td>2. criteria or more</td><td>0.85</td><td>0.41</td></tr><tr><td>3. criteria or more</td><td>0.83</td><td>0.52</td></tr><tr><td>4. criteria or more</td><td>0.78</td><td>0.69</td></tr><tr><td>5. criteria or more</td><td>0.70</td><td>0.85</td></tr><tr><td>6. criteria or more</td><td>0.50</td><td>0.94</td></tr><tr><td>7. criteria</td><td>0.18</td><td>0.98</td></tr></table>
76fa78a5e9c951545a106b1d503dfac21aea3219ec5b1a59a4aff9e2f804ed15.png
simple
<table><tr><td>Confounder</td><td>Variables</td><td>How to measure</td></tr><tr><td>Demographic characteristics</td><td>Age, sex, social status, family size, educational attainment, occupational history, income</td><td>Questionnaire</td></tr><tr><td>Lifestyle</td><td>Smoking, alcohol</td><td>Questionnaire</td></tr><tr><td>Genetic factor</td><td>Family history of diabetes/hypertension</td><td>Questionnaire</td></tr><tr><td>Drugs</td><td>Different medications for diabetes and hypertension</td><td>Clinical record</td></tr></table>
6872f6ac52fa0740c644238eda095e9f94e81c2feda280ceb66edb2b19182842.png
simple
<table><tr><td></td><td>CHr pgmean (SD)</td><td>RSf fLmean (SD)</td></tr><tr><td>Healthy</td><td>33.2 (1.6)</td><td>100.9 (5.3)</td></tr><tr><td>IDA</td><td>24.5 (4.4)</td><td>88.1 (7.8)</td></tr><tr><td>IDA APR</td><td>25.6 (2.5)</td><td>84.7 (4.1)</td></tr><tr><td>ACD</td><td>30.8 (5.1)</td><td>105.5 (10.9)</td></tr><tr><td>CKD</td><td>31.6 (3.5)</td><td>110.6 (8.7)</td></tr></table>
2062b9b06699f1aff2fd0365c3d5837655c508d902c5fa33e022b90fef9ae9ea.png
complex
<table><tr><td rowspan="2">Subgroup</td><td rowspan="2">No. of studies</td><td rowspan="2">ES (95% CI)</td><td rowspan="2"><i>P</i> value</td><td colspan="2">Heterogeneity test</td></tr><tr><td><i>I</i><sup>2</sup>(%)</td><td><i>P</i> value</td></tr><tr><td>T, ES was described by OR</td><td></td><td colspan="2"></td><td colspan="2"></td></tr><tr><td> All</td><td>15</td><td>1.23 (0.98&#8211;1.55)</td><td>0.074</td><td>0</td><td>0.636</td></tr><tr><td> OC</td><td>5</td><td>1.32 (0.89&#8211;1.97)</td><td>0.173</td><td>1.9</td><td>0.396</td></tr><tr><td> LC</td><td>4</td><td>1.08 (0.70&#8211;1.67)</td><td>0.721</td><td>0</td><td>0.469</td></tr><tr><td> NPC</td><td>3</td><td>1.50 (0.86&#8211;2.60)</td><td>0.150</td><td>0</td><td>0.682</td></tr><tr><td> HNC</td><td>2</td><td>0.92 (0.46&#8211;1.83)</td><td>0.808</td><td>62.9</td><td>0.101</td></tr><tr><td>N, ES was described by OR</td><td></td><td colspan="2"></td><td colspan="2"></td></tr><tr><td> All</td><td>17</td><td>1.28 (1.03&#8211;1.60)</td><td>0.027</td><td>21.6</td><td>0.202</td></tr><tr><td> OC</td><td>6</td><td>1.49 (1.01&#8211;2.20)</td><td>0.043</td><td>0</td><td>0.604</td></tr><tr><td> LC</td><td>4</td><td>0.90 (0.46&#8211;1.76)</td><td>0.763</td><td>65.4</td><td>0.034</td></tr><tr><td> NPC</td><td>3</td><td>1.36 (0.88&#8211;2.09)</td><td>0.165</td><td>0</td><td>0.381</td></tr><tr><td> HNC</td><td>3</td><td>1.38 (0.83&#8211;2.28)</td><td>0.215</td><td>27.9</td><td>0.250</td></tr><tr><td>TNM, ES was described by OR</td><td></td><td colspan="2"></td><td colspan="2"></td></tr><tr><td> All</td><td>14</td><td>1.33 (1.06&#8211;1.66)</td><td>0.015</td><td>0</td><td>0.505</td></tr><tr><td> OC</td><td>5</td><td>1.58 (1.05&#8211;2.37)</td><td>0.030</td><td>0</td><td>0.926</td></tr><tr><td> LC</td><td>2</td><td>1.22 (0.67&#8211;2.25)</td><td>0.519</td><td>56.4</td><td>0.130</td></tr><tr><td> NPC</td><td>3</td><td>1.01 (0.61&#8211;1.67)</td><td>0.979</td><td>0</td><td>0.843</td></tr><tr><td> HNC</td><td>3</td><td>1.64 (1.02&#8211;2.62)</td><td>0.041</td><td>64.8</td><td>0.058</td></tr><tr><td>OS, ES was described by HR</td><td></td><td colspan="2"></td><td colspan="2"></td></tr><tr><td> All</td><td>19</td><td>1.93 (1.29&#8211;2.90)</td><td>0.001</td><td>87.9</td><td>0.000</td></tr><tr><td> OC</td><td>5</td><td>1.65 (0.90&#8211;3.03)</td><td>0.106</td><td>53.3</td><td>0.073</td></tr><tr><td> LC</td><td>3</td><td>4.80 (0.73&#8211;31.6)</td><td>0.103</td><td>90.6</td><td>0.000</td></tr><tr><td> NPC</td><td>6</td><td>1.51 (0.52&#8211;4.42)</td><td>0.452</td><td>94.5</td><td>0.000</td></tr><tr><td> HNC</td><td>2</td><td>1.79 (0.85&#8211;3.77)</td><td>0.128</td><td>55.6</td><td>0.013</td></tr><tr><td>RFS, ES was described by HR</td><td></td><td colspan="2"></td><td colspan="2"></td></tr><tr><td> All</td><td>7</td><td>2.02 (1.00&#8211;4.08)</td><td>0.050</td><td>82.5</td><td>0.000</td></tr><tr><td> LC</td><td>3</td><td>2.35 (0.98&#8211;5.63)</td><td>0.055</td><td>49.3</td><td>0.139</td></tr><tr><td> NPC</td><td>2</td><td>2.24 (0.31&#8211;16.2)</td><td>0.422</td><td>94.3</td><td>0.000</td></tr><tr><td>DFS, ES was described by HR</td><td></td><td colspan="2"></td><td colspan="2"></td></tr><tr><td> All</td><td>3</td><td>5.14 (2.84&#8211;9.31)</td><td>0.000</td><td>61.6</td><td>0.074</td></tr></table>
3095852603a48962cb2af47497e19929cdccc4dd58aa6a613317b8a416a8c2b2.png
complex
<table><tr><td></td><td colspan="3">Nucleotides</td><td colspan="4">Amino acids</td></tr><tr><td></td><td>MCMCTreeWAG + G</td><td>PhyloBayesLG + G</td><td>PhyloBayesCAT-GTR + G</td><td>MCMCTree GTR + G</td><td>PhyloBayes GTR + G</td><td>PhyloBayesCAT-GTR + G</td><td>TimeTreemean/median<sup>b</sup></td></tr><tr><td>Turtles and archosaurs MRCA</td><td>229 (200 to 253)</td><td>228 (208 to 252)</td><td>249 (233 to 270)</td><td>228 (188 to 256)</td><td>225 (212 to 240)</td><td>258 (238 to 274)</td><td>244/265</td></tr><tr><td>Archosaurs MRCA</td><td>200 (166 to 231)</td><td>188 (162 to 217)</td><td>211 (186 to 236)</td><td>209 (168 to 241)</td><td>201 (180 to 221)</td><td>226 (199 to 249)</td><td>238/245</td></tr><tr><td>Turtles MRCA</td><td>121 (63 to 183)</td><td>126 (85 to 166)</td><td>147 (104 to 185)</td><td>107 (53 to 183)</td><td>133 (93 to 171)</td><td>167 (120 to 207)</td><td>207/211</td></tr><tr><td><i>Caretta</i>/<i>Emys </i>+ <i>Cheloinidis</i></td><td>77 (40 to 127)</td><td>83 (47 to 117)</td><td>99 (64 to 139)</td><td>69 (34 to 129)</td><td>90 (52 to 125)</td><td>115 (71 to 154)</td><td>97/99</td></tr><tr><td><i>Emys</i>/<i>Chelonoidis</i></td><td>65 (25 to 116)</td><td>71 (38 to 102)</td><td>87 (54 to 124)</td><td>52 (16 to 112)</td><td>74 (39 to 106)</td><td>95 (56 to 131)</td><td>70/70</td></tr><tr><td><i>Caiman</i>/<i>Alligator</i></td><td>72 (15 to 156)</td><td>54 (33 to 86)</td><td>61 (35 to 93)</td><td>60 (11 to 160)</td><td>39 (21 to 66)</td><td>46 (24 to 87)</td><td>70/72</td></tr><tr><td><i>Podarcis</i>/<i>Python + Anolis</i></td><td>171 (119 to 218)</td><td>150 (116 to 183)</td><td>134 (100 to 172)</td><td>167 (108 to 219)</td><td>150 (122 to 181)</td><td>119 (90 to 151)</td><td>190/178</td></tr><tr><td><i>Python</i>/<i>Anolis</i></td><td>147 (81 to 198)</td><td>136 (98 to 71)</td><td>127 (93 to 167)</td><td>141 (58 to 199)</td><td>135 (101 to 161)</td><td>105 (74 to 136)</td><td>171/163</td></tr></table>
e18bea0c15ae6d8f45ab6317fe4bc19b972e19472bac858db41f610941b1fc94.png
simple
<table><tr><td>Variable</td><td>Year/Region</td><td>With WNV Mean Rank</td><td>Without WNV Mean Rank</td><td>z-score</td><td><i>P</i></td></tr><tr><td>Precipitation</td><td>2002/East</td><td>701</td><td>695</td><td>-0.16</td><td>0.88</td></tr><tr><td></td><td>2002/West</td><td>776</td><td>619</td><td>-2.31</td><td>0.021</td></tr><tr><td></td><td>2003/East</td><td>733</td><td>694</td><td>-0.53</td><td>0.6</td></tr><tr><td></td><td>2003/West</td><td>465</td><td>637</td><td>-4.57</td><td>&lt;0.001</td></tr><tr><td></td><td>2004/East</td><td>678</td><td>695</td><td>-0.14</td><td>0.89</td></tr><tr><td></td><td>2004/West</td><td>626</td><td>623</td><td>-0.23</td><td>0.98</td></tr><tr><td></td><td>2005/East</td><td>679</td><td>695</td><td>-0.96</td><td>0.92</td></tr><tr><td></td><td>2005/West</td><td>623</td><td>624</td><td>-0.01</td><td>0.99</td></tr><tr><td></td><td>2006/East</td><td>421</td><td>697</td><td>-2.27</td><td>0.023</td></tr><tr><td></td><td>2006/West</td><td>526</td><td>625</td><td>-1.35</td><td>0.18</td></tr><tr><td>Dewpoint</td><td>2002/East</td><td>708</td><td>695</td><td>-0.74</td><td>0.94</td></tr><tr><td></td><td>2002/West</td><td>581</td><td>625</td><td>-0.65</td><td>0.52</td></tr><tr><td></td><td>2003/East</td><td>747</td><td>694</td><td>-0.71</td><td>0.48</td></tr><tr><td></td><td>2003/West</td><td>479</td><td>636</td><td>-4.15</td><td>&lt;0.001</td></tr><tr><td></td><td>2004/East</td><td>516</td><td>696</td><td>-1.49</td><td>0.14</td></tr><tr><td></td><td>2004/West</td><td>512</td><td>625</td><td>-1.08</td><td>0.28</td></tr><tr><td></td><td>2005/East</td><td>547</td><td>695</td><td>-0.91</td><td>0.37</td></tr><tr><td></td><td>2005/West</td><td>616</td><td>624</td><td>-0.11</td><td>0.91</td></tr><tr><td></td><td>2006/East</td><td>881</td><td>694</td><td>-1.55</td><td>0.12</td></tr><tr><td></td><td>2006/West</td><td>450</td><td>627</td><td>-2.4</td><td>0.017</td></tr><tr><td>Max. Temp.</td><td>2002/East</td><td>780</td><td>694</td><td>-1.04</td><td>0.3</td></tr><tr><td></td><td>2002/West</td><td>579</td><td>625</td><td>-0.67</td><td>0.5</td></tr><tr><td></td><td>2003/East</td><td>730</td><td>695</td><td>-0.49</td><td>0.63</td></tr><tr><td></td><td>2003/West</td><td>607</td><td>636</td><td>-0.48</td><td>0.64</td></tr><tr><td></td><td>2004/East</td><td>536</td><td>696</td><td>-1.32</td><td>0.19</td></tr><tr><td></td><td>2004/West</td><td>412</td><td>626</td><td>-2.05</td><td>0.041</td></tr><tr><td></td><td>2005/East</td><td>532</td><td>696</td><td>-1.0</td><td>0.32</td></tr><tr><td></td><td>2005/West</td><td>557</td><td>625</td><td>-1.01</td><td>0.31</td></tr><tr><td></td><td>2006/East</td><td>877</td><td>694</td><td>-1.51</td><td>0.13</td></tr><tr><td></td><td>2006/West</td><td>559</td><td>625</td><td>-0.88</td><td>0.38</td></tr><tr><td>Min. Temp.</td><td>2002/East</td><td>741</td><td>694</td><td>-0.57</td><td>0.57</td></tr><tr><td></td><td>2002/West</td><td>532</td><td>626</td><td>-1.38</td><td>0.17</td></tr><tr><td></td><td>2003/East</td><td>712</td><td>695</td><td>-0.234</td><td>0.81</td></tr><tr><td></td><td>2003/West</td><td>483</td><td>636</td><td>-4.04</td><td>&lt;0.001</td></tr><tr><td></td><td>2004/East</td><td>598</td><td>695</td><td>-0.80</td><td>0.42</td></tr><tr><td></td><td>2004/West</td><td>397</td><td>626</td><td>-2.19</td><td>0.029</td></tr><tr><td></td><td>2005/East</td><td>556</td><td>696</td><td>-0.85</td><td>0.40</td></tr><tr><td></td><td>2005/West</td><td>486</td><td>627</td><td>-2.08</td><td>0.037</td></tr><tr><td></td><td>2006/East</td><td>820</td><td>694</td><td>-1.04</td><td>0.30</td></tr><tr><td></td><td>2006/West</td><td>397</td><td>628</td><td>-3.12</td><td>0.002</td></tr></table>
e7452b9574b027d94284e7ab9c45a9c4d0db464ea83191a2ed95f77780a9dc52.png
simple
<table><tr><td>Tissue type</td><td>Pegcantratinib (MF)</td><td>CT340 (MF)</td><td>Ratio</td></tr><tr><td>Skin with anagen follicles</td><td>1.05</td><td>1.05</td><td>1.00</td></tr><tr><td>Cylindroma and spiradenoma</td><td>0.97</td><td>0.96</td><td>1.01</td></tr><tr><td>Cylindroma only</td><td>1.07</td><td>1.05</td><td>1.02</td></tr><tr><td>Spiradenoma only:</td><td>0.92</td><td>1.01</td><td>0.91</td></tr><tr><td>&#8211; Mean</td><td>1.00</td><td>1.02</td><td>0.99</td></tr><tr><td>&#8211; SD</td><td>0.07</td><td>0.04</td><td>0.05</td></tr><tr><td>&#8211; CV (%)</td><td>7.1</td><td>3.9</td><td>5.0</td></tr></table>
ae46e567858241206f420034a3c4403d6ef8a151af113c9a231afaf6c848a19a.png
simple
<table><tr><td>Case no.</td><td><sup>@</sup>Age/ <sup>$</sup>Gender</td><td>Stage</td><td>Grade</td><td>#Recurrence</td><td>MSI</td></tr><tr><td>BC 1</td><td>45/M</td><td>T2</td><td>High, G3</td><td>2</td><td>*High (BAT &#8211; 26, BAT &#8211; 40)</td></tr><tr><td>BC 2</td><td>59/M</td><td>T1</td><td>High, G2</td><td>1</td><td>High (BAT &#8211; 26, BAT &#8211; 40, D9S1851)</td></tr><tr><td>BC 3</td><td>66/M</td><td>Ta</td><td>Low, G1</td><td>0</td><td>High (D9S283, D9S1851)</td></tr><tr><td>BC 4</td><td>39/M</td><td>T2</td><td>High, G3</td><td>0</td><td>High (BAT &#8211; 26, BAT &#8211; 40, D9S283)</td></tr><tr><td>BC 5</td><td>72/M</td><td>T2</td><td>High, G3</td><td>0</td><td>High (BAT &#8211; 40, D9S1851)</td></tr><tr><td>BC 6</td><td>59/M</td><td>T2</td><td>High, G2</td><td>1</td><td>Low (D9S1851)</td></tr><tr><td>BC 7</td><td>78/M</td><td>T2</td><td>High, G3</td><td>0</td><td>High (D9S283, D9S1851)</td></tr><tr><td>BC 8</td><td>52/M</td><td>Ta</td><td>High, G2</td><td>0</td><td>High (BAT &#8211; 40, D9S283, D9S1851)</td></tr><tr><td>BC 9</td><td>71/M</td><td>Ta</td><td>High, G2</td><td>0</td><td>**Low (BAT &#8211; 40)</td></tr><tr><td>BC 10</td><td>84/M</td><td>T1</td><td>High, G2</td><td>0</td><td>***MSS</td></tr><tr><td>BC 11</td><td>55/M</td><td>T1</td><td>High, G1</td><td>0</td><td>MSS</td></tr><tr><td>BC 12</td><td>53/M</td><td>T2</td><td>High, G2</td><td>0</td><td>Low (D18S58)</td></tr><tr><td>BC 13</td><td>52/M</td><td>T3</td><td>High, G3</td><td>0</td><td>High (D9S283, D9S1851)</td></tr><tr><td>BC 14</td><td>40/M</td><td>T3</td><td>High, G3</td><td>0</td><td>MSS</td></tr><tr><td>BC 15</td><td>55/M</td><td>T2</td><td>High, G3</td><td>0</td><td>MSS</td></tr><tr><td>BC 16</td><td>60/M</td><td>T2</td><td>High, G3</td><td>0</td><td>High (BAT &#8211; 40, D9S283, D18S58)</td></tr><tr><td>BC 17</td><td>66/M</td><td>T1</td><td>High, G3</td><td>1</td><td>High (BAT &#8211; 40, D2S123, D9S283, D9S1851, D18S58)</td></tr><tr><td>BC 18</td><td>80/M</td><td>T1</td><td>High, G3</td><td>1</td><td>High (BAT &#8211; 26, D9S283, D18S58)</td></tr><tr><td>BC 19</td><td>42/M</td><td>T1</td><td>High, G2</td><td>0</td><td>Low (D9S283)</td></tr><tr><td>BC 20</td><td>73/M</td><td>T3a</td><td>High, G3</td><td>0</td><td>MSS</td></tr><tr><td>BC 21</td><td>55/M</td><td>T2</td><td>High, G3</td><td>0</td><td>Low (D2S123)</td></tr><tr><td>BC 22</td><td>58/M</td><td>T2</td><td>High, G3</td><td>0</td><td>High (BAT &#8211; 26, D2S123)</td></tr><tr><td>BC 23</td><td>70/M</td><td>T1</td><td>High, G2</td><td>0</td><td>Low (BAT &#8211; 26)</td></tr><tr><td>BC 24</td><td>53/M</td><td>Ta</td><td>High, G3</td><td>0</td><td>High (D9S1851, D18S58)</td></tr><tr><td>BC 25</td><td>60/M</td><td>T2</td><td>High, G3</td><td>0</td><td>High (D9S283, D9S1851)</td></tr><tr><td>BC 26</td><td>54/M</td><td>Ta</td><td>Low, G1</td><td>0</td><td>MSS</td></tr><tr><td>BC 27</td><td>72/M</td><td>Ta</td><td>High, G2</td><td>0</td><td>MSS</td></tr><tr><td>BC 28</td><td>58/M</td><td>T1</td><td>High, G3</td><td>0</td><td>Low (D9S283)</td></tr><tr><td>BC 29</td><td>80/M</td><td>T2</td><td>High, G3</td><td>0</td><td>High (D9S283, D9S1851)</td></tr><tr><td>BC 30</td><td>64/M</td><td>Ta</td><td>High, G2</td><td>2</td><td>Low (BAT &#8211; 40)</td></tr><tr><td>BC 31</td><td>74/M</td><td>Ta</td><td>High, G3</td><td>0</td><td>High (D9S283, D9S1851)</td></tr><tr><td>BC 32</td><td>60/M</td><td>T1</td><td>Low, G1</td><td>0</td><td>MSS</td></tr><tr><td>BC 33</td><td>41/M</td><td>T1</td><td>Low, G1</td><td>3</td><td>Low (BAT &#8211; 26)</td></tr><tr><td>BC 34</td><td>66/ F</td><td>T2</td><td>High, G3</td><td>0</td><td>High (D2S123, D9S283)</td></tr><tr><td>BC 35</td><td>53/M</td><td>T1</td><td>Low, G1</td><td>0</td><td>Low (D2S123)</td></tr><tr><td>BC 36</td><td>66/M</td><td>T1</td><td>High, G2</td><td>1</td><td>High (D2S123, D9S283, D18S58)</td></tr><tr><td>BC 37</td><td>55/M</td><td>T2</td><td>High, G3</td><td>0</td><td>High (BAT &#8211; 26, BAT &#8211; 40, D9S1851)</td></tr><tr><td>BC 38</td><td>65/M</td><td>T2</td><td>High, G3</td><td>0</td><td>Low (D18S58)</td></tr><tr><td>BC 39</td><td>69/M</td><td>T1</td><td>Low, G1</td><td>0</td><td>Low (D9S283)</td></tr><tr><td>BC 40</td><td>74/M</td><td>T1</td><td>High, G2</td><td>1</td><td>MSS</td></tr><tr><td>BC 41</td><td>72/ F</td><td>T2</td><td>Low, G1</td><td>0</td><td>MSS</td></tr><tr><td>BC 42</td><td>71/M</td><td>T1</td><td>High, G3</td><td>1</td><td>Low (D9S283)</td></tr><tr><td>BC 43</td><td>64/M</td><td>T2</td><td>High, G3</td><td>0</td><td>High (BAT &#8211; 40, D9S1851)</td></tr><tr><td>BC 44</td><td>73/M</td><td>T1</td><td>High, G2</td><td>1</td><td>Low (D9S283)</td></tr></table>
fd44408e30e534d42e02c2069622a3663ce130f882b7ef31b3927dde0026c1cf.png
complex
<table><tr><td></td><td colspan="2">Total</td><td colspan="2">Physical</td><td colspan="2">Psychological</td><td colspan="2">Self-Esteem</td><td colspan="2">Family</td><td colspan="2">Friends</td><td colspan="2">School</td></tr><tr><td></td><td>OR</td><td>95%CI</td><td>OR</td><td>95%CI</td><td>OR</td><td>95%CI</td><td>OR</td><td>95%CI</td><td>OR</td><td>95%CI</td><td>OR</td><td>95%CI</td><td>OR</td><td>95%CI</td></tr><tr><td>Age (years)</td><td>0.98</td><td>(0.94-1.02)</td><td>1.02</td><td>(0.98-1.07)</td><td>0.98</td><td>(0.94-1.03)</td><td>0.95</td><td>(0.91-1.00)</td><td>1.03</td><td>(0.98-1.09)</td><td>1.05</td><td>(1.01-1.10)</td><td>0.89</td><td>(0.85-0.92)</td></tr><tr><td>Gender</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Girls</td><td>1</td><td></td><td>1</td><td></td><td>1</td><td></td><td>1</td><td></td><td>1</td><td></td><td>1</td><td></td><td>1</td><td></td></tr><tr><td>Boys</td><td>1.07</td><td>(0.94-1.23)</td><td>1.32</td><td>(1.13-1.56)</td><td>1.16</td><td>(0.99-1.36)</td><td>1.01</td><td>(0.86-1.18)</td><td>1.02</td><td>(0.82-1.26)</td><td>1.23</td><td>(1.03-1.46)</td><td>0.87</td><td>(0.73-1.03)</td></tr><tr><td>respondents</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Mother</td><td>1</td><td></td><td>1</td><td></td><td>1</td><td></td><td>1</td><td></td><td>1</td><td></td><td>1</td><td></td><td>1</td><td></td></tr><tr><td>Father</td><td>1.07</td><td>(0.85-1.34)</td><td>1.23</td><td>(0.97-1.56)</td><td>1.14</td><td>(0.87-1.48)</td><td>1.31</td><td>(1.03-1.67)</td><td>1.18</td><td>(0.87-1.60)</td><td>0.94</td><td>(0.73-1.21)</td><td>1.02</td><td>(0.80-1.31)</td></tr><tr><td>Mother and Father</td><td>1.11</td><td>(0.79-1.56)</td><td>1.55</td><td>(1.13-2.11)</td><td>1.12</td><td>(0.72-1.74)</td><td>1.27</td><td>(0.87-1.85)</td><td>0.86</td><td>(0.51-1.45)</td><td>0.81</td><td>(0.54-1.23)</td><td>0.75</td><td>(0.52-1.08)</td></tr><tr><td>Other Person</td><td>0.61</td><td>(0.31-1.17)</td><td>2.08</td><td>(1.12-3.88)</td><td>0.47</td><td>(0.11-1.94)</td><td>0.70</td><td>(0.29-1.71)</td><td>1.16</td><td>(0.44-3.03)</td><td>0.81</td><td>(0.38-1.72)</td><td>0.55</td><td>(0.27-1.09)</td></tr><tr><td>region</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>East</td><td>1</td><td></td><td>1</td><td></td><td>1</td><td></td><td>1</td><td></td><td>1</td><td></td><td>1</td><td></td><td>1</td><td></td></tr><tr><td>West</td><td>0.99</td><td>(0.84-1.16)</td><td>0.99</td><td>(0.84-1.18)</td><td>0.90</td><td>(0.74-1.10)</td><td>1.10</td><td>(0.96-1.27)</td><td>0.91</td><td>(0.75-1.10)</td><td>0.98</td><td>(0.82-1.17)</td><td>1.23</td><td>(1.05-1.44)</td></tr><tr><td>Migration background</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>No</td><td>1</td><td></td><td>1</td><td></td><td>1</td><td></td><td>1</td><td></td><td>1</td><td></td><td>1</td><td></td><td>1</td><td></td></tr><tr><td>Yes</td><td>1.47</td><td>(1.15-1.88)</td><td>0.92</td><td>(0.72-1.19)</td><td>1.33</td><td>(0.95-1.87)</td><td>1.28</td><td>(0.96-1.72)</td><td>1.79</td><td>(1.35-2.39)</td><td>1.36</td><td>(1.05-1.76)</td><td>0.67</td><td>(0.53-0.85)</td></tr><tr><td>Social status</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Low</td><td>1</td><td></td><td>1</td><td></td><td>1</td><td></td><td>1</td><td></td><td>1</td><td></td><td>1</td><td></td><td>1</td><td></td></tr><tr><td>Intermediate</td><td>0.87</td><td>(0.73-1.03)</td><td>1.00</td><td>(0.82-1.21)</td><td>0.75</td><td>(0.60-0.93)</td><td>1.04</td><td>(0.85-1.28)</td><td>1.01</td><td>(0.78-1.29)</td><td>0.81</td><td>(0.66-0.99)</td><td>1.03</td><td>(0.87-1.23)</td></tr><tr><td>Upper</td><td>0.91</td><td>(0.75-1.11)</td><td>1.02</td><td>(0.83-1.25)</td><td>0.78</td><td>(0.61-1.00)</td><td>1.07</td><td>(0.87-1.33)</td><td>0.90</td><td>(0.67-1.19)</td><td>0.66</td><td>(0.53-0.83)</td><td>1.18</td><td>(0.96-1.46)</td></tr><tr><td>Family climate</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Normal</td><td>1</td><td></td><td>1</td><td></td><td>1</td><td></td><td>1</td><td></td><td>1</td><td></td><td>1</td><td></td><td>1</td><td></td></tr><tr><td>Borderline</td><td>0.86</td><td>(0.70-1.07)</td><td>1.16</td><td>(0.91-1.48)</td><td>0.71</td><td>(0.54-0.94)</td><td>0.98</td><td>(0.78-1.21)</td><td>0.84</td><td>(0.65-1.09)</td><td>0.85</td><td>(0.66-1.10)</td><td>0.97</td><td>(0.79-1.20)</td></tr><tr><td>In deficite</td><td>0.73</td><td>(0.55-0.97)</td><td>1.22</td><td>(0.92-1.61)</td><td>0.50</td><td>(0.35-0.73)</td><td>0.62</td><td>(0.47-0.84)</td><td>1.15</td><td>(0.80-1.64)</td><td>0.91</td><td>(0.67-1.24)</td><td>1.04</td><td>(0.80-1.36)</td></tr><tr><td>Parent rated total SDQ</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Normal</td><td>1</td><td></td><td>1</td><td></td><td>1</td><td></td><td>1</td><td></td><td>1</td><td></td><td>1</td><td></td><td>1</td><td></td></tr><tr><td>Borderline</td><td>0.35</td><td>(0.24-0.50)</td><td>0.65</td><td>(0.47-0.90)</td><td>0.27</td><td>(0.17-0.44)</td><td>0.54</td><td>(0.38-0.75)</td><td>0.47</td><td>(0.32-0.68)</td><td>0.39</td><td>(0.26-0.58)</td><td>0.47</td><td>(0.34-0.67)</td></tr><tr><td>Abnormal</td><td>0.15</td><td>(0.10-0.23)</td><td>0.36</td><td>(0.24-0.54)</td><td>0.15</td><td>(0.09-0.27)</td><td>0.23</td><td>(0.16-0.33)</td><td>0.27</td><td>(0.16-0.47)</td><td>0.30</td><td>(0.19-0.47)</td><td>0.38</td><td>(0.27-0.53)</td></tr><tr><td>Parent rated health status</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Very good</td><td>1</td><td></td><td>1</td><td></td><td>1</td><td></td><td>1</td><td></td><td>1</td><td></td><td>1</td><td></td><td>1</td><td></td></tr><tr><td>Good</td><td>0.55</td><td>(0.47-0.65)</td><td>0.54</td><td>(0.45-0.64)</td><td>0.67</td><td>(0.55-0.79)</td><td>0.62</td><td>(0.52-0.74)</td><td>0.92</td><td>(0.74-1.13)</td><td>0.68</td><td>(0.58-0.81)</td><td>0.74</td><td>(0.64-0.87)</td></tr><tr><td>Moderate/bad/very bad</td><td>0.22</td><td>(0.15-0.31)</td><td>0.26</td><td>(0.18-0.37)</td><td>0.38</td><td>(0.23-0.62)</td><td>0.41</td><td>(0.29-0.57)</td><td>0.72</td><td>(0.48-1.10)</td><td>0.45</td><td>(0.32-0.65)</td><td>0.59</td><td>(0.43-0.82)</td></tr><tr><td>CSHCN-Screener</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Negativ</td><td>1</td><td></td><td>1</td><td></td><td>1</td><td></td><td>1</td><td></td><td>1</td><td></td><td>1</td><td></td><td>1</td><td></td></tr><tr><td>Positiv</td><td>0.93</td><td>(0.75-1.16)</td><td>0.86</td><td>(0.69-1.09)</td><td>0.73</td><td>(0.53-1.02)</td><td>0.79</td><td>(0.64-0.98)</td><td>0.91</td><td>(0.72-1.15)</td><td>0.78</td><td>(0.59-1.02)</td><td>0.92</td><td>(0.74-1.14)</td></tr><tr><td>pain (last 3 month)</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>No</td><td>1</td><td></td><td>1</td><td></td><td>1</td><td></td><td>1</td><td></td><td>1</td><td></td><td>1</td><td></td><td>1</td><td></td></tr><tr><td>Yes</td><td>0.91</td><td>(0.76-1.10)</td><td>0.90</td><td>(0.75-1.08)</td><td>1.07</td><td>(0.85-1.34)</td><td>0.93</td><td>(0.79-1.10)</td><td>0.91</td><td>(0.72-1.15)</td><td>1.23</td><td>(1.01-1.51)</td><td>1.07</td><td>(0.88-1.28)</td></tr><tr><td>Child rating (10 points)</td><td>0.28</td><td>(0.25-0.32)</td><td>0.50</td><td>(0.47-0.53)</td><td>0.26</td><td>(0.23-0.29)</td><td>0.39</td><td>(0.36-0.42)</td><td>0.46</td><td>(0.43-0.50)</td><td>0.40</td><td>(0.37-0.43)</td><td>0.47</td><td>(0.44-0.50)</td></tr><tr><td>R<sup>2</sup></td><td>38.6</td><td></td><td>30.9</td><td></td><td>42.6</td><td></td><td>48.2</td><td></td><td>35.2</td><td></td><td>40.1</td><td></td><td>36.1</td><td></td></tr></table>
2c24d065726133ee419751842c5f161d57774802deec8618908dd3dfda762945.png
complex
<table><tr><td>Statements</td><td colspan="2">At my PHCC,<sup>a</sup> management is positive toward our work with promotion of healthy lifestyles</td><td colspan="2">At my PHCC, we collaborate with other stakeholders such as municipalities and community associations about our patients&#8217; lifestyles</td><td colspan="2">At my PHCC, there are incentives to promote healthy lifestyles among our patients</td><td colspan="2">At my PHCC, there are local guidelines/care programs on how we should promote healthy lifestyles among our patients</td><td colspan="2">At my PHCC, there are many factors that facilitate the promotion of healthy lifestyles among our patients</td><td colspan="2">At my PHCC, there are many factors that hinder the promotion of healthy lifestyles among our patients</td><td colspan="2">I perceive there is a need for National CPGs<sup>b</sup> for lifestyle interventions in the work at my PHCC</td></tr><tr><td>Characteristics</td><td>%</td><td><i>P</i>-value</td><td>%</td><td><i>P</i>-value</td><td>%</td><td><i>P</i>-value</td><td>%</td><td><i>P</i>-value</td><td>%</td><td><i>P</i>-value</td><td>%</td><td><i>P</i>-value</td><td>%</td><td><i>P</i>-value</td></tr><tr><td>Profession</td><td></td><td>0.782</td><td></td><td>0.207</td><td></td><td>0.465</td><td></td><td>0.618</td><td></td><td>0.154</td><td></td><td>0.729</td><td></td><td>0.049</td></tr><tr><td>Registered nurse</td><td>80</td><td></td><td>37</td><td></td><td>60</td><td></td><td>63</td><td></td><td>37</td><td></td><td>17</td><td></td><td>77</td><td></td></tr><tr><td>Public health nurse</td><td>71</td><td></td><td>22</td><td></td><td>57</td><td></td><td>51</td><td></td><td>42</td><td></td><td>17</td><td></td><td>84</td><td></td></tr><tr><td>Physician</td><td>68</td><td></td><td>20</td><td></td><td>63</td><td></td><td>50</td><td></td><td>43</td><td></td><td>12</td><td></td><td>65</td><td></td></tr><tr><td>Resident<sup>c</sup></td><td>68</td><td></td><td>14</td><td></td><td>50</td><td></td><td>50</td><td></td><td>14</td><td></td><td>18</td><td></td><td>68</td><td></td></tr><tr><td>General practitioner</td><td>72</td><td></td><td>19</td><td></td><td>72</td><td></td><td>72</td><td></td><td>38</td><td></td><td>25</td><td></td><td>75</td><td></td></tr><tr><td>Years in profession</td><td></td><td>0.489</td><td></td><td>0.829</td><td></td><td>0.111</td><td></td><td>0.948</td><td></td><td>0.075</td><td></td><td>0.861</td><td></td><td>0.783</td></tr><tr><td>0&#8211;10</td><td>74</td><td></td><td>22</td><td></td><td>54</td><td></td><td>51</td><td></td><td>27</td><td></td><td>18</td><td></td><td>79</td><td></td></tr><tr><td>&#8805;11</td><td>70</td><td></td><td>23</td><td></td><td>63</td><td></td><td>52</td><td></td><td>37</td><td></td><td>17</td><td></td><td>78</td><td></td></tr><tr><td>Total</td><td>71</td><td></td><td>22</td><td></td><td>59</td><td></td><td>51</td><td></td><td>33</td><td></td><td>17</td><td></td><td>78</td><td></td></tr></table>
bbb1a8de917bafbd8aafb567d21348c5e131ba80ec819ebd4bbe4e7770a3cb25.png
complex
<table><tr><td colspan="2">Type of triangulation</td><td>Example</td></tr><tr><td>Data source triangulation</td><td>Existing data review</td><td>Analyzed main health problem by reviewing existing health data from CDC</td></tr><tr><td></td><td>Investigation</td><td>Prioritized health problem by investigating health problem and risk factors with different methods</td></tr><tr><td>Methods triangulation</td><td>Participation (Ranking)</td><td>Prioritized health problem by listing and ranking health concerns (people's perceived needs and priorities)</td></tr><tr><td></td><td>FGD</td><td>Discussed the health problems, risk factors and their influencing factors (people's perceived needs, priorities, influence factors)</td></tr><tr><td></td><td>Key informant interview</td><td>Assessed the health resources for health promotion (resources, policy)</td></tr><tr><td></td><td>Questionnaires</td><td>Surveyed the health problems ("actual needs"), risk factors</td></tr><tr><td>Researchers triangulation</td><td>Teachers</td><td>Role of moderator in 4 FGDs and key informants interviews, and analyzed all FGDs and key informants interviews</td></tr><tr><td></td><td>Graduates</td><td>Role of moderator in 8 FGDs</td></tr></table>
e948aeb2bb0c22b1be17c831a31aebb8c9787175be12fecb43ca7efcd420a924.png
complex
<table><tr><td> </td><td> </td><td colspan="2">Menstrual</td><td colspan="2">Follicular</td><td colspan="2">Luteal</td></tr><tr><td> </td><td> </td><td>r</td><td>95% CI</td><td>r</td><td>95% CI</td><td>r</td><td>95% CI</td></tr><tr><td rowspan="2">Craving (VAS)</td><td>Number of cigarettes</td><td>0.611<sup>***</sup></td><td>0.20&#8211;0.84</td><td>0.598<sup>***</sup></td><td>0.18&#8211;0.83</td><td>0.718<sup>***</sup></td><td>0.38&#8211;0.89</td></tr><tr><td>CO concentration</td><td>0.530<sup>**</sup></td><td>0.09&#8211;0.80</td><td>0.430<sup>*</sup></td><td>0.08&#8211;0.69</td><td>0.811<sup>***</sup></td><td>0.55&#8211;0.93</td></tr><tr><td rowspan="2">Depressiveness (CES-D)</td><td>Number of cigarettes</td><td>0.387<sup>*</sup></td><td>0.02&#8211;0.66</td><td>0.374<sup>*</sup></td><td>0.01&#8211;0.65</td><td>0.546<sup>**</sup></td><td>0.24&#8211;0.77</td></tr><tr><td>CO concentration</td><td>0.490<sup>**</sup></td><td>0.03&#8211;0.78</td><td>0.484<sup>**</sup></td><td>0.02&#8211;0.78</td><td>0.607<sup>***</sup></td><td>0.20&#8211;0.84</td></tr><tr><td>Menstrual phase-associated symptoms(MDQ)</td><td>Number of cigarettes</td><td>0.405<sup>*</sup></td><td>0.05&#8211;0.67</td><td>0.097</td><td>&#8722;0.28&#8211;0.45</td><td>0.530<sup>**</sup></td><td>0.08&#8211;0.80</td></tr><tr><td> </td><td>CO concentration</td><td>0.488<sup>**</sup></td><td>0.03&#8211;0.78</td><td>0.274</td><td>&#8722;0.10&#8211;0.58</td><td>0.588<sup>**</sup></td><td>0.17&#8211;0.83</td></tr></table>
186c783c6f3fe119cbd4c55542d76a6059136bd3d35535fa1e19c09faec6310d.png
complex
<table><tr><td colspan="7">Classification results L2-norm SVM</td></tr><tr><td>Features</td><td>Accuracy (%)</td><td>Accuracy p-value</td><td>Sensitivity (%)</td><td>Specificity (%)</td><td>Sparsity (%)</td><td>Stability (%)</td></tr><tr><td colspan="7"><i>Event-related fMRI dataset</i></td></tr><tr><td>Sparse inverse covariance</td><td>73.68</td><td>0.01&#8270;</td><td>73.68</td><td>73.68</td><td>&#8211;</td><td>37.81 &#177; 0.26</td></tr><tr><td>Full inverse covariance</td><td>44.73</td><td>&gt; 0.05</td><td>47.37</td><td>42.11</td><td>&#8211;</td><td>9.90 &#177; 0.78</td></tr><tr><td>Correlation</td><td>68.42</td><td>0.02&#8270;</td><td>84.21</td><td>52.63</td><td>&#8211;</td><td>9.29 &#177; 1.56</td></tr><tr><td>Partial correlation</td><td>65.78</td><td>&gt; 0.05</td><td>73.68</td><td>57.89</td><td>&#8211;</td><td>11.33 &#177; 0.16</td></tr><tr><td colspan="7">&#8232;&#8232;</td></tr><tr><td colspan="7"><i>Block-related fMRI dataset</i></td></tr><tr><td>Sparse inverse covariance</td><td>78.33</td><td>0.01&#8270;</td><td>80.00</td><td>76.67</td><td>&#8211;</td><td>25.81 &#177; 0.45</td></tr><tr><td>Full inverse covariance</td><td>40.00</td><td>&gt; 0.05</td><td>20.00</td><td>60.00</td><td>&#8211;</td><td>12.81 &#177; 0.89</td></tr><tr><td>Correlation</td><td>60.00</td><td>&gt; 0.05</td><td>86.67</td><td>33.33</td><td>&#8211;</td><td>8.61 &#177; 2.17</td></tr><tr><td>Partial correlation</td><td>58.33</td><td>&gt; 0.05</td><td>53.33</td><td>63.33</td><td>&#8211;</td><td>10.93 &#177; 0.78</td></tr></table>
2c206b788b95cee4a5f201ee8684a12bc69a58191dbad7ad876ca1a09efbcee0.png
simple
<table><tr><td>Sample month</td><td>Raw sludge enteric virus (PFU/4 g)</td><td>Treated biosolids enteric virus (PFU/4 g)</td></tr><tr><td>1</td><td>&lt; 1</td><td>&lt; 1</td></tr><tr><td>2</td><td>&lt; 1</td><td>&lt; 1</td></tr><tr><td>3</td><td>&lt; 1</td><td>&lt; 1</td></tr><tr><td>4</td><td>&lt; 1</td><td>&lt; 1</td></tr><tr><td>5</td><td>&lt; 1</td><td>&lt; 1</td></tr><tr><td>6</td><td>5</td><td>&lt; 1</td></tr><tr><td>7</td><td>2</td><td>&lt; 1</td></tr><tr><td>8</td><td>1</td><td>&lt; 1</td></tr><tr><td>9</td><td>1</td><td>&lt; 1</td></tr><tr><td>10</td><td>7</td><td>&lt; 1</td></tr><tr><td>11</td><td>6</td><td>1</td></tr><tr><td>12</td><td>31</td><td>&lt; 1</td></tr></table>
6c0fea12b2f43e332e23da709a0870fd60dc4a4210a3689cf5b6937d553ab3b3.png
complex
<table><tr><td></td><td>Landmarks on single curves</td></tr><tr><td rowspan="2">Sellion</td><td><i>The most posterior point of the frontonasal soft tissue contour in the midline of the base of the nasal root</i></td></tr><tr><td>The point of maximal curvature of the mid&#8208;line nasal profile curve at its nasal root end</td></tr><tr><td rowspan="2">Subnasale</td><td><i>The point where the nasal septum merges with the upper cutaneous lip in the mid&#8208;sagittal plane</i></td></tr><tr><td>The point of maximal curvature on the mid&#8208;line curve at the base of the nasal septum</td></tr><tr><td rowspan="2">Alare</td><td><i>The most lateral point on each alar contour</i></td></tr><tr><td>The point of maximal curvature along the alar curve</td></tr><tr><td rowspan="2">Alare crest</td><td><i>The facial insertion of each alar base</i></td></tr><tr><td>The point of maximum curvature on the alar curve where this meets the paranasal area</td></tr><tr><td rowspan="2">Cheilion</td><td><i>The point located at each labial commissure</i></td></tr><tr><td>The point of maximum curvature at the lateral end of the labial seal curve</td></tr><tr><td rowspan="2">Sublabiale</td><td><i>The most posterior mid&#8208;point on the labiomental soft tissue contour that defines the border between the lower lip and the chin</i></td></tr><tr><td>The point of maximal curvature in the mid&#8208;line curve as it passes through the <i>mentolabial sulcus</i></td></tr><tr><td rowspan="2">Tragion</td><td><i>The point located at the upper margin of each tragus</i></td></tr><tr><td>The point of maximum curvature at the superior end of the tragus curve</td></tr><tr><td rowspan="2">Otobasion inferius</td><td><i>The point of attachment of the ear lobe to the cheek, which determines the lower border of the ear insertion</i></td></tr><tr><td>The final point at the preauricular end of the ear rim curve.</td></tr></table>
36b00f22e02d9aa3ccaddd41385219afdd42a70c7945d3ef4991e03903a224f5.png
simple
<table><tr><td>Characteristic</td><td>Patients</td><td>Controls</td><td></td></tr><tr><td></td><td><i>n</i> = 57 (%)</td><td><i>n</i> = 20 (%)</td><td></td></tr><tr><td>Age (years, mean &#177; SD)</td><td>55.4 &#177; 12.8</td><td>54.8 &#177; 14.3</td><td>0.853*</td></tr><tr><td>&lt;55</td><td>28 (49)</td><td>12 (60)</td><td>0.48**</td></tr><tr><td>&#8805;55</td><td>29 (51)</td><td>8 (40)</td><td></td></tr><tr><td>Menopause</td><td></td><td></td><td></td></tr><tr><td>Pre-menopausal</td><td>24 (42.1)</td><td>N/A</td><td></td></tr><tr><td>Post-menopausal</td><td>33 (57.9)</td><td>N/A</td><td></td></tr><tr><td>Histology</td><td></td><td></td><td></td></tr><tr><td>Ductal</td><td>50 (87.7)</td><td></td><td></td></tr><tr><td>Lobular</td><td>5 (8.8)</td><td></td><td></td></tr><tr><td>Other</td><td>2 (3.5)</td><td></td><td></td></tr><tr><td>Histological grade</td><td></td><td></td><td></td></tr><tr><td>1</td><td>7 (12.3)</td><td></td><td></td></tr><tr><td>2</td><td>25 (43.9)</td><td></td><td></td></tr><tr><td>3</td><td>23 (40.4)</td><td></td><td></td></tr><tr><td>TNM Stage</td><td></td><td></td><td></td></tr><tr><td>I</td><td>14 (24.6)</td><td></td><td></td></tr><tr><td>II</td><td>13 (22.8)</td><td></td><td></td></tr><tr><td>III</td><td>17 (29.8)</td><td></td><td></td></tr><tr><td>IV</td><td>13 (22.8)</td><td></td><td></td></tr><tr><td>Lymph nodes involved</td><td></td><td></td><td></td></tr><tr><td>No</td><td>20 (35.1)</td><td></td><td></td></tr><tr><td>Yes</td><td>37 (64.9)</td><td></td><td></td></tr><tr><td>Hormonal Receptors</td><td></td><td></td><td></td></tr><tr><td>Positive</td><td>42 (73.7)</td><td></td><td></td></tr><tr><td>Negative</td><td>14 (24.6)</td><td></td><td></td></tr><tr><td>HER2</td><td></td><td></td><td></td></tr><tr><td>Positive</td><td>14 (24.6 )</td><td></td><td></td></tr><tr><td>Negative</td><td>42 (73.7 )</td><td></td><td></td></tr><tr><td>MIB1</td><td></td><td></td><td></td></tr><tr><td>&lt;25%</td><td>40 (70.2)</td><td></td><td></td></tr><tr><td>&gt;25%</td><td>14 (24.6)</td><td></td><td></td></tr><tr><td>Type</td><td></td><td></td><td></td></tr><tr><td>Luminal</td><td>32 (56.1)</td><td></td><td></td></tr><tr><td>HER2</td><td>14 (24.6)</td><td></td><td></td></tr><tr><td>Triple negative</td><td>10 (17.5)</td><td></td><td></td></tr><tr><td>R0</td><td>28 (49.1)</td><td></td><td></td></tr><tr><td>R2</td><td>29 (50.9)</td><td></td><td></td></tr></table>
a2f83d6656004e1aa8257b52ad6cbd9eca99191a6d4ece707c75f3c0c07868c9.png
complex
<table><tr><td>Effect (b)</td><td colspan="4">PCBMR</td><td colspan="4">Single-Trait Association</td></tr><tr><td></td><td>GEN</td><td>ADD</td><td>DOM</td><td>REC</td><td>GEN</td><td>ADD</td><td>DOM</td><td>REC</td></tr><tr><td>0</td><td>4.7</td><td>5</td><td>5.6</td><td>3.9</td><td>5.0(3.2)</td><td>5.3(2.7)</td><td>5.7(3.3)</td><td>4.2(2.4)</td></tr><tr><td>0.5</td><td>7.6</td><td>8.8</td><td>7.5</td><td>6.4</td><td>7.4(4.1)</td><td>8.4(4.7)</td><td>7.1(4.6)</td><td>6.1(3.3)</td></tr><tr><td>1</td><td>18.1</td><td>22.4</td><td>22</td><td>11.2</td><td>17.8(11.2)</td><td>22.4(16.2)</td><td>21.2(14.1)</td><td>11.2(7.2)</td></tr><tr><td>1.5</td><td>35.3</td><td>45.2</td><td>40.1</td><td>20.3</td><td>35.8(24.8)</td><td>45.8(34.3)</td><td>40.2(28.4)</td><td>20.2(13.8)</td></tr><tr><td>2</td><td>60.4</td><td>70.1</td><td>66</td><td>29.2</td><td>60.2(50.3)</td><td>70.2(59.8)</td><td>66.5(54.9)</td><td>28.9(22.0)</td></tr><tr><td>2.5</td><td>79.2</td><td>87.4</td><td>82.5</td><td>40.8</td><td>79.1(70.1)</td><td>86.8(79.0)</td><td>82.2(75.1)</td><td>40.2(30.2)</td></tr><tr><td>3</td><td>91.2</td><td>95.9</td><td>93.4</td><td>50.6</td><td>91.1(85.5)</td><td>95.8(91.7)</td><td>93.3(88.6)</td><td>50.7(40.4)</td></tr><tr><td>3.5</td><td>97.2</td><td>99.3</td><td>97.6</td><td>62</td><td>97.6(94.9)</td><td>99.4(98.0)</td><td>97.8(96.0)</td><td>62.5(50.6)</td></tr><tr><td>4</td><td>99.6</td><td>99.7</td><td>99.5</td><td>75.4</td><td>99.4(98.9)</td><td>99.7(99.5)</td><td>99.5(99.0)</td><td>75.9(63.9)</td></tr></table>
da413f2f4b175f615cef87f6f14ef0b316657801f85d2dd52618f175a667b34f.png
complex
<table><tr><td>Time</td><td colspan="2">Acupuncture</td><td colspan="2">Counselling</td><td colspan="2">Usual care</td><td colspan="3">Effect of trial arm</td></tr><tr><td>Week</td><td>Mean</td><td>SE</td><td>Mean</td><td>SE</td><td>Mean</td><td>SE</td><td>F</td><td>df</td><td>p</td></tr><tr><td>2</td><td>5.56</td><td>0.136</td><td>5.73</td><td>0.143</td><td>5.74</td><td>0.195</td><td>0.48</td><td>2</td><td>.621</td></tr><tr><td>3</td><td>5.76</td><td>0.134</td><td>5.56</td><td>0.142</td><td>5.60</td><td>0.191</td><td>0.54</td><td>2</td><td>.582</td></tr><tr><td>4</td><td>5.49</td><td>0.133</td><td>5.54</td><td>0.142</td><td>5.44</td><td>0.191</td><td>0.10</td><td>2</td><td>.909</td></tr><tr><td>5</td><td>5.26</td><td>0.132</td><td>5.30</td><td>0.142</td><td>5.57</td><td>0.188</td><td>0.98</td><td>2</td><td>.375</td></tr><tr><td>6</td><td>5.10</td><td>0.135</td><td>5.18</td><td>0.144</td><td>5.25</td><td>0.193</td><td>0.22</td><td>2</td><td>.806</td></tr><tr><td>7</td><td>4.95</td><td>0.137</td><td>5.03</td><td>0.146</td><td>5.31</td><td>0.193</td><td>1.23</td><td>2</td><td>.292</td></tr><tr><td>8</td><td>4.80</td><td>0.141</td><td>4.95</td><td>0.147</td><td>5.35</td><td>0.198</td><td>2.60</td><td>2</td><td>.074</td></tr><tr><td>9</td><td>4.78</td><td>0.144</td><td>4.74</td><td>0.152</td><td>5.15</td><td>0.199</td><td>1.56</td><td>2</td><td>.211</td></tr><tr><td>10</td><td>4.62</td><td>0.147</td><td>4.57</td><td>0.154</td><td>5.39</td><td>0.207</td><td>5.91</td><td>2</td><td>.003</td></tr><tr><td>11</td><td>4.67</td><td>0.153</td><td>4.69</td><td>0.161</td><td>5.67</td><td>0.213</td><td>8.55</td><td>2</td><td>.000</td></tr><tr><td>12</td><td>4.60</td><td>0.157</td><td>4.47</td><td>0.165</td><td>5.64</td><td>0.219</td><td>10.08</td><td>2</td><td>.000</td></tr><tr><td>13</td><td>4.36</td><td>0.162</td><td>4.62</td><td>0.172</td><td>5.20</td><td>0.225</td><td>4.60</td><td>2</td><td>.010</td></tr><tr><td>14</td><td>4.21</td><td>0.169</td><td>4.64</td><td>0.176</td><td>5.10</td><td>0.238</td><td>4.82</td><td>2</td><td>.008</td></tr><tr><td>15</td><td>4.18</td><td>0.177</td><td>4.53</td><td>0.185</td><td>5.11</td><td>0.243</td><td>4.78</td><td>2</td><td>.008</td></tr><tr><td>16</td><td>4.18</td><td>0.184</td><td>4.39</td><td>0.193</td><td>5.24</td><td>0.253</td><td>5.93</td><td>2</td><td>.003</td></tr></table>
a47e90981e88a58b013846153966e0dad737ebafca0b63c47cafcc283d5bb72b.png
simple
<table><tr><td>Study</td><td>N</td><td>TP</td><td>FN</td><td>TN</td><td>FP</td><td>Sensitivity% (CI)</td><td>Specificity% (CI)</td><td>PPV% (CI)</td><td>NPV% (CI)</td></tr><tr><td>Marcellin 2011 [60]</td><td>79</td><td>39</td><td>1</td><td>38</td><td>1</td><td>97.5 (85.7&#8211;100)</td><td>97.4 (82.4&#8211;99.4)</td><td>97.5 (88.5&#8211;100)</td><td>97.4 (92.5&#8211;100)</td></tr><tr><td>Martinez de Tejada 2006 [52]</td><td>34</td><td>20</td><td>0</td><td>13</td><td>1</td><td>100 (79.9&#8211;100)</td><td>92.8 (64.2&#8211;99.6)</td><td>95.2 (74.1&#8211;99.7)</td><td>100 (71.7&#8211;100)</td></tr><tr><td>Akercan 2005 [54]</td><td>45</td><td>25</td><td>0</td><td>19</td><td>1</td><td>100 (83.4&#8211;100)</td><td>95.0 (73.1&#8211;99.7)</td><td>96.1 (78.4&#8211;99.8)</td><td>100 (79.1&#8211;100)</td></tr><tr><td>Erdermoglu 2004 [47]</td><td>71</td><td>35</td><td>1</td><td>34</td><td>1</td><td>97.2 (83.8&#8211;99.8)</td><td>97.1 (83.4&#8211;99.8)</td><td>97.2 (83.8&#8211;99.8)</td><td>97.1 (83.4&#8211;99,8)</td></tr><tr><td>Darj 1998 [51]</td><td>75</td><td>44</td><td>2</td><td>27</td><td>2</td><td>95.6 (84.0&#8211;99.2)</td><td>93.1 (75.8&#8211;98.8)</td><td>95.7 (84.0&#8211;99.2)</td><td>93.1 (75.8&#8211;98.8)</td></tr><tr><td>Gaucherand 1997 [53]</td><td>69</td><td>34</td><td>1</td><td>34</td><td>0</td><td>97.1 (83.4&#8211;99.8)</td><td>100 (87.4&#8211;99.8)</td><td>100 (87.4&#8211;100)</td><td>97.1 (83.4&#8211;99.8)</td></tr><tr><td>Guibourdenche 1999 [48]</td><td>30</td><td>15</td><td>0</td><td>14</td><td>1</td><td>100 (74.6&#8211;100)</td><td>93.3 (66.0&#8211;99.7)</td><td>93.8 (67.7&#8211;99.7)</td><td>100 (73.2&#8211;100)</td></tr><tr><td>Rutanen 1996 [12]</td><td>130</td><td>55</td><td>0</td><td>71</td><td>4</td><td>100 (91.9&#8211;100)</td><td>94.7 (86.2&#8211;98.3)</td><td>93.2 (82.7&#8211;97.8)</td><td>100 (93.6&#8211;100)</td></tr><tr><td>Actim PROM&#174; pooled</td><td>533</td><td>267</td><td>5</td><td>250</td><td>11</td><td>98.2 (95.5&#8211;99.3)</td><td>95.8 (92.4&#8211;97.8)</td><td>96.0 (92.8&#8211;97.9)</td><td>98.0 (95.2&#8211;99.3)</td></tr><tr><td>Abdelazim 2012 [58]</td><td>150</td><td>73</td><td>2</td><td>74</td><td>1</td><td>97.3 (89.8&#8211;99.5)</td><td>98.7 (91.8&#8211;99.9)</td><td>98.6 (91.7&#8211;99.9)</td><td>97.4 (90.0&#8211;99.5)</td></tr><tr><td>Marcellin 2011 [60]</td><td>79</td><td>38</td><td>2</td><td>38</td><td>1</td><td>95.0 (82.4&#8211;99.4)</td><td>94.8 (79.3&#8211;98.0)</td><td>95.0 (84.7&#8211;100)</td><td>94.8 (87.9&#8211;100)</td></tr><tr><td>AmniSure&#174; pooled</td><td>229</td><td>111</td><td>4</td><td>112</td><td>2</td><td>96.5 (90.8&#8211;98.9)</td><td>98.2 (93.2&#8211;99.7)</td><td>98.2 (93.1&#8211;99.7)</td><td>96.5 (90.9&#8211;98.9)</td></tr></table>
2b2b5592a08a9e0d85b08d5ccc0aebd63824d4c2e56758fc12ab6b818a0da1e6.png
complex
<table><tr><td rowspan="2">Characteristic</td><td>Standardized coefficients</td><td rowspan="2"><i>P</i>-value</td><td colspan="2">95 % Confidence Interval for B</td></tr><tr><td>Beta</td><td>Lower bound</td><td>Lower bound</td></tr><tr><td>Number of medications for each patient</td><td>0.556</td><td>&lt;0.001</td><td>0.196</td><td>0.288</td></tr><tr><td>Patient age group</td><td>0.045</td><td>0.381</td><td>&#8722;0.090</td><td>0.235</td></tr><tr><td>Number of comorbid diseases the patient have</td><td>0.049</td><td>0.367</td><td>&#8722;0.056</td><td>0.151</td></tr></table>
483a23be6fed70cc2163536d62625887c2d5655797a3723b2c92f27882a80bee.png
complex
<table><tr><td></td><td>AUC</td><td>SE</td><td>95 % CI</td><td>Cutoff<sup>a</sup></td><td>Sensitivity (%)</td><td>Specificity (%)</td><td>Correctly classified<sup>b</sup> (%)</td></tr><tr><td>A&#946;42</td><td>0.935</td><td>0.0394</td><td>0.806&#8211;0.989</td><td>853</td><td>100</td><td>83.87</td><td>87</td></tr><tr><td>ttau</td><td>0.733</td><td>0.132</td><td>0.565&#8211;0.863</td><td>352</td><td>71.43</td><td>77.42</td><td>76</td></tr><tr><td>ptau</td><td>0.675</td><td>0.139</td><td>0.504&#8211;0.818</td><td>86</td><td>42.86</td><td>93.55</td><td>84</td></tr><tr><td>A&#946;42/ttau</td><td>0.880</td><td>0.0878</td><td>0.734&#8211;0.963</td><td>2.258</td><td>85.71</td><td>90.32</td><td>89</td></tr><tr><td>Specificity of 90 %</td><td colspan="2">Sensitivity (%)</td><td>95 % CI</td><td>Cutoff<sup>a</sup></td><td>Difference<sup>c</sup> (%)</td><td><i>P</i> value<sup>d</sup></td><td>Correctly classified<sup>b</sup> (%)</td></tr><tr><td> A&#946;42</td><td colspan="2">85.71</td><td>11.54&#8211;100.00</td><td>798</td><td>7.90</td><td>0.25</td><td>89</td></tr><tr><td> ttau</td><td colspan="2">57.14</td><td>14.29&#8211;100.00</td><td>465</td><td>10.53</td><td>0.125</td><td>82</td></tr><tr><td> ptau</td><td colspan="2">42.96</td><td>0.00&#8211;85.71</td><td>87</td><td>5.26</td><td>0.5</td><td>79</td></tr><tr><td> A&#946;42/ttau</td><td colspan="2">85.71</td><td>28.57&#8211;100.00</td><td>2.263</td><td>0</td><td>1</td><td>89</td></tr><tr><td>Specificity of 95 %</td><td colspan="2">Sensitivity (%)</td><td>95 % CI</td><td>Cutoff<sup>a</sup></td><td>Difference<sup>c</sup> (%)</td><td><i>P</i> value<sup>d</sup></td><td>Correctly classified<sup>b</sup> (%)</td></tr><tr><td> A&#946;42</td><td colspan="2">42.86</td><td>4.05&#8211;100.00</td><td>672</td><td>21.05</td><td>0.008</td><td>87</td></tr><tr><td> ttau</td><td colspan="2">14.29</td><td>0.00&#8211;85.71</td><td>566</td><td>23.69</td><td>0.004</td><td>82</td></tr><tr><td> ptau</td><td colspan="2">28.57</td><td>0.00&#8211;71.43</td><td>94</td><td>2.63</td><td>1</td><td>82</td></tr><tr><td> A&#946;42/ttau</td><td colspan="2">71.43</td><td>8.71&#8211;100.00</td><td>2.093</td><td>7.90</td><td>0.25</td><td>92</td></tr></table>
41401b5768eb1b6ad85d4e4a2ee355892d0056fb3c8db0aa353af2ed2ffe82f5.png
simple
<table><tr><td>Highest stage of education achieved by participants&#8217; parent(s) No. (%)</td><td>Entry route into Undergraduate Medical Education No. (%)</td><td>Medical Degree Type No. (%)</td><td>Medical Degree Stage No. (%)</td></tr><tr><td>- Primary Level 1 (5)- Secondary Level14 (70)- Tertiary Level 5(25)</td><td>-Direct entry from Tertiary Education15 (75)-Gap year between Tertiary Education and Medical School 2 (10)-Graduate Entry 3 (15)</td><td>-Extended (6 Years) 11 (55)-MBBS (5 Years) 9 (45)</td><td>-Pre-Clinical Stage 10 (50%)-Clinical Stage 10 (50%)</td></tr><tr><td>Total 20(100)</td><td>Total 20(100)</td><td>Total 20(100)</td><td>Total 20(100)</td></tr></table>
ef98b38bf4aaed9d21d6ca2b10ebcd44c8d4992fae49f5330945595218694c20.png
simple
<table><tr><td></td><td>LI-PD group (n = 17)</td><td>NLI-PD group (n = 14)</td><td>Control group (n = 20)</td><td><i>P</i>, LI-PD cf. NLI-PD</td><td><i>P</i>, LI-PD cf. control</td><td><i>P</i>, NLI-PD cf. control</td></tr><tr><td>Men</td><td>12</td><td>6</td><td>12</td><td>0.157</td><td>0.731</td><td>0.487</td></tr><tr><td>Women</td><td>5</td><td>8</td><td>8</td><td></td><td></td><td></td></tr><tr><td>Age, y</td><td>63.59 &#177; 8.62</td><td>63.07 &#177; 9.43</td><td>64.85 &#177; 8.27</td><td>0.843</td><td>0.653</td><td>0.564</td></tr><tr><td>Age at onset, y</td><td>55.06 &#177; 10.92</td><td>56.36 &#177; 10.95</td><td>NA</td><td>0.781</td><td>NA</td><td>NA</td></tr><tr><td>Formal education, y</td><td>10.53 &#177; 2.67</td><td>11.00 &#177; 3.60</td><td>10.95 &#177; 2.69</td><td>0.780</td><td>0.637</td><td>0.983</td></tr><tr><td>Disease duration, y</td><td>8.53 &#177; 4.49</td><td>6.71 &#177; 3.29</td><td>NA</td><td>0.327</td><td>NA</td><td>NA</td></tr><tr><td>Hoehn-Yahr stage</td><td>2.50 &#177; 0.55</td><td>2.57 &#177; 0.39</td><td>NA</td><td>0.415</td><td>NA</td><td>NA</td></tr><tr><td>UPDRS part II</td><td>15.69 &#177; 8.39</td><td>11.79 &#177; 4.87</td><td>NA</td><td>0.138</td><td>NA</td><td>NA</td></tr><tr><td>UPDRS part III</td><td>38.87 &#177; 12.11</td><td>32.86 &#177; 8.76</td><td>NA</td><td>0.135</td><td>NA</td><td>NA</td></tr><tr><td>HAMD-17 scores</td><td>8.88 &#177; 2.34</td><td>7.86 &#177; 2.18</td><td>7.45 &#177; 2.44</td><td>0.691</td><td>0.208</td><td>1.000</td></tr><tr><td>MoCA scores</td><td>19.60 &#177; 4.75</td><td>22.75 &#177; 3.14</td><td>25.80 &#177; 1.64</td><td>0.142</td><td>0.000<sup>b</sup></td><td>0.021<sup>b</sup></td></tr></table>